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ABSTRACT
 Introduction: Studies examining the association between individual dietary 
components and breast cancer have been inconclusive. The use of dietary patterns is a 
holistic approach which may yield stronger associations. We sought to develop a dietary 
pattern based on an estrogen metabolite (EM) profile hypothesized to increase breast 
cancer risk (high unconjugated estradiol and low ratio of 2- to 16-hydroxylated EMs 
(2/16 ratio)). This estrogen-related dietary pattern (ERDP) was examined for associations 
with postmenopausal breast cancer in two study populations and was incorporated into an 
estrogen-related lifestyle score (ERLS) with other modifiable risk factors for breast 
cancer. Methods: EM and dietary data from 653 postmenopausal women from the 
Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) were used to 
develop the ERDP. Reduced rank regression modeling was applied to identify food 
groups which explained the largest variation in the two EMs. The resulting dietary pattern 
was then applied separately in 28,304 and 37,752 women from PLCO and the Sister 
Study (SS), respectively, to examine associations with breast cancer using Cox 
proportional hazards models. The ERDP was incorporated into the ERLS with alcohol 
consumption, body mass index, and physical activity among PLCO participants. 
Increasing scores of the ERLS represent a lower combined exposure to estrogen with a 
total range of scores from 0 to 6. Results: ERDP scores contained foods with positively 
weighted intakes (non-whole/refined grains, tomatoes, cruciferous vegetables, cheese, 
fish/shellfish high in ω-3 fatty acids, franks/luncheon meats) and foods with negatively 
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weighted intakes (nuts and seeds, other vegetables, fish/shellfish low in ω-3 fatty acids, 
yogurt, coffee). In PLCO, a 1-unit increase in the ERDP score was associated with a 9%, 
13%, and 13% increase in total (HR: 1.09, 95%CI: 1.01-1.18), invasive (HR: 1.13; 
95%CI: 1.04=1.04-1.24) and estrogen receptor-positive (HR: 1.13, 95%CI: 1.02- 1.24) 
breast cancer, respectively.  No association was observed in SS. PLCO participants in the 
highest ERLS category had a 34% (HR: 0.66; 95%CI: 0.56-0.78) reduction in risk of total 
breast cancer compared to the lowest category. Conclusions: A dietary pattern correlated 
with a high-risk estrogen profile was positively associated with postmenopausal breast 
cancer within the cohort in which it was derived. Potential differences in other risk 
factors or dietary assessment tools may explain differences in associations seen between 
PLCO and SS. Adopting a lifestyle that has a lower combined exposure to estrogen is 
likely effective in reducing the risk of postmenopausal breast cancer.
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CHAPTER 1 
INTRODUCTION
1.1 Statement of the Problem  
Breast cancer, the most commonly diagnosed cancer among women worldwide, is 
a disease of strong hormonal influence.1 An attenuation in the production of ovarian 
hormones is characteristic of the onset of menopause, which also corresponds to a change 
in disease risk.2 Postmenopausal women, the population in which the highest proportion 
of incident breast cancer cases occur, have significantly lower circulating levels of 
estrogen compared to premenopausal women.2,3 Many of the well-established factors 
associated with breast cancer, such as lactation, age at menarche, and parity are 
significantly associated with estrogen metabolism.4–6 Additionally, serum and urinary 
levels of estrogen metabolites (EM) have been shown to be consistently associated with 
postmenopausal breast cancer risk in prospective investigations.4,7–12 Therefore, 
modifiable lifestyle risk factors for postmenopausal breast cancer that are associated with 
estrogen metabolism may present opportunities for primary prevention. 
There are many nutrition-related lifestyle factors that have been identified with 
sufficient evidence that influence the development postmenopausal breast cancer.2,13 Both 
sides of the energy balance equation, excess intake in the form of adiposity and greater 
energy expenditure in the form of physical activity (PA), show evidence of a positive and 
inverse association with postmenopausal breast cancer, respectively.2,13 Consumption of 
alcohol has also been shown to increase breast cancer risk.2,13 Using indices to assess 
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modifiable lifestyle factors as one aggregate score has been promising in identifying 
associations with breast cancer risk.14–16 The study of dietary factors, however, with the 
exception of alcohol, has yielded conflicting results in relation to breast cancer risk.2,13,17–
23 Other individual dietary factors, such as non-starchy vegetables and foods containing 
carotenoids have limited but suggestive evidence of an association with breast cancer 
according to the latest report by the World Cancer Research Fund (WCRF) and the 
American Institute for Cancer Research (AICR).24 Furthermore, most other food 
components (e.g., fiber, fruit, and total fat intake) have such limited or conflicting 
evidence, the report deems their association with breast cancer to be entirely 
inconclusive.24 
 It is likely that the practice of studying dietary components in isolation is 
contributing to the inconclusive findings for associations with many diseases, according 
to United States Department of Agriculture’s (USDA) Dietary Guidelines for Americans 
(DGA).25 Nutrients are consumed in combinations, and many of these nutrients interact 
with one another with regards to digestion and metabolism. Therefore, it is beneficial to 
study diet in its entirety, as it is consumed, using dietary pattern analyses when 
investigating a potential association with breast cancer.26 Emerging evidence has 
supported an association between some dietary patterns and incident breast cancer 
risk.17,18,27 Many of the diets that have indicated an inverse relationship with breast cancer 
are characterized by high intakes of fruits and vegetables, and diets with increased risk 
typically have higher intakes in fat and animal products.17,21,28 Although these 
components show no or weak associations with breast cancer when studied in isolation, 
they may influence risk when consumed as a part of a whole diet. 
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In order to address the inconclusive findings in the literature on diet and breast 
cancer, it may be beneficial to consider the mechanistic pathway by which a potential 
association may occur. Nutritional status, namely malnutrition, can influence many 
hormonal processes in women, such as the development of breasts, and the onset of both 
menarche and menopause.29,30 Therefore, diet likely has some role in altering estrogen 
metabolism and subsequently breast cancer risk, similar to adiposity and PA.13 A 
relatively new approach to dietary pattern analyses, reduced rank regression (RRR), 
allows the use of disease biomarkers, such as EMs, to develop a dietary pattern and then 
investigate its association with disease endpoints.31 Previously, Fung et al. developed a 
dietary pattern correlated with serum levels of estradiol and estrone sulfate using RRR, 
but the pattern subsequently was not associated with breast cancer among 
postmenopausal women in the Nurses’ Health Study (NHS).32 However, application of 
the same estrogen-correlated dietary pattern in a Swedish cohort identified a positive 
association with incident breast cancer.27 The potential effect of a dietary pattern based 
on estrogen metabolism, in isolation and in combination with other nutritional lifestyle 
factors, needs to be studied further in an attempt to identify primary prevention methods 
for public health intervention. 
 
1.2 Purpose and Objectives 
 We used data from postmenopausal women in the Prostate, Lung, Colorectal, and 
Ovarian Cancer Screening Trial (PLCO) to develop a dietary pattern based on food 
groups that are correlated with serum estrogen levels. The estrogen-related dietary pattern 
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(ERDP) was applied to examine associations with postmenopausal breast cancer in 
PLCO. In order to examine the ERDP in a separate population from which it was 
developed, associations with breast cancer were also examined in the Sister Study (SS). 
Finally, in PLCO, the ERDP was combined with other lifestyle factors to assess the 
impact of an estrogen-related lifestyle score (ERLS) on the development of breast cancer.  
An initiative of the National Cancer Institute (NCI), PLCO is a large population-
based randomized trial to investigate the effect of regular cancer screenings on cancer 
mortality in men and women aged 55-74.33 Control arm participants continued standard 
of care screening practices, while participants in the intervention arm underwent more 
frequent screenings over a six-year period. Enrollment took place from 1993-2001, with 
follow-up collected until 2015. The SS, sponsored by the National Institute of 
Environmental Health Sciences (NIEHS), is a large cohort study designed to examine 
genetic and environmental risk factors of breast cancer.34 More than 50,000 sisters of 
breast cancer patients aged 35-74 were enrolled from 2003-2009 with follow-up data 
collection occurring every few years. Using these cohorts, we hypothesized that diets 
high in whole grains and vegetables, particularly dark green vegetables, and low in 
animal products would be characteristic of low ERDP scores. We expected the ERDP 
scores to be associated with postmenopausal breast cancer independently, and as a part of 
the ERLS. Our study aims were as follows:   
Aim I: To derive a dietary pattern based on estrogen metabolites and apply it to 
examine risk of postmenopausal breast cancer. 
 Fifteen EMs have been assayed using baseline serum samples from a nested case-
control study of postmenopausal women enrolled in PLCO.35 In Aim #1, we identified 
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food groups most strongly associated with EMs to create a dietary pattern that 
characterized a woman’s diet based on its hypothesized cumulative estrogenic properties. 
Two EMs with sufficient evidence of an association with postmenopausal breast cancer 
were used in the development of the ERDP. Previous research on dietary patterns and 
breast cancer has been inconclusive, however, most of the patterns have not considered 
disease mechanisms specific to breast cancer.17,21,28,36–40 Evidence from two studies that 
utilized an estrogen correlated dietary pattern have been mixed.27,32 Using data from all 
postmenopausal women in PLCO’s intervention arm, the ERDP was used to 
prospectively assess its association with overall postmenopausal breast cancer and by 
estrogen receptor (ER) subtype, with consideration of potential effect modifiers. We 
aimed to answer the following questions under Aim #1: 
1. What food groups are most strongly correlated with serum EMs? 
2. How much of the variation in serum EMs are explained by the ERDP? 
3. Is there an association between the ERDP and overall breast cancer risk among 
postmenopausal women? 
4. Does the association between the ERDP and postmenopausal breast cancer vary 
by ER subtype? 
5. Is the association between the ERDP and postmenopausal breast cancer modified 
by other estrogen-related risk factors (e.g., obesity, parity, alcohol consumption, 
hormone replacement therapy (HRT))? 
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Aim II: To examine the association between the ERDP and postmenopausal breast 
cancer in an external study population from which it was developed. 
 A potential association between the ERDP derived in Aim #1 and breast cancer 
was investigated further in Aim #2, using prospective data from postmenopausal women 
enrolled in SS. Use of data from the SS allowed for the examination of the association 
between the ERDP and breast cancer in a different population from the one in which it 
was derived as a potential validation study for any observed associations in PLCO. 
Similar to Aim#1, the association was investigated for overall breast cancer and by ER 
subtype, with consideration of potential effect modifiers. The following questions 
pertained to Aim #2: 
1. Is there an association between the ERDP and overall breast cancer risk among 
postmenopausal women? 
2. Does the association between the ERDP and postmenopausal breast cancer vary 
by ER subtype? 
3. Is the association between the ERDP and postmenopausal breast cancer modified 
by other estrogen-related risk factors? 
4. Did the association between the ERDP and postmenopausal breast cancer differ 
between participants of SS and PLCO? 
Aim III: To assess the relationship between an estrogen-related lifestyle score and 
postmenopausal breast cancer risk. 
 In Aim #3, a lifestyle score was developed using the ERDP in combination with 
other estrogen-related lifestyle factors known to be associated with postmenopausal 
breast cancer. Previous aggregate lifestyle scores have shown strong inverse associations 
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with breast cancer risk, but not always specific to postmenopausal breast cancer.14–16 The 
scores have been based on cancer prevention recommendations from the WCRF/AICR,14 
or using investigator-defined components,15 such as diet, physical activity, tobacco use, 
alcohol intake, and/or anthropometry.16 Furthermore, to the best of our knowledge, no 
lifestyle scores have been developed to focus on a single disease mechanism, such as 
alteration of estrogen metabolism. Using data from all postmenopausal women in 
PLCO’s intervention arm, the ERDP, body mass index (BMI), alcohol use, and PA were 
used to characterize an ERLS. The ERLS was investigated in relation to overall 
postmenopausal breast cancer and by ER subtype, with consideration of potential effect 
modifiers. We aimed to answer the following questions under Aim #3: 
1. Is there an association between the ERLS and overall breast cancer risk among 
postmenopausal women? 
2. Which components of the ERLS are the strongest contributors to a potential 
association with breast cancer? 
3. Does the association between the ERLS and postmenopausal breast cancer vary 
by ER subtype? 
4. Is the association between the ERLS and postmenopausal breast cancer modified 
by other estrogen-related risk factors (e.g., parity, HRT)? 
 
1.3 Significance of the research 
 Previous research on the association between diet and breast cancer has been 
inconclusive. The research performed in this dissertation is innovative in that it addressed 
a disease mechanism specific to breast cancer by identifying a dietary pattern associated 
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with EMs. The association between the dietary pattern and breast cancer incidence was 
assessed using two large, federally-sponsored prospective cohort studies. The EM data in 
PLCO were generated using accurate and sensitive methods for assaying the low 
concentrations present in postmenopausal women, allowing for minor discrepancies in 
EM levels from dietary exposures to be quantified.41 The previously derived estrogen-
correlated dietary pattern has shown mixed but promising associations between diet and 
postmenopausal breast cancer.27,32 The methods employed in this dissertation are 
believed to have improved on the previous study by creating a newly derived pattern 
using different EMs, which may be more representative of breast cancer risk than the 
previously-used parent estrogens. Furthermore, a more sensitive assay was used in 
measurement of the EMs that may be particularly meaningful considering the low levels 
of EMs present in postmenopausal women. Evaluation of the ERDP in multiple study 
populations and as a part of the ERLS attempted to quantify the magnitude of the effect 
of estrogen-related nutritional factors on breast cancer in postmenopausal breast cancer. 
1.3.1 Public health impact 
In recent years, advances in the treatment of breast cancer have led to a substantial 
reduction in mortality rates.42 However, 1 out of every 8 women born in the U.S. will be 
diagnosed with breast cancer in their lifetime.2 As increasing worldwide industrialization 
and urbanization has resulted in rising global incidence rates, the need for primary 
prevention methods for breast cancer is of upmost importance.24 The collaborative 2012 
Breast Cancer Campaign, made up of over 100 international experts in breast cancer, 
identified the need for sustainable lifestyle prevention methods as one of the 10 most 
important gaps in translational breast cancer research.43 The results from this dissertation 
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contribute to the literature on dietary habits, alone and in combination with other lifestyle 
factors, with the intent to lower future breast cancer incidence among postmenopausal 
women.  
1.3.2 Role of diet in breast cancer is inconclusive 
 Results from research examining dietary exposures and breast cancer risk have 
been inconsistent, although a modest effect has been suggested.2,13,22 According to the 
WCRF/AICR, the only nutritional factors with conclusive or probable evidence of an 
association with postmenopausal breast cancer are alcohol consumption, body and 
abdominal fatness, and PA.13,24 There is suggestive evidence of an effect from starchy 
vegetables, foods containing carotenoids, and diets high calcium; however, the evidence 
and biologic plausibility are lacking.24 Studying associations between diet and breast 
cancer may be inconclusive due to the heterogeneity in disease characteristics for pre- 
and post-menopausal women and hormonal subtypes.22,44 
 However, it has been suggested that dietary habits and other lifestyle behaviors 
are often adopted together, and may have a collective effect on cancer risk.45,46 There is 
evidence that choosing to eat healthy foods together, thus improving overall diet quality, 
is associated with reduced cancer risk, such as with the Mediterranean diet 
(MeD).17,40,47,48 When higher dietary quality is measured by patterns based on 
associations with certain markers of disease risk, such as inflammation or estrogen 
metabolism, associations with breast cancer have been identified in some studies,27,49,50 
but not all.32,51 Together, the research indicates that when diet is evaluated as the sum of 
individual components, which likely interact with each other, a dietary influence on the 
development of breast cancer in postmenopausal women is more likely to be found than 
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when examining individual dietary factors. Individual components may influence disease 
risk in multiple different mechanistic pathways or by predominantly converging on a 
single pathogenic pathway.  
1.4 Study outline 
The overall goal of this dissertation was to investigate the relationship between 
diet and postmenopausal breast cancer, in addition to other lifestyle factors, with 
consideration of estrogen metabolism as a possible disease mechanism. The rationale and 
significance of the research proposed is outlined in Chapter 1.  Chapter 2 details the 
background for all of the potential relationships considered, as well as important 
confounders. The current knowledge on the associations between estrogen and breast 
cancer, diet and estrogen, and diet and breast cancer are presented, along with other risk 
factors for breast cancer, in Chapter 2. The background review served as the rationale for 
the methods proposed in Chapter 3. Descriptions of the study populations and the analytic 
approaches used can be found in Chapter 3. The results from each of the three 
dissertation aims are reported in Chapters 4, 5, and 6 separately. Those chapters are 
written in a manner so that each one represents a publishable manuscript. Chapter 7 is a 
synthesis of the three aims and discussion of the collective results.
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CHAPTER 2 
BACKGROUND 
2.1 Estrogen and breast cancer 
 There are a number of well-established risk factors for breast cancer that, when 
looked at collectively, highlight the presence of a hormonal influence on the development 
and prognosis of breast cancer.2,4,12,13 Menopausal status, age at menarche, parity, age at 
menopause, adiposity, and alcohol intake, to name a few, all have a commonality other 
than their association with breast cancer risk.4,52 These factors, described in more detail in 
section 2.4, have been shown to have a significant relationship with endogenous estrogen 
levels.4,12 For example, adipose tissue is recognized to have endocrine functionality and 
has been shown to promote the synthesis of estrogens via high expression of aromatase, 
especially in postmenopausal women.53–56 Estrogen itself, measured either in serum or 
urine, has repeatedly shown a positive association with postmenopausal breast cancer 
risk, as discussed below (section 2.1.3).11,35,57 Although estrogen is the strongest sex 
hormone correlate of breast cancer, there is evidence of an association with breast cancer 
for various other sex hormones, including androstenedione, dehydroepiandrosterone 
(DHEA) and testosterone.58–61  
The role of hormones in breast cancer risk extends beyond steroidal hormones. In 
addition to estrogen, adipose tissue has the capability of producing non-steroidal 
hormones, such as leptin and adiponectin, which can influence mammary carcinogenesis 
both directly and indirectly.62,63 Leptin has been shown to have a proliferative effect on 
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breast cancer cells through enhancement of multiple signaling pathways, whereas 
adiponectin has been suggested to down-regulate cell proliferation and even induce 
apoptosis.62,64 In addition, there are other breast cancer risk factors that are associated 
with important hormones other than estrogen in the development of cancer, such as 
prolactin in breastfeeding.13,65  
Perhaps the most compelling argument to characterize breast cancer as a disease 
of major hormonal influence is the recognition of four distinct molecular subtypes of 
breast cancers.66 Characterized by the presence of hormonal receptors for estrogen and 
progesterone (PR), in addition to levels of human epidermal growth factor 2 receptors 
(HER2), each molecular subtype differs with regard to incidence rates, risk profiles, and 
prognosis.2,67 The association between estrogen and many breast cancer risk factors, 
along with its influence on the way the disease manifests and progresses, highlight the 
importance of incorporating the extensive influence of estrogen in investigations of breast 
cancer.  
2.1.2 Laboratory methodology  
 The majority of epidemiologic research on estrogen metabolism in relation to 
breast cancer risk over the last 20 years was conducted using a radioimmunoassay (RIA) 
or an enzyme immunoassay (EIA).11,57,68 The RIA method is known as an extraction 
assay because it includes an extraction and subsequent purification step, but also requires 
a large volume of the serum sample, thus limiting its application.69 To help test the 
association with estrogen and breast cancer in large epidemiologic studies, EIA was 
developed because of its rapid and inexpensive application.11 The assay can be applied to 
both urine and serum samples and was called a “direct” assay because it did not involve 
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any purification or extraction steps in the process.68 Although useful in ranking 
individuals, EIA was inadequate for absolute measurements of hormones from samples.69 
A study evaluating EIA was able to show the method was reproducible in premenopausal 
women, with a coefficient of variation (CV) between 8-14% for urine samples.68 
However, when EIA was applied to urine samples from postmenopausal women the 
mean levels increased over 50% from the 4-month interval to the 12-month interval of 
reproducibility.68 Comparing against the standard at the time of publication, gas 
chromatography-mass spectrometry (GC/MS), EIA was shown to have a lower 
specificity and reproducibility.41,68 Quantitative comparison studies had shown that 
although they were sensitive among premenopausal women, RIA and EIA had poor 
specificity and accuracy, likely a result of cross-reactivity and batch-to-batch variation of 
the antibodies in the urine samples.70 Cumulative evidence clearly showed that more 
precise and accurate assay methods were needed to assess the relationship between 
estrogen metabolism and breast cancer, particularly among postmenopausal 
women.11,41,70,71 
 The use of GC/MS in large scale studies is impractical because of its cost and 
arduous application, however mass spectrometry assays have been shown to be most 
accurate and reproducible.70 Coupling the need for an inexpensive, accurate and 
reproducible method with the increasing recognition of the influence of estrogen 
metabolism in all its forms and pathways, liquid chromatography-tandem mass 
spectrometry (LC/MS-MS) was developed for urine and serum samples.41,70 Comparing 
urine samples from 430 women using EIA and LC/MS-MS, absolute concentrations of 2-
hydroxyestrone (2OHE-1) and 16-hydroxyestrone (16OHE-1) were consistently higher in 
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EIA.72 The difference of the assays by menopausal status was particularly striking, with 
mean concentrations for premenopausal 2-4 times higher and for postmenopausal 7-12 
times higher when comparing EIA to LC/MS-MS.72 
Using LC/MS-MS, researchers can concurrently measure 15 EMs in an accurate 
and reproducible method with enough sensitivity to detect the low levels present in 
postmenopausal women.11 In the nested case-control of postmenopausal women enrolled 
in PLCO used in the present proposal, blind quality control serum samples were shown to 
have a CV <5% for all 15 EMs using LC/MS-MS.35 Furthermore, the CV for the parent 
estrogens, estradiol and estrone, were <3% in the samples.35 In the previous study of an 
estrogen-correlated dietary pattern by Fung et al., the RIA method was utilized and only 
estradiol and estrone sulfate were assayed with reported CVs<15%.32 The LC/MS-MS 
method has been shown to have an intraclass correlation greater than 95% among 
postmenopausal women and the lowest limit of detection with reliable and reproducible 
estimates is between 1-2 pmol/L from serum samples.35,73,74 For reference, the measured 
levels of estradiol in postmenopausal women who are not currently undergoing HRT 
typically range from 0-117 pmol/L.69,75,76 The current and previously referenced evidence 
supports the use of LC/MS-MS as an accurate, sensitive, and reproducible method to 
measure EM in postmenopausal women. 
2.1.3 Evidence from observational studies 
 The precursors and downstream metabolites of estrogen have different 
physiologic effects as a result of their chemical structures.4 Both parent estrogens, 
estradiol and estrone, are derived from the sex hormone, androstenedione (Figure 3.1). 
Androstenedione can be directly aromatized in estrone, but requires an additional step to 
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synthesize estradiol.77 Androstenedione must first be reduced to testosterone, which can 
be subsequently aromatized to produce estradiol.77 Estrone can be converted to estradiol, 
the most biologically active estrogen, by the 17β-hydroxysteroid dehydrogenase 
enzyme.78 Once the parent estrogens have been synthesized, they may be metabolized 
down one of three, competing and irreversible pathways.4 The three pathways are 
characterized by the carbon position (2, 4, or 16) that is hydroxylated by the cytochrome 
P540 enzyme.4 The result of the hydroxylation produces catechol estrogens, which may 
undergo methylation to be further metabolized into methoxyestrogens.4   
 Early epidemiologic studies established a relationship between high levels of 
circulating estradiol and estrone with breast cancer in patients using case-control study 
designs.57 However, due to the potential for reverse causality, it was unclear whether the 
higher levels among cases were markers of disease risk or of the presence of disease. The 
estrogen hypothesis was studied further in large scale prospective studies, starting around 
1990.57 An international group called the Endogenous Hormones and Breast Cancer 
Collaborative Group (EHBCCG) conducted a meta-analysis of circulating hormones 
from nine prospective studies of postmenopausal women not using exogenous hormones, 
including 663 cases and 1765 controls.57 Results showed significant associations with 
breast cancer comparing the highest quintile to the lowest for all hormones (estradiol, free 
estradiol, non-sex hormone binding globulin (SHBG) bound estradiol, estrone, estrone 
sulfate, androstenedione, DHEA, DHEA sulphate, testosterone).57 Most effect estimates 
remained significant even after adjustment for estradiol, which was correlated with all 
hormones investigated.57 The highest effect estimates were for free estradiol (relative risk 
(RR): 2.58; 95% confidence interval (CI): 1.76-3.78) and non-SHBG (RR): 2.39, 95% 
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CI: 1.62-3.54).57 Apart from SHBG (RR: 0.66; 95% CI: 0.43-1.00), all associations were 
in the positive direction.57 The inverse association between SHBG and breast cancer risk 
is hypothesized to be a result of its role in reducing circulating bioavailable estradiol.8 
Since then, EHBCCG conducted an updated meta-analysis comparing results of eighteen 
different prospective studies with consideration of the assay method used, while 
excluding women currently taking exogenous hormones.69 The hormones of interest were 
estradiol, estrone, and testosterone. All 3 hormones, across all three assay methods 
(extraction, direct, and mass spectrometry), were significantly associated with 
postmenopausal breast cancer risk, with the exception of testosterone measured by mass 
spectrometry.69 Again comparing the highest quintile to the lowest, the effect estimates 
ranged from 1.46 to 2.46.69 Combining results from all assay methods, individuals in the 
highest quintiles experienced around twice the risk compared to the lowest quintile for 
estradiol (RR: 2.15; 95% CI: 1.87-2.46), estrone (RR: 1.81; 95% CI: 1.56-2.10), and 
testosterone (RR: 2.04; 95% CI: 1.76-2.37).69 Since the most recent EHBCCG meta-
analysis has been published, results from three prospective studies of postmenopausal 
women using LC/MS-MS have corroborated their results for the parent estrogens (estrone 
and estradiol), with unconjugated estradiol consistently showing the largest magnitude of 
an effect on breast cancer risk.35,79,80 Data from the nested PLCO study to be used in the 
present proposal showed a doubling of risk comparing the highest and lowest decile for 
unconjugated estradiol (hazard ratio (HR): 2.07; 95% CI: 1.19-3.62) using serum 
samples.35 
 While there is an established relationship between circulating parent estrogens 
and breast cancer risk among postmenopausal women, there is not as much research on 
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other estrogen metabolites, partly due to limitations of previous laboratory assay 
methods.11,57 As previously stated, the parent estrogens may be hydroxylated down one of 
three different metabolic pathways.11 It has been hypothesized that shifts in these 
competing pathways may influence breast cancer risk.11 Initial research in a case-control 
study had shown that breast cancer patients had 60% higher circulating levels of 16OHE-
1 than controls, whereas 2OHE-1 and 4-hydroxyestrone (4OHE-1) levels were similar 
across the two groups.11 Further research concluded the 2OHE-1 and 16OHE-1 were 
competing metabolic pathways representative of breast cancer risk, with women having a 
higher ratio of 2OHE-1 to 16OHE-1 (2/16 ratio) experiencing reduced risk of breast 
cancer.11 Results of studies investigating the 2/16 ratio using EIA were inconsistent.11  
However, in studies using the advanced LC/MS-MS to measure estrogen 
metabolism in postmenopausal women, results have more consistently shown a reduction 
in risk with increasing 2/16 ratio when looking at all estrogen metabolites combined, not 
only estrone and its hydroxylated forms.35,79,80 In a nested case-control study from the 
Columbia Missouri Serum Bank (CMSB), comparison of 215 postmenopausal cases and 
215 matched controls yielded a non-significant reduction in risk for the 2/16 ratio (odds 
ratio (OR): 0.63; 95% CI: 0.35-1.12) comparing the highest to the lowest quintiles.80 Data 
from a larger case-cohort from the Breast and Bone Follow-up to the Fracture 
Intervention Trial (B~FIT), including 407 postmenopausal cases and 487 controls, 
identified a significant difference in risk comparing the highest and lowest quintile for the 
total 2/16 ratio from serum samples.79 Women in the highest quintile had a 40% 
reduction in risk of breast cancer (HR: 0.60; 95% CI: 0.40–0.90).79 In PLCO’s nested 
case-control study, a similar reduction in risk was observed across the interdecile range of 
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the 2/16 ratio before adjustment for unconjugated estradiol (HR: 0.62; 95% CI: 0.45-
0.86) and retained a similar magnitude of association, although insignificant, after 
adjustment (HR: 0.69; 95% CI: 0.47-1.02).35 
 The ratios of other EMs have also been investigated after the advent of LC/MS-
MS. While results have been inconsistent with regards to statistical significance, the 
direction of the effects has been consistent throughout all three LC/MS-MS studies.11 In 
addition to the 2/16 ratio, there is evidence the 2/parent estrogen ratio is associated with 
reduced risk in postmenopausal women.35,79,80 In the CMSB study, the 2/parent ratio 
yielded a non-significant reduction in risk (OR: 0.63; 95% CI: 0.35, 1.12).80 Similarly, 
results from B~FIT showed a non-significant reduction in risk of a similar magnitude 
(HR: 0.69; 95% CI: 0.46-1.05), but the test for trend was statistically significant 
(p=0.01).79 In the PLCO population to be used in the present analysis, the 2/parent ratio 
was associated with reduced risk before (HR: 0.66; 95% CI: 0.51-0.87) and after (HR: 
0.72; 95% CI: 0.52-1.00) adjustment for unconjugated estradiol.35 In fact, data from 
PLCO yielded significant effect estimates for both the 2/16 and 2/parent ratios, but not 
unconjugated estradiol, when all three were entered into the model at once.35 In the same 
PLCO study, the ratio of the 4-catechols to the 4-methylated catechols (4/4-methylated) 
was positively associated with postmenopausal breast cancer.35 This supports laboratory 
evidence indicating the instability of 4-cathechol DNA adducts can be blocked by 
methylation.81 However, other observational evidence has failed to support the findings 
from PLCO.11 
 
 
 19 
2.1.4 Potential mechanisms 
 Collectively, the results from epidemiologic studies suggest increased circulating 
parent estrogens, particularly estradiol, is associated with an increase in postmenopausal 
breast cancer risk. Furthermore, it appears that enhancement of the 2-hydroxylation 
pathway, compared to both the 16-pathway and parent estrogens, is characteristic of a 
reduction in the risk of postmenopausal breast cancer. The mechanisms behind the 
influence of estrogen on breast cancer risk are not completely understood, and may act 
both independently and dependently through their receptors.8 There is evidence of 
carcinogenic effects of estrogen in mammary tissue through multiple pathways from 
animal and human studies.4,8,82,83 Treatment of mice with estrogen has been shown to be 
positively associated with mammary tumors.82 In mature human breast tissue, there is 
evidence estrogen increases the rate of cellular proliferation.8,83 In vivo and in vitro 
studies have shown downstream that metabolites of estrogen can lead to unstable adducts 
of adenine and guanine in DNA, consequently leading to mutations.82 Conversely, other 
quinones produced in estrogen metabolism can establish a redox cycle, resulting in 
reactive oxygen species that can have detrimental oxidative effects on DNA.8 
 A pathway-specific investigation of estrogen metabolism may help to elucidate 
how the metabolite ratios can potentially affect breast cancer risk. The increase in 
2/parent and 2/16 ratios are indicative of a possible protective effect of metabolites in the 
2-hydroxylation pathway.4,8,82 The downstream 2-hydroxylated metabolites have been 
shown to have a lower affinity for estrogen receptors, possibly due to a decreased 
hormonal effectiveness compared to estradiol.4 There is some evidence that metabolites 
in the 2-hydroxylation pathway inhibit cellular growth and proliferation and are 
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associated with apoptosis.4 On the contrary, metabolites from the 16-hydroxylation 
pathway have been shown to exhibit carcinogenic and genotoxic properties.84 Mouse 
models with treatment of 16OHE-1 have resulted in spontaneous DNA synthesis in 
mammary epithelial cells.4 Additionally, cancerous mammary tissue has been reported to 
have nearly eight times the amount of 16OHE-1 compared to fat tissue in the breast.4 The 
competing nature of the 2- and 16-hydroxylation pathways, and their relative cellular 
effects, can help to explain why higher 2/16 and 2/parent ratios are associated with a 
reduction in postmenopausal breast cancer risk. 
  
2.2 Diet and estrogen 
 In order to reduce the incidence of postmenopausal breast cancer, it is imperative 
to identify primary prevention methods, such as dietary intervention targets. While 
circulating levels of estrogen are an established risk factor, and many other risk factors 
are associated with estrogen metabolism, the evidence of a link between diet and estrogen 
is scarce.2,13 The hypothesized relationship between diet and estrogen first originated in 
an attempt to explain results from ecological and migrant studies. Women from Eastern 
regions of the world experience much lower rates of breast cancer than Western women, 
possibly due to vast differences in diet.85 When women migrate to the U.S., their disease 
risk begins to parallel that of U.S. born women.86,87 A comparison of White U.S. women 
with Asian immigrants reported a 3-fold increase in plasma estradiol and lower fecal 
excretion of estrogen among Whites, hypothesized to be reflective of differences in diet.88 
Supporting literature on diet and estrogen metabolism is scarce, highlighting the need for 
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more investigations into the effects of single dietary components as well as dietary 
patterns on EMs.  
2.2.1 Single dietary components and estrogen 
One of the earliest published studies of diet and estrogen investigated differences 
in plasma, fecal, and urinary excretions between vegetarians and omnivorous women.89 
Over 4 months of follow-up, fecal excretion of estrogen was higher among vegetarians 
(p<0.001), and plasma estrone and estradiol levels were negatively correlated with fecal 
excretion of estrogen (p=0.005).89 The researchers concluded that a vegetarian diet that 
led to larger excretion of estrogen, and subsequently lower plasma levels of estrogen, 
may be reflective of low intakes of fat and high fiber. Investigations of animal products in 
relation to estrogen metabolism support a positive relationship between fat intake and 
estrogen. A cross-sectional study of 766 postmenopausal women reported 13% lower 
mean plasma levels of SHBG in women in the highest quartile of red meat consumption 
compared to the lowest, with a significant test for trend (p<0.01).90 Women in the highest 
quartile of dairy product consumption from the same study had 15% and 14% higher 
levels of total and free estradiol compared to the first quartile, again with significant 
trends (p=0.02 and p=0.03, respectively).90 The observed association may be a result of 
the hormones that are present in the milk consumed, however, it has been suggested that 
the levels in milk are too low to have a physiological effect and may become inactive 
following digestion.91,92 
Regarding dietary fiber, a mostly consistent inverse association with circulating 
estrogen has been shown in premenopausal women.93–98 In postmenopausal women, 
however, the evidence of an association is not as strong. A study of 291 women in a 
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dietary intervention trial reported reduced serum bioavailable estradiol (p<0.01) and total 
estradiol (p <0.05) concentrations as a result of increased fiber intake after one year of 
follow-up.99 Using data from Hispanic women in the Multiethnic Cohort study (MEC), 
differences of -22% (p=0.023) and -17% (p=0.045) for serum estrone and estradiol, 
respectively, were observed when comparing postmenopausal women in the highest 
quintile of fiber intake to the lowest.100 It has been hypothesized that steroid hormones 
bind to certain types of fiber, which could also explain the increased fecal excretion of 
estrogen among vegetarians.89,101 However, results from larger observational studies, 
mostly of cross-sectional design, have reported no association between dietary fiber and 
estrogen or other hormones.102–106  
One of the more frequently studied dietary components in relation to estrogen is 
fat intake because of the established relationship between adipose tissue and estrogen 
synthesis. Results from intervention studies in postmenopausal women reported a 
significant reduction of plasma estradiol after lowering dietary fat,107 a reduction in 
estradiol after a low-fat, high carbohydrate diet,108 and lowered urinary excretion of 
estrone after participation in a low-fat intervention with high ω-3 fatty acid intake.109 In a 
subset of postmenopausal women with plasma samples from the Women’s Health 
Initiative (WHI) Dietary Modification Trial, which was designed to assess the 
relationship between a low-fat diet and breast cancer risk, a reduction of estradiol 
(relative change in geometric mean: 0.85; 95% CI: 0.72-1.00) and increase in SHBG 
(relative change: 1.09; 95% CI: 1.03-1.16) was observed among the intervention 
group.110 A meta-analysis of 13 low-fat intervention studies reported a pooled estimate of 
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a 23% reduction (95% CI: 18.1%-27.7%) in circulating estradiol post baseline among 
postmenopausal women in the intervention groups.111  
Results of observational studies examining associations between dietary fat and 
estrogen have been less conclusive. Cross-sectional studies have repeatedly shown no 
association between dietary fat intake and hormonal concentrations in postmenopausal 
women.103,104,112,113 It is possible that weight loss mediated the association between a 
decrease in dietary fat and circulating estrogen observed in intervention studies. 
However, a cross-sectional analysis from the NHS reported 4.3% lower plasma estradiol 
(95% CI: 0.2%-8.3%) for every 5% decrease in energy from fat intake among 384 
postmenopausal women.102 In a Japanese study of postmenopausal women, baseline 
serum estrone was positively associated with baseline percentage of calories from total 
fat intake (p=0.04), and borderline significantly associated with monounsaturated fat 
(MUFA) and polyunsaturated fat (PUFA) (p=0.05 for both) intakes.114 The same study 
reported significant positive associations between DHEAS from serum samples with 
percentage of energy from total fat (p=0.007), saturated fat (SFA) (p=0.009), MUFA 
(p=0.006), and PUFA  (p=0.04).105,114 Although a relationship between dietary fat and 
estrogen is still inconclusive, it is possible an observed association is a combination of 
effects from weight loss, reduced animal product intake, and increased fiber from plants.  
In addition to vegetarianism or increased fiber from plants, other plant products 
have been associated with estrogen metabolism. Indole-3-carbinol (I3C), abundantly 
found in cruciferous vegetables, has displayed anti-estrogenic properties.115,116 
Consumption of I3C extracts in 10 women for 2 months resulted in a 0.26 
nmol/mmolcreatine decrease (95% CI: 0.06 to 0.46) in urinary estradiol after 
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intervention.117 Decreases were also seen in  estrone, estriol, and 16OHE-1 along with an 
increase in 2OHE-1, indicative of a beneficial alteration in estrogen metabolism.117 An 
intervention study of cruciferous vegetables, particularly broccoli, found a 0.08 increase 
(95% CI, 0.02–0.15) in the 2/16 ratio from urine samples for each 10-g/day increase in 
cruciferous vegetables, showing a beneficial shift in estrogen metabolism.118 In another 
intervention study of 13 premenopausal women, consumption of a powder from dried 
cruciferous vegetables increased the mean 2/16 ratio from 1.25 to 2.28 (p=0.01) using 
urine samples.119 This association with serum or urinary estrogens has failed to be 
replicated in epidemiologic studies, likely due to the low consumption levels of 
cruciferous vegetables in some populations.120 However, in studies of tumor cells there is 
evidence that cruciferous vegetables can shift estrogen metabolism in a favorable manner, 
particularly in reference to the 2-hydroxylation pathway.121 The shift towards the 2-
hydroxylation pathway is possibly a change in the relative production of cytochrome 
P540 proteins, resulting from exposure to I3C, which influences the metabolic pathways 
of the parent estrogens.8,122 
 As a result of the drastic differences in breast cancer rates among Asian countries 
and the U.S., and the relative differences in diet, soy intake has been hypothesized to 
beneficially affect estrogen metabolism.88,123,124 Isoflavones, a type of phytoestrogen 
contained in soy, may alter endogenous estrogen metabolism and have the ability to bind 
to estrogen receptors.125 In experimental studies of premenopausal women, those 
consuming increased soy products had decreased urinary estradiol, estrone, 16OHE-1, 
and a significant increase in 2OHE-1.126,127 However, an intervention study of 97 
postmenopausal women reported no change among urinary SHBG or estradiol after 
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consuming a high-soy diet for four weeks.128 Collective evidence from a meta-analysis of 
intervention studies concluded no statistically significant effects of soy or isoflavone 
consumption on levels of estrone or SHBG among postmenopausal women, with similar 
results among premenopausal women.129 A modest, non-significant increase in estradiol 
in the soy consumption groups (14%, p = 0.07) was reported. It is possible the null results 
were due to a failure to take into account the assay used to measure estrogen in the 
pooled analysis, and the authors used a funnel plot to show studies finding extreme 
increases or decreases in estradiol may have been excluded from their analysis.129 
Data from observational studies regarding soy intake and estrogen metabolism are 
limited. A cross-sectional study of Asian-American women reported significant 16% 
higher urinary levels of 2OHE-1 (ptrend=0.02) accompanied by 11% lower levels of 
16OHE-1 (ptrend<0.01) comparing the highest versus lowest tertiles of soy 
consumption.130 Results from another study among postmenopausal Chinese women 
showed 15% lower plasma levels of estrone among the highest quartile of soy consumers 
compared to the lowest.112 In a study of predominantly White, British women, no 
association was found between plasma EMs and soy milk intake for pre- and post-
menopausal women.131 There is evidence of a reduction in estradiol which depends on the 
presence of certain polymorphisms, suggesting a gene-diet interaction which could help 
to explain the differences observed by race/ethnicity.132 It has also been hypothesized the 
large discrepancies in intake and lifetime exposure to soy explain the differences 
observed between Asian and non-Asian populations.124  
Alcohol intake, another dietary factor that could explain the large differences in 
breast cancer incidence rates across the world, has strong evidence of an association with 
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estrogen metabolism.2,12,133,134 A positive association between alcohol intake and 
circulating levels of hormones has been demonstrated in premenopausal women.135,136 In 
a six-month cross-over trial of 34 premenopausal women, 30 g/day ethanol intake was 
associated with increased levels of urinary estrone by 15.2% (p=0.05), estradiol by 21.6% 
(p=0.02), and estriol by 29.1% (p=0.03).137 In a prospective study of 66 premenopausal 
women, a modest but significant positive association was observed using Spearman 
correlation coefficients (r=0.29; p<0.05) between alcohol intake and serum estradiol 
concentrations.138 There has been some evidence of a stronger effect among women using 
oral contraceptives (OC).139 Studies of postmenopausal women have been more 
inconsistent.135,140–142 In a randomized, controlled 6 week cross-over trial in which 40 and 
30 g of alcohol consumption per day for men and women, respectively, for three weeks 
was compared to a three week abstinent period, plasma DHEAS increased but estradiol 
was not affected by alcohol intake, among 10 postmenopausal women.143 In the 
reanalysis of 13 studies of postmenopausal women, all hormones measured were 
positively associated with at least 20 g/day of ethanol, with the highest difference in 
mean concentrations observed for DHEA sulphate (25%; p<0.001) compared to women 
who abstained from drinking.12 Using data from nearly 2000 women enrolled in the 
European Prospective Investigation into Cancer and Nutrition (EPIC), pre- and 
postmenopausal women who consumed at least 25 g/day of ethanol had nearly 40% 
(p<0.001) and 20% (p<0.001) higher serum concentrations of estrone, respectively, 
compared to non-consumers.136 Similar to a potential effect modification by OC in 
premenopausal women, there is evidence of a stronger association between alcohol intake 
and breast cancer among HRT users.135 
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2.2.2 Dietary patterns and estrogen 
 The literature on dietary patterns and estrogen metabolism are scarce, but there is 
some evidence of an association. Dietary data from postmenopausal women enrolled in 
the NHS showed associations with sex hormones in a cross sectional analysis of dietary 
patterns.144 The Alternate Healthy Eating Index (AHEI), an a priori dietary pattern based 
on the USDA’s DGA, was inversely associated with plasma estradiol (p<0.001) and 
positively associated with SHBG (p=0.01).144 The results indicate a beneficial effect of 
better diet quality on estrogen metabolism, although results were attenuated after 
adjustment for BMI (p=0.08 and p=0.37, respectively).144 Using principal component 
analysis to derive a posteriori patterns, the prudent pattern, characteristic of intake of 
plant products and whole grains, was not associated with EM.144 The Western pattern, 
comprised of processed foods and animal products, was inversely associated with SHBG 
(p=0.008) before adjustment for BMI, but not after adjustment.144 The Western pattern 
also was positively associated with total (p=0.01) and free (p=0.006) estradiol, but after 
adjusting for BMI, only the association with free estradiol remained statistically 
significant (p=0.03) when comparing the highest and lowest quintiles of the dietary 
pattern score.144 The association for the Western pattern was replicated in a case-control 
of Mexican women, with authors reporting a 16.2% increase in the serum concentrations 
of free estradiol (β=0.15; 95% CI: 0.01-0.29) for every 1-unit increase in the dietary 
pattern score.145 Although premenopausal women may be less sensitive to dietary 
estrogenic effects due to their higher mean circulating estrogen concentrations, an NHS 
investigation observed associations for the AHEI.146 Women in the highest quartile of the 
AHEI had lower mean plasma levels of total estradiol (-6.7 %; 95% CI: -14.3% -1.5%; 
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ptrend=0.04) and androstenedione (-7.8%; 95% CI: -15.4%-0.4%; ptrend=0.03) compared to 
the first quartile, although no associations were evident for adherence to the Dietary 
Approaches to Stop Hypertension (DASH) or the alternate Mediterranean Diet 
(aMeD).146 The (MeD) and its alternate form (aMeD) are based on the dietary 
characteristic of people living in that region, as opposed to dietary guidelines like the 
previously mentioned a priori indices. The MeD is usually high in fruits and vegetables, 
legumes, oils, and other foods that result in a higher proportion of MUFA and PUFA 
compared to saturated fats.47 While the previously mentioned study reported no 
association for the aMeD, an intervention study using the MeD reported a roughly 40% 
decrease in total urinary estrogen levels (p<0.02) in postmenopausal women, showing 
some anti-estrogenic properties.147 Collectively, the published results show some 
evidence of associations between dietary patterns and estrogen metabolism, although 
results have been inconsistent. 
 
2.3 Diet and breast cancer 
 An important lifestyle contributor to disease is diet, which has been estimated to 
be the second most preventable cause of cancer.148 Prior research has indicated that 32% 
of all cancers may be avoided through proper dietary modification, with at least 1 in 5 
cancer deaths preventable through diet.149 However, cancers of differing anatomical sites 
are different diseases, as is their etiology. Information on lifestyle prevention measures, 
including diet, has been identified as one of the ten most important gaps in translational 
breast cancer research.43 Although much of the research into diet and breast cancer has 
been inconclusive, it may be due to the heterogeneity of cancer subtypes, or due to the 
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relatively small effects from single dietary components, that may be magnified when 
studying diet holistically.  
2.3.1 Single dietary components and breast cancer 
 According to the most recent 2017 Continuous Update Project (CUP) of the 
WCRF/AICR’s Second Expert Report, alcohol intake is the only dietary factor designated 
to have a “convincing” association with an increased risk of breast cancer.24 The report 
cited a recent meta-analysis of 22 prospective cohort studies, identifying an 9% increase 
in postmenopausal breast cancer for every 10g of ethanol consumed each day.24 In an 
additional pooled analysis of including over 33,000 incident breast cancer cases, a 
significant increase in risk of 11% per 10g ethanol consumed per day was identified.24 In 
analyses stratified by hormone receptor status, a meta-analysis of six studies did not find 
an association with ER-/PR- breast cancer.24 However, for every 10g in ethanol 
consumption per day, increased risks of 6% and 12% were seen for ER+/PR+ and 
ER+/PR-, respectively.24 
 Animal and cell culture models provide evidence that ethanol metabolites enhance 
mammographic carcinogenesis.24,135 It has been suggested that derivatives of alcohol act 
as a carcinogen, increasing DNA damage in breast tissue.135 Alcohol also may promote 
the movement of other carcinogens into cells within the breast due to its ability to act as a 
solvent for other molecules.24 Characteristics of the diets of high alcohol consumers are 
likely to contribute to the development of cancer, as they are typically deprived of certain 
essential nutrients that can subsequently increase the susceptibility of cells to the effects 
of carcinogens.24 Based on the CUP’s summation of observational studies and the 
aforementioned biologic plausibility, the WCRF/AICR has concluded that alcohol intake 
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has a convincing positive association with breast cancer risk, including sufficient 
evidence of a dose-response relationship, although no threshold in risk has been 
identified.24 Furthermore, the previously described epidemiologic evidence of the 
estrogenic properties of alcohol intake in section 2.2.1 support the hypothesis of estrogen 
metabolism mediating the association between alcohol intake and breast cancer. 
Evidence of an inverse association between dietary fiber and estrogen 
metabolism, outlined in section 2.2.1, has supported the hypothesis of an association 
between dietary fiber and breast cancer risk. Data from case-control studies have reported 
a reduction in risk with increasing fiber intake, but overall evidence is inconclusive 
according to the WCRF/AICR.24 One meta-analysis of 16 prospective studies reported a 
reduction in risk among the highest consumers compared to the lowest for total dietary 
fiber (RR: 0.93; 95% CI: 0.89-0.98).150 Similar reductions in risk were observed for fruit 
fiber, vegetable fiber, and cereal fiber, but the authors reported no association for 
insoluble fiber.150 The associations observed between dietary fiber may be a result of 
facilitated excretion of estrogen, or it could be due to the high correlation between fiber 
with fruit and vegetable intake. Currently, the WCRF/AICR has concluded there is 
limited evidence to suggest an association between fruit and vegetable intake with 
postmenopausal breast cancer risk.24 In the 2017 CUP report, however, there is 
suggestive evidence that non-starchy vegetables are associated with decreased risk of ER- 
subtypes, only.24 A pooled analysis of over 35,000 cases showed a 18% decrease in risk 
of developing ER- subtypes when comparing the highest quintile of non-starchy 
vegetables intake compared to the lowest.24 Data from the EPIC study reported no 
association for fruits, but observed a significant inverse association between vegetable 
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intake and overall breast cancer when comparing the highest and lowest quintiles (HR: 
0.87; 95% CI: 0.80, 0.94), with the strongest association observed for ER-/PR- breast 
cancer cases (HR: 0.74; 95% CI: 0.57, 0.96).151 An investigation in to the Italian section 
of EPIC, identified a significant inverse association comparing the highest and lowest 
quintiles of consumption for total vegetables (HR: 0.65; 95% CI: 0.53-0.81) and for leafy 
vegetables (HR: 0.70; 95% CI: 0.57-0.86).152 A meta-analysis of 15 prospective studies 
identified a significant association for fruits and vegetables combined (HR: 0.92; 95% CI: 
0.86-0.98) but not vegetables alone when comparing the highest and lowest quintiles of 
intake.20 A subgroup analysis of postmenopausal women identified an inverse association 
for fruits only (RR: 0.89; 95% CI: 0.83-0.95), but not for vegetables or their 
combination.20 A more recent pooled analysis of nearly 1,000,000 women reported no 
associations between fruits and vegetables, only fruits, or only vegetables with overall 
breast cancer.153 However, when only considering ER- breast cancer cases a significant 
inverse association between the highest and lowest quintiles of vegetable intake was 
identified (RR: 0.82; 95% CI: 0.74-0.90).153 Stronger associations were observed in 
premenopausal women.153 One explanation for the inconclusive results is the method of 
consumption. Fruits are almost always consumed raw, but vegetables are cooked in a 
variety of ways that may alter the availability of constituents that influence breast cancer 
risk.154 
The 2017 CUP report has designated foods high in carotenoids with a “limited – 
suggestive” association with a decrease in breast cancer risk.24 A meta-analysis of 9 
studies showed an 18% decrease in risk of breast cancer per 100 μg/dL of circulating 
carotenoids, however the report also cited a meta-analysis of 18 studies that found no 
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association with dietary beta-carotene.24 In addition to non-starchy vegetables and foods 
high in carotenoids, diets high in calcium have “limited – suggestive” designation for an 
association with breast cancer.24 Six of seven studies cited in the CUP reported an inverse 
association with postmenopausal breast cancer.24 In a dose-response meta-analysis, a 300 
mg increase of dietary calcium was associated with a 4% reduction in risk.24 Although 
mechanisms are unclear, it likely has to do with the prominent role of calcium in cellular 
signaling that can influence proliferation and apoptosis.155 
 Many other dietary factors have been deemed to have a “limited – no conclusion” 
designation with respect to the development of postmenopausal breast cancer in the 
WCRF/AICR’s CUP.24 Dietary fat has been frequently studied with regard to increasing 
risk of breast cancer, yet the evidence has been inconclusive.2 A meta-analyses from over 
140 mice studies concluded dietary fat promoted mammary carcinogenesis independent 
of total energy intake.156,157 However, results from observational evidence have failed to 
support the animal models.158 The 2010 CUP report on breast cancer based its “limited” 
designation for dietary fat on evidence from 10 cohort studies and 16 case-control 
studies, with no updates in the 2017 report.24,159 Separate meta-analyses for the cohort 
and case-control studies included in the report yielded a non-significant and significant 
positive association for total dietary fat and postmenopausal breast cancer, 
respectively.159 Of  six cohort studies investigating percentage of total energy intake from 
fat, the majority reported a decrease in risk, but one study reported a significant positive 
association with postmenopausal breast cancer risk.159 In the WHI Dietary Modification 
Trial, in which the intervention group was meant to reduce fat intake by 20%, no 
significant difference in risk of postmenopausal breast cancer was seen after 8 years.110 
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However, among women who consumed at least 36.8% of all energy from fat at baseline, 
a significant decreased in risk was seen in the intervention group compared to controls 
(HR: 0.78; 95% CI: 0.64-0.95).110 According to the authors, the HR estimates and upper 
bound of the CI lowered when accounting for greater adherence to the intervention, 
suggesting the presence of an association.110 If there is a true association between dietary 
fat and breast cancer risk, it has been proposed that dietary fat may work through an 
influence on estrogen metabolism.111 
 The bulk of evidence from studies of intakes of different types of fatty acids, 
rather than total fat, has yielded similar inconclusive results. A cohort of nearly 50,000 
women identified no association when examining SFA, MUFA, and PUFA in relation to 
overall breast cancer risk.160 However, when only considering women over the age of 50, 
most of whom were presumably postmenopausal, women in the highest MUFA and 
PUFA quintile intake experienced less incidence of breast cancer compared to the lowest 
quintile (HR: 0.45; 95% CI: 0.25-0.99 and HR: 0.54; 95% CI: 0.35-0.85, respectively).160 
Inverse associations between PUFA intake and breast cancer risk have been observed, but 
results are inconsistent.161,162 Women enrolled in EPIC who were in the highest 
consumption quintile of SFA had 13% increased risk of breast cancer compared to the 
lowest quintile (HR: 1.13, 95% CI: 1.00-1.27; ptrend=0.038).
163 Meta-analyses of MUFA 
and breast cancer have reported both positive164 and inverse associations with breast 
cancer risk.165,166 The sources of the MUFA may be one reason for the inconsistencies.162 
Studies of fat from animal sources in association with breast cancer have also been 
inconclusive.23   
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 Consumption of soy foods has been associated with reduced risk of breast cancer, 
however results across different study populations have been inconsistent.167 Two 
different recent meta-analyses identified 35 and 14 studies investigating an association 
between soy and breast cancer.168,169 The former identified a significant inverse 
association comparing the highest consumption groups to the lowest groups (RR: 0.89; 
95% CI: 0.79–0.99).169 When stratified by the origin of the study population, the 
association remained significant for Asian countries (RR: 0.76; 95% CI: 0.65–0.86) but 
not in Western study populations (RR: 0.97; 95% CI: 0.87–1.06).169 The other analysis 
based on a smaller number of studies, stratified by menopausal status and reached the 
same conclusion for both pre- (OR: 0.59, 95%CI: 0.48-0.69) and post-menopausal Asian 
women (OR: 0.59, 95% CI: 0.44-0.74).168 In Western populations, results from 
premenopausal women were not significant and postmenopausal women exhibited an 
inverse association nearing significance (OR: 0.92; 95% CI: 0.83-1.00).168 Another 
literature review concluded there was no association between breast cancer and soy 
consumption in Japanese women.170 The differences in the associations observed between 
Asian and Western study populations is most likely driven by the relative intakes of soy 
foods, which is much more common among Asian countries.167 It also has been 
hypothesized that early life exposure to soy may be more important than intake in 
adulthood.132,167 As mentioned in section 2.2.2, it is possible genetic polymorphisms 
affect the relationship between soy intake and breast cancer risk, through modulation of 
soy’s effect on estrogen metabolism.124   
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2.3.2 Dietary patterns and breast cancer 
 As shown in section 2.3.1, for many nutrients and dietary components there is 
inconclusive evidence of an association with breast cancer risk. It is possible the 
uncertainty in the hypothesized relationship between breast cancer and diet is due to the 
complex interactions that occur in reality when combinations of foods and nutrients are 
consumed. The USDA’s DGA called for a focus on dietary patterns because “the totality 
of diet […] may have synergistic and cumulative effects on health and disease.”171 
Dietary pattern analyses incorporate the potential for this web of influence by assessing 
diet in its entirety, accounting for multiple foods consumed, rather than singular specific 
components. Therefore, dietary pattern analyses may detect a dietary effect on breast 
cancer due to the combinations of foods, that is not seen when studying isolated 
components. However, similar to single nutritional factors, the evidence of an association 
between dietary patterns and breast cancer has been inconclusive.17,18,21,39,40,172  
There are two prevailing methods used in dietary pattern analyses.173 Data-driven 
patterns, or a posteriori, are empirically determined from each study population in which 
the analysis occurs.26,173,174 Within data-driven patterns, methods can be further 
delineated by the outcome-dependent or -independent properties of the approach.26,173,174 
Contrastingly, investigator-defined patterns, or a priori, are based on hypotheses of diet-
disease relationships or on certain guidelines that constitute a healthy diet, before any 
analysis occurs.26,173,174 It is possible that the inconsistency of associations between 
dietary patterns and breast cancer is a result of the high heterogeneity in applied 
methodologies to derive and study dietary patterns. 
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 In studies of breast cancer and data-driven dietary patterns, the “Western” or 
“unhealthy” pattern is often hypothesized to increase the risk of breast cancer because it 
is typically characterized by high intakes of animal products, refined grains, and sugars. 
One meta-analysis did not identify an association,18 however multiple reviews and 
original research articles have supported evidence for a positive association with breast 
cancer.17,18,36,175–178 Among studies reporting no association between the “Western” 
pattern and overall breast cancer, multiple studies identified a significant positive 
relationship when limiting to postmenopausal,36,177–179 ER+,177,180 or normal weight 
women.180 The “prudent” or “healthy” dietary pattern with high intakes of fruit and 
vegetables, whole-grains, legumes, olive oil and fish, has shown a more consistent 
association with evidence of a reduction in risk.17,18,21,28,177,181 Similar to the “Western” 
pattern, some studies suggest the magnitude of the association is strongest in 
postmenopausal21,182 or normal weight women,38,183 or with ER+ subtypes.37 When 
looking at only vegetarians and non-vegetarians, no significant difference in risk has been 
suggested.123,184 Using data from the EPIC-Potsdam study, a dietary pattern was derived 
using RRR to explain variation in fatty acid intake (SFA, MUFA, ω-3 PUFA, ω-6 
PUFA).185 Women in the highest tertile of the pattern had twice (HR: 2.00; 95% CI: 1.30 
– 3.09) the risk of developing breast cancer, with no effect modification by menopausal 
status.185 
 The heterogeneity of food groups identified in the “Western” or “prudent” 
patterns is shared in development of a priori patterns. Although they differ in what 
constitutes a healthy diet or are aimed at prevention of different diseases, some evidence 
of associations with breast cancer have been shown. Typically, higher scores on these a 
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priori patterns correlate with high intakes of fruits, vegetables, legumes, whole grains, 
and seafood. Contrastingly, low scores correlate with high intakes of red meat, highly 
processed foods, including refined grains, and other animal products. In addition to the 
AHEI, common a priori dietary patterns are the Recommended Food Score (RFS) which 
is based on current intake guidelines in the U.S., and the Diet Quality Index Revised 
(DQI-R) from the National Research Council. AHEI, which was inversely associated 
with estrogen, also was inversely associated with postmenopausal breast cancer (HR: 
0.78;95% CI: 0.59-1.04; ptrend=0.01) when comparing across quintiles, but not for overall 
breast cancer.186 Another study also reported no association between the AHEI and 
overall breast cancer risk, however they did not stratify by menopausal status.187 
Similarly, the association for the RFS (HR: 0.69; 95% CI: 0.51-0.94) with 
postmenopausal breast cancer was only present among ER- cases.188 Although they were 
not statistically significant, associations with the AHEI and RFS with overall 
postmenopausal breast cancer showed a consistent inverse association.186–188 The DQI-R 
was not associated with breast cancer except women with genetic predispositions to 
breast cancer.187,188 Although the majority of studies using dietary patterns based on 
guidelines failed to find statistically significant associations, all have shown inverse 
associations, suggesting overall diet quality may reduce the risk of breast cancer. 
Selection of foods that are hypothesized to have an effect on breast cancer in an a priori 
pattern, and not necessarily foods that constitute an overall healthy diet, may result in 
stronger associations. 
 Like the AHEI, the previously described MeD has exhibited anti-estrogenic 
effects,147 and is inversely associated with many chronic diseases.189 One recent review 
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reported weak evidence of an association between MeD and breast cancer from 
observational studies.40 However, a meta-analysis of 23 observational studies reported an 
inverse association (RR: 0.93; 95%: CI 0.87-0.99).190 In the NHS, the aMeD was only 
statistically significant for ER- breast cancer among postmenopausal women comparing 
the highest quintile to the lowest (HR: 0.79; 95% CI: 0.60-1.03; ptrend=0.03).
188 In a 
randomized controlled trial of over 4,000 women aged 60 to 80, women allocated to the 
MeD supplemented with extra virgin olive oil intervention group experienced nearly 70% 
less risk of breast cancer than the control group (HR: 0.32; 95% CI: 0.13-0.79).48 
 Another commonly used category of a priori dietary patterns is those developed 
based on hypothesized disease pathways. The DASH diet was developed as a potential 
tool for intervening on hypertension.191 Surprisingly, even though it was developed based 
on a mechanistic pathway for a different disease, the DASH diet has shown an 
association with breast cancer, although only for HER-2 positive cases (HR: 0.44; 95% 
CI: 0.25-0.77).186 A dietary pattern developed on the basis of foods associated with 
inflammatory markers, the Dietary Inflammatory Index (DII™), has shown mixed results 
for breast cancer.49–51,192,193 Although one study reported no association with 
postmenopausal breast cancer,192 others have reported significant associations with breast 
cancer, with larger estimates observed in postmenopausal49,193 or obese women,49 and 
with breast cancer mortality.51 Together, the evidence suggests a pro-inflammatory diet is 
associated with greater incidence and mortality from breast cancer. Specific to breast 
cancer, a previously described pattern was based on food groups correlated with 
circulating estrogen levels, which was subsequently not associated with postmenopausal 
breast cancer in NHS.32 However, when the same pattern was applied in a Swedish 
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cohort, a 29% increase in breast cancer risk  (HR: 1.29; 95% CI: 1.08-1.55) was reported 
when comparing women in the highest quartile with the lowest.27 
 
2.4 Risk factors for breast cancer 
 Breast cancer is the most diagnosed cancer among women after non-melanoma 
skin cancer, with over two-thirds of cases occurring in women over the age of 55, and 
results in the second most cancer-fatalities after lung cancer.2 Established risk factors for 
breast cancer include age, obesity, physical inactivity, alcohol intake, and reproductive 
factors, most of which affect the development of mammographic tumors through 
hormonal influences. Due to the high incidence of breast cancer, modifiable primary 
prevention methods, such as dietary intervention, are of great interest. 
2.4.1 Menopausal status  
 There is evidence that risk factors, incidence, and prognosis of breast cancer vary 
between pre- and postmenopausal women, highlighting the significant differences 
between the two disease strata.2,194,195 The heterogeneity in the two diseases may be 
crucial to explaining some of the inconclusive findings in the relationship between diet 
and breast cancer, as the grouping of both menopause statuses as one occurs frequently in 
the literature.21 The onset of menopause is a marker for a reduction in ovarian endocrine 
activity. Subsequently, levels of sex hormones, including estrogen, are significantly 
attenuated in postmenopausal women.56,58 Sex hormones in premenopausal women have 
high within-person variability corresponding to their menstrual cycle.196 Contrastingly, 
due the termination of menstruation after menopause, postmenopausal women have 
lower, less variable levels of circulation estrogen.56,197 The reduced variability and 
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magnitude of the hormone levels is hypothesized to make postmenopausal women more 
sensitive to estrogenic effects in relation to breast cancer risk.4,9,195,198,199 This hypothesis 
is supported by many of the estrogen-related risk factors for breast cancer, as described 
below, which appear to have a greater effect in postmenopausal women.2,13,195 In addition 
to, and partially as a result of the hormonal changes after menopause, there are paralleled 
atrophic changes to mammary tissue, with increasing amounts of adipose in the breast.198 
Increased amounts of adiposity in the breast results in higher localized levels of estrogen 
as a result of the estrogenic properties of adipose tissue.198   
2.4.2 Weight status and physical activity 
 Multiple factors related to increased adiposity and PA are associated with the 
development of breast cancer in postmenopausal women.13,200,201 Using the Centers for 
Disease Control and Prevention’s (CDC) BMI cutoffs for overweight (25.0-29.9 kg/m2) 
and obesity (≥30 kg/m2), risk of postmenopausal breast cancer is 1.5 and 2 times that of 
normal weight women (18.5-24.9 kg/m2), respectively.2 In the WCRF/AICR’s Second 
Expert Report CUP, total body fatness has “convincing” evidence and biological 
plausibility to increase risk of postmenopausal breast cancer.24 The designation is based 
on an updated meta-analysis of more than 56 studies showing a 12% significant increase 
in risk per 5 kg/m2 increase in BMI, with stronger evidence among ER+ subtypes.24 In 
addition to total body fatness, measures of abdominal fatness, such as waist 
circumference (WC) and waist-to-hip ratio (WHR) have a “probable” association with 
increased risk of postmenopausal breast cancer.13,24 Pooled evidence from 11 cohort 
studies showed an 11% increase in risk for an 10 cm increase in WC.24 Similarly, the 
report cited a 10% increase for a 0.1 increase in WHR.24 Estimates were slightly 
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attenuated, but still significant, when only considering studies that adjusted for BMI.24 
Women who gain weight as adults are even more susceptible to breast cancer.2,13 For a 5 
kg gain in weight during adulthood, a meta-analyses of 15 studies reported a 6% 
significant increase in risk of postmenopausal breast cancer.24 
 The biologic mechanisms of increased weight status and postmenopausal breast 
cancer risk are due to the hormonal properties of adipose tissue.2,24 The chronic state of 
inflammation that is present in obese individuals is mediated by adipokines, such as  
tumor necrosis factor alpha (TNF-α).53,202 The downstream effects of adipokine secretion 
lead to an altered immune response that can facilitate cell proliferation and tumor 
growth.203 Furthermore, TNF-α in adipocytes inhibits glucose uptake resulting in 
sustained levels of increased insulin.204,205 There is some evidence hyperinsulinemia is 
associated with increased breast cancer risk, likely due to its ability to promote DNA 
synthesis and the activity of insulin-like growth factor (IGF).63 The influence of IGF on 
breast cancer risk has become increasingly apparent, primarily due to its mitogenic 
properties affecting cellular growth and differentiation.63  
 The predominant hypothesis by which increased weight status, specifically 
increased accumulation of adipose tissue, affects postmenopausal breast cancer risk is the 
ability of adipose tissue to synthesize estrogen.62,63,206 Adipose tissue is the largest source 
of endogenous estrogen in postmenopausal women, and there is strong evidence for a 
positive linear association between adipose tissue and estrogen levels in postmenopausal 
women.2,63,207 Adipose tissue contains high levels of the enzyme aromatase, which plays 
a significant catalytic role in estrogen synthesis.63 Aromatization is the last step in the 
conversion of cholesterol to estrogen for both estradiol and estrone.53 The influence of 
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adipose tissue on breast cancer risk through estrogen metabolism is evident when looking 
at various strata of estrogen-related breast cancer risk factors. For example, the influence 
of HRT on breast cancer risk is strongest among lean women, likely because the 
exogenous estrogen from the therapy has a relatively greater effect in the absence of (or 
reduced amount of) adipose-derived estrogen.208  
 Contrary to postmenopausal breast cancer, increased adiposity is associated with a 
decrease in the risk of breast cancer in premenopausal women.24 Results from the 
WCRF/AICR’s CUP meta-analysis indicated an 7% decrease in risk of premenopausal 
breast cancer for every 5 kg/m2 increase in BMI.24 The mechanisms behind the inverse 
association between adiposity and premenopausal breast cancer are unclear. It has been 
hypothesized that the increased levels of adipose-derived hormones, such as IGF, may 
promote anovulation which reduces a woman’s lifetime exposure to estrogen.209 It is also 
possible that increases early life exposure to adipose-derived estrogen may alter breast 
differentiation in a way that is beneficial to prevent malignancies.210  
Potentially through its effects on adiposity and other mechanisms, energy 
expenditure through PA has an inverse association with postmenopausal breast cancer 
risk.2 The majority of cohort studies in the WCRF/AICR’s report showed a significant 
inverse association between recreational PA and postmenopausal breast cancer, resulting 
in a “probable” designation for decreasing risk.24 A meta-analysis yielded a 13% 
reduction in risk when comparing the highest level of PA with the lowest, with a similar 
10% reduction in risk when only looking at vigorous PA.24 The hypothesized beneficial 
effect of increasing PA is related to the promotion of metabolic efficiency, translating to 
a reduction of adipose tissue and increase in lean mass.62 Subsequently, PA improves 
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insulin response and protects against chronic inflammation.62 Increased PA has also been 
shown to have an inverse association with circulating estrogen, possibly through 
increased levels of SHBG.24,62 Intervention studies have shown a reduction of circulating 
estrogen after participating in PA, suggesting PA may reduce breast cancer risk through 
attenuation of exposure to estrogen.211,212  
2.4.3 Hormone replacement therapy and contraceptives 
 Exogenous hormones use, such as in contraception or postmenopausal HRT, has a 
positive association with breast cancer incidence.2 There is evidence that use of OCs that 
contain estrogen and/or progesterone, has a minor effect on risk.2 Women who use OCs, 
specifically those manufactured with high hormonal dosage, show the greatest increase in 
risk when use starts before the age of 20.2 The increase in risk attenuates when use of 
OCs is terminated.2 Evidence suggests that a previous user of OCs has the same risk 
profile of someone who never used if it has been at least 10 years since their last use.2  
 The other main source of exogenous estrogen, HRT, is used among women who 
underwent hysterectomy and cannot produce their own estrogen, or among women who 
are trying to mitigate the effects of menopause due to low levels of estrogen. There has 
been a drastic reduction in the latter HRT use after initial results from the landmark 
randomized controlled trial in the WHI.213,214 Originally designed to investigate a 
hypothesized protective effect of estrogen plus progestin in relation to coronary heart 
disease and all-cause mortality among women, the trial was prematurely terminated as 
intermediate results identified an increase in risk of many conditions in the intervention 
group.214 Compared to controls, women who underwent estrogen plus progestin therapy 
had a significant 26% increase in risk of breast cancer.214 Increasing duration of use 
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showed stronger associations, however, termination of use causes a women’s risk to 
revert to what it would be if she never used, similar to what has been observed among OC 
users.214,215 Results from the WHI were corroborated in multiple other studies with 
regards to the effect of estrogen plus progestin.208,215,216 Interestingly, there is evidence of 
an effect modification by BMI in the association between HRT and breast cancer risk.208 
Although adipose tissue promotes estrogen production, the risk estimates between HRT 
and breast cancer were higher in lean women, compared to obese women, in a reanalysis 
of 51 observational studies.208 It is possible that the amount of estrogen produced by 
adipose tissue is enough to cause a sufficient increase in risk, thereby masking any 
additional effect of HRT use on breast cancer risk. This would explain why HRT has a 
greater effect on risk among lean women, because these women do not have as much 
adipose-derived estrogen. 
 There are forms of HRT that do not use the combination of estrogen plus 
progestin, which have shown inconclusive results regarding breast cancer risk.208 The 
Million Women Study in the United Kingdom showed a significant 30% increased risk of 
breast cancer among women who used an estrogen-only replacement therapy compared 
to women with no HRT.215 Contrastingly, women in the WHI’s estrogen-only trial 
showed evidence of a significant decrease in risk after adjustment for adherence (HR: 
0.67; 95%CI: 0.47-0.97).217 Tibolone, a synthetic hormone with androgenic properties, 
has also been shown to increase risk.215 
2.4.4 Reproductive factors 
 Numerous factors regarding a women’s reproductive history can influence their 
risk of postmenopausal breast cancer, often also effecting their exposure to endogenous 
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estrogens, as evident by a stronger association with ER+ cases.2 The earliest reproductive 
factor affecting breast cancer is age at menarche.  There is an inverse association between 
age at menarche and breast cancer, with women who experience menarche at the age of 
12 and younger with the greatest risk.2,218 After the age of 12, a 10-20% reduction in risk 
has been estimated for each 1-year increase in age that menarche occurs.218 Similar to the 
relationship with late onset of menopause and breast cancer, women who experience 
early menarche typically have a greater lifetime exposure to ovarian hormones.2,218 
Once of child-bearing age, those women who never have children, or do so at an 
older age, are at an increased risk of breast cancer compared to women who have an 
earlier age at first birth.2,219,220 Increasing parity and age at first birth are both inversely 
associated with breast cancer.2,219,220 Compared to nulliparous women, those who were 
parous have significantly lower levels of serum estrogen and greater concentrations of 
SHBG. Therefore, it is plausible that multiparous women who gave birth at a young age 
have a lower lifetime exposure to estrogen.221 However, it also is possible that a woman’s 
nulliparity status results from infertility due to low levels of steroid hormones, which 
would indicate a lower exposure to estrogen.222 
 Among women who have children, there is evidence that those who breastfeed are 
at a lower risk.2 Furthermore, the longer a women breastfeeds has shown greater 
reduction in risk.2 The mechanism behind this decrease in risk most likely has to do with 
increased differentiation of breast tissue, however it is also possible the paralleled 
inhibition of menstruation that occurs during lactation plays a role.2,13 By inhibiting the 
number of menstrual cycles, lactation reduces a woman’s lifetime exposure to 
endogenous estrogen.2,13 
 46 
2.4.5 Inherited risk 
 Although most incident breast cancer cases occur in women without a history of 
the disease, there is a strong link between risk and an individual’s personal and family 
history of breast cancer. Early onset breast cancer is often a result of inherited risk, as 
genetic factors are likely to have a stronger influence, whereas accumulation of 
environmental and lifestyle factors take effect in cases of older, postmenopausal 
women.2,223 Women who have one, two or at least three first-degree relatives experience 
2, 3, and 4 times the risk of developing breast cancer, respectively.2 The younger the 
relatives were diagnosed the stronger the association with risk in family members.2 In 
addition to family history of breast cancer, women with relatives who have been 
diagnosed with ovarian, prostate and endometrial cancers, all of which are cancers with 
strong hormonal properties, are also at increased risk.2,224 Women who have previously 
been diagnosed with cancer are approximately 1.5 times as likely to develop a secondary 
breast cancer compared to women with no personal history.2 
 For some previously diagnosed women, the increased risk of secondary breast 
cancer is due to their genetic predisposition. The strongest associated and most frequently 
analyzed genetic mutations for increased breast cancer risk are in the BRCA1 and BRCA2 
genes.2 Although the mutations occur in less than 1% of the female population, there are 
estimates that they account for as much as 10% of all breast cancer cases.2 Women who 
carry the a mutation in BRCA1 and BRCA2 have between a 50-80% lifetime risk of breast 
cancer, compared to a 12% lifetime risk in the general population.225 There is evidence 
that other genetic variations present low increases in risk, in addition to a strong belief 
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that these variations interact with lifestyle factors, such as dietary habits, to affect breast 
cancer risk.2,226  
2.4.6 Demographics 
 As with most major chronic diseases, there are multiple demographic risk factors 
strongly associated with incident breast cancer. Incidence rates differ among many strata 
of age, social class, ethnicities, and races. Many, but not all, demographic and 
socioeconomic risk factors for breast cancer are related to screening behaviors.2 For 
example, the lifetime risk of developing breast cancer has increased in the past 40 years, 
partly as a result of increased life expectancy, but also due to better detection and 
increased participation in screening.2 
 The strongest risk factor for breast cancer is age, due to the prominent role of 
cellular damage, or mutations, in the development of proliferation of cancer cells.6 As 
women age and the number of cellular divisions take place over time, there is a greater 
chance of improper division and damage to the DNA. The subsequent effect of the 
damage in the mutated DNA is exacerbated in the diminished capability of cellular repair 
mechanisms of older individuals.6 Furthermore, environmental exposures that accumulate 
over time can result in DNA damage and alter DNA expression.227 According to the 
American Cancer Society (ACS), the median age at breast cancer diagnosis in the U.S. 
was 61 years old between 2008-2012.2 The Surveillance, Epidemiology, and End Results 
(SEER) program estimated the age group with the highest percentage of incident cases is 
between 55-64 years old using data from 2009-2013.228 Only 10.7% of all new cases 
occur in women under the age of 45, whereas 68% of all new cases occur in women 55 
years and older.228  
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Annual age-adjusted incidence rates reported in the 2009-2013 SEER database 
were highest among White women (128.0 per 100,000), with Black women experiencing 
similar rates (125.2) during this time period.228 However, comparing White and Black 
women, the ACS reported significantly higher rates of breast cancer among White 
women between the ages of 60 to 84, and higher rates in Black women younger than 45.2 
In addition to being diagnosed at younger ages, Black women are more likely to have 
aggressive cases, such as triple negative, or advanced stage cancer and subsequently 
higher breast cancer mortality over their lifetime compared to White women.228,229 Risk 
of developing breast cancer is lower among Hispanics and Asian/Pacific Islanders 
compared to Black and White women.2,228  
Regardless of ethnicity or race, socioeconomic status has repeatedly shown a 
positive association with breast cancer incidence, using education, income, or their 
aggregate measure to define social class.229–231 More years of education and highest 
degree obtained have both shown positive associations with breast cancer incidence,232–
234 as well as annual income234,235 and occupational supervisory rank.236 This association 
is strongly influenced by screening behaviors, as shown in ACS data from 2010 where 
the prevalence of a mammography within the past two years ranged from 24-28% less in 
poor women (defined as 100-199% of poverty) compared to non-poor.206 Incidence is 
lower and mortality is higher among women who reside in rural areas compared to urban 
dwellers, due to the aforementioned reduced access to screening and detection at a more 
advanced stage.237–239 
 
 
 49 
2.4.7 Tobacco use 
 Evidence of an association between smoking tobacco and breast cancer has been 
suggestive but inconclusive.2 Some have hypothesized an association among those who 
are heavy smokers, or who have been smoking for a long duration.2 A recent meta-
analysis reported an 8% increase in risk of breast cancer when comparing current 
smokers and never smokers using data from 27 prospective studies (RR: 1.08; 95 % CI: 
1.02-1.14).240 When looking at passive smoking, a meta-analysis reported an increase in 
risk (OR: 1.62; 95% CI: 1.39-1.85) but no association with active smoking.241 Together, 
the results suggest tobacco smoke may play a role in developing breast cancer. The 
predominant pathway by which tobacco smoking affects breast cancer is through 
increased inflammation, along with the carcinogenic effects of tobacco smoke.242 Some 
have identified associations between high levels of estrogen and smoking,12 while others 
have reported an anti-estrogenic effect,243 and even associations with the 2-hydroxylation 
pathway suggesting a beneficial alteration of estrogen metabolism with smoking.244  
2.4.7 Lifestyle indices 
 There is evidence of an association between individual modifiable lifestyle 
characteristics, such as PA and alcohol use, with development of postmenopausal breast 
cancer. Lifestyle factors often cluster together in individuals who adopt healthy or 
unhealthy lifestyle, so it may be beneficial to study lifestyle factors using a combined 
lifestyle score.245 An a priori healthy lifestyle index score (HLIS) based on diet, tobacco 
use, alcohol, PA and BMI reported 21% lower risk of breast cancer (HR: 0.79, 95% CI: 
0.73-0.85) among the fourth, or most healthy group, compared to the second group in the 
EPIC cohort.246 Application of the HLIS, with a slight modification of the diet to include 
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fish, folate, glycemic index, and other breast cancer risk-specific dietary components also 
showed an inverse association with postmenopausal breast cancer risk comparing the 
highest category to the second (HR: 0.74; 95% CI: 0.66–0.83).16 The association was 
strongest for ER-/PR- (HR: 0.60; 95% CI: 0.40-0.90) but also significant for ER+/+ 
breast cancer (HR: 0.81; 95% CI: 0.67-0.98).16 In both of the previously mentioned 
HLIS’s, the second group served as the referent due to low numbers of individuals 
adopting the healthiest behaviors for some of the scoring components in the first group. 
Also using data from EPIC, a lifestyle score was developed to evaluate adherence to the 
WCRF/AICR recommendations on body fatness, PA, energy dense foods and drinks, 
plant foods, animal foods, alcohol use, and breastfeeding in women. Compared to the 
lowest scores, all categories showed a significant inverse association with breast cancer, 
with the strongest association in the highest scoring groups (HR: 0.84; 95% CI: 0.78-
0.90).14 Adherence to WCRF/AICR recommendations and their association with breast 
cancer risk has been studied in other populations, as well.247–249 In the Swedish 
Mammography cohort, women who met at least six of the seven recommendations had 
nearly half the risk (HR: 0.49; 95% CI: 0.35-0.70), with a greater reduction in ER+/PR+ 
subtypes compared to ER-/PR-.247 In the Iowa Women’s Health Study, an inverse 
association was observed with postmenopausal breast cancer, and that association did not 
differ in the presence of non-modifiable risk factors, such as taller height, family history 
of breast cancer, or greater number of potentially fertile years.249  
Some lifestyle scores have been developed for a specific study population. One 
score was developed to assess increasing incidence of breast cancer among indigenous 
women in New Zealand using 11 scoring criteria (red meat, protein, seafood, energy 
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dense foods, solid fats, plant foods, smoking, exercise, BMI, and breastfeeding).250 No 
association was observed among non-indigenous women but the highest lifestyle score 
tertile had a significantly lower odds of breast cancer (OR: 0.47; 95% CI: 0.23-0.94) 
compared to the lowest tertile among indigenous women.250 Investigators of a large case-
control study of Mexican women developed a similar lifestyle score using the same five 
components, except adherence to the “Western” diet was used to inversely derive the 
dietary component.15 The authors reported an inverse association with breast cancer in 
postmenopausal women (OR: 0.20, 95% CI: 0.11–0.37) when comparing the highest 
versus lowest quintiles, with PA and alcohol use as the main contributors to the 
association.
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CHAPTER 3 
METHODS
3.1 Statement of aims and hypotheses 
 The overarching goal the dissertation work was to derive and evaluate a dietary 
pattern based on estrogen metabolism in relation to postmenopausal breast cancer risk 
solely as a dietary exposure and as part of an aggregate score for estrogen-related lifestyle 
factors. We hypothesized that a dietary pattern that is characteristic of increased estrogen 
exposure would be positively associated with postmenopausal breast cancer. An 
aggregate lifestyle score representative of habits that are beneficial to estrogen 
metabolism was hypothesized to be inversely associated with postmenopausal breast 
cancer. We expected to see the strongest associations for ER+ cancer subtypes, with 
effect modification by other estrogen-related risk factors for breast cancer. 
 In Aim #1, a dietary pattern was developed based on food groups associated with 
various measures of estrogen metabolism, and was subsequently applied in a prospective 
investigation into postmenopausal breast cancer risk. We hypothesized that diets high in 
animal products, and low in vegetables and fiber would be associated with high 
estrogenic potential, measured as a high ERDP score. Similar to the first aim, we 
investigated an association between the ERDP with postmenopausal breast cancer risk in 
Aim #2, but used a study population different from the one in which it was derived. In 
both prospective investigations, using the PLCO and SS, we hypothesized a positive 
association between the ERDP and incident breast cancer. We expected to see a stronger 
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association among breast cancer cases that are ER+ compared to ER-. We also 
hypothesized that the strongest association would be observed in strata of effect modifiers 
assumed to lower estrogen exposure, such as leaner women compared to overweight 
women, where the estrogenic effect of diet will have a larger relative influence. In Aim 
#3, the ERDP was incorporated into the ERLS with alcohol intake, BMI, and PA, all of 
which are hypothesized to influence estrogen metabolism. We hypothesized that higher 
ERLS scores, representative of a lower collective estrogenic effect of lifestyle factors, 
would be inversely associated with postmenopausal breast cancer. Like the ERDP, we 
expected to see the largest magnitude of associations for ER+ cases, and among strata of 
effect modifiers that have a smaller estrogenic effect.  
 
3.2 Descriptions of the study populations 
 Multiple study populations, including a subset of one of the larger studies, were 
used to complete the dissertation aims. Participants of PLCO were utilized in Aim #1 and 
Aim #3. Derivation of the ERDP within Aim #1 took place in a subset of PLCO 
participants with information on baseline serum EM concentrations, which is described in 
detail after an overview of PLCO below. To examine the ERDP in a study population 
external to the one in which it was developed, the SS was used in Aim #2. Detailed 
descriptions can be found in the next three sections. 
3.2.1 Prostate, Lung, Colorectal and Ovarian Screening Trial 
 An initiative of the NCI, the PLCO is a large population-based screening trial 
designed to determine the effects of screening on cancer prognosis and mortality. Design 
and implementation has been described in detail elsewhere.33 Briefly, participants were 
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recruited between 1993 and 2001, with the intervention trial completing in 2006 and 
follow up continuing through 2015. Recruitment of 76,685 men and 78,216 women aged 
55 to 74 at enrollment took place at 10 different screening centers across the nation. After 
randomization to the intervention arm, women participated in regular chest x-rays, 
flexible sigmoidoscopy, CA-125 blood tests, and transvaginal ultrasound during the first 
six years and were followed up for an additional seven years. Women were excluded at 
recruitment if they had a history of lung, colorectal, or ovarian cancer. If women were 
currently undergoing treatment for any previously diagnosed cancers, or if they were 
participating in another screening or primary prevention trial, they were also excluded. 
Prior to October 1996, women who previously had both ovaries surgically removed were 
excluded from enrollment. Eligible participants underwent a physical examination and 
filled out a questionnaire with information on demographics, medical history, family 
history, lifestyle factors, and recent history of participation in screening examinations at 
baseline. 
For the dissertation work, only data from the 39,104 women randomized to the 
intervention arm of the study, who participated in standard of care screening practices, 
were used. Use of only women in the intervention arm is required for a couple of reasons. 
First, the sample of women included in the nested case-control study with baseline serum 
estrogen data were selected as a subset of the intervention arm. Additionally, only women 
in the intervention arm were asked to complete the dietary questionnaire (DQX) at 
baseline. A different dietary instrument, the diet history questionnaire (DHQ), began to 
be administered to both arms of the study 3 years after baseline. Therefore, it would be 
inappropriate to use the DHQ in an investigation of baseline serum estrogen levels due to 
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the issue of temporality. Before any analytic exclusions were made, less than 15% of 
women in the intervention arm self-identified as a racial/ethnic minority: 5.5% non-
Hispanic Black (n=2,170), 1.5% Hispanic (n=605), and 3.2% Asian (n=1,259). 
3.2.1 PLCO nested case-control 
 A subset of postmenopausal women randomized to the intervention arm of PLCO 
with information on serum EMs were included in the analyses to derive the ERDP. 
Complete information on the nested study has been published elsewhere.35 Briefly, the 
nested study population was drawn from all 1,141 incident breast cancer cases diagnosed 
from the start of recruitment in 1993 through June 30, 2005, and a random sample of 
1,141 control subjects. After excluding women who were not postmenopausal, were 
using HRT at baseline, or had prior diagnoses of cancer, the sample was reduced to 390 
cases and 453 controls. For the purposes of the present analysis, cases who were 
diagnosed <2 years after serum sample donation (n=98) were excluded to avoid the 
possibility of disease processes affecting estrogen levels. Women without a valid DQX 
(n=77) or with implausible EM levels (i.e., if they were outside of 25th and 75th 
percentile, plus/minus three times interquartile range; n=15) were further excluded. The 
final analytic sample included 393 controls and 260 confirmed cases, with a mean of 5.25 
years from sample donation to breast cancer diagnosis among cases. Use of some cases 
served to increase the sample size for this aim and is justifiable because most breast 
cancer cases are diagnosed without symptoms. Therefore, we believe their diets likely did 
not change dramatically leading up to their diagnosis. Details of the laboratory methods 
used are explained in section 3.3. 
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3.2.3 Sister Study 
 The SS is a large prospective cohort study designed by the NIEHS to investigate 
environmental and genetic determinants of breast cancer.34 A total of 50,884 women aged 
35 to 74 who had a sister that was diagnosed with breast cancer were recruited between 
2003 and 2009 from all 50 U.S. states and Puerto Rico. Community based recruitment 
efforts were used through local volunteers, study participants, local and national events, 
and extensive media campaigns. Recruitment strategies included attempts to enroll 
women who were of racial/ethnic minorities, older age, and lower income. After 
enrollment, baseline information was collected via Computer Aided Telephone Interview 
(CATI) and self-completed risk factor questionnaires on demographics, dietary 
information, lifestyle and medical history, and exposures from the prior 24 hours. Study 
staff conducted a home visit to collect blood and urine samples, toenail clippings, and 
dust collection from the home for environmental exposures. Anthropometric and blood 
pressure measurements also took place at the home visit. All women are being followed 
up for at least 10 years. Participants were contacted annually for brief health updates, 
with a comprehensive follow-up questionnaire administered every two to three years.  
 A similar proportion of participants enrolled in SS identified as non-Hispanic 
White (81.0%; n=42,558) as in the PLCO study population. The distribution of 
racial/ethnic minorities was slightly different, however, with 8.5% identifying as non-
Hispanic Blacks (n=4,462) and 4.8% identifying as Hispanic (n=2,515). Over half of the 
participants were aged 55 and older at baseline (50.97%). In the present work, all women 
who contributed person-time after the onset of menopause with complete information 
were used in the investigation of the ERDP and breast cancer.  
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3.3 Dietary assessment 
 In PLCO, usual dietary intakes over the prior 12 months were collected via the 
DQX, which is a 137-item food frequency questionnaire (FFQ) administered at baseline. 
Over 82% of participants in the intervention arm completed the DQX. Dietary data in SS 
was assessed using two different versions of the 110-item 1998 Block full diet FFQ. 
Version 2 of the FFQ contains the same information as the first version, with additional 
questions on organic foods, microwave use, restaurant and frozen foods – none of which 
were used in the current dissertation work. Over 16% of SS participants completed 
version 1, with another 81% completing version 2, totaling over 97% of participants with 
dietary information.  
 A qualitative side-by-side comparison of dietary assessment tools used in PLCO 
and SS showed strong agreement in the foods measured. Both study populations filled out 
dietary information on usual food consumption, preparation methods, and supplement 
use. Overall, both dietary assessment tools include the same foods with some minor 
differences. The DQX had a larger number of line items dedicated to fruits and 
vegetables than the Block FFQ. However, most of the fruits and vegetables in the DQX 
are on the 1998 Block FFQ, just combined into fewer lines. Other minor differences 
included a greater number of lines designed to assess grain intakes and nuts/seed 
consumption on the 1998 Block FFQ. Both the DQX and 1998 Block FFQ used the 
USDA’s National Nutrient Database for Standard Reference for nutrient analysis.  
 Usual intakes from the dietary assessment tools were categorized into 1 of 29 
food groups based on the USDA’s My Pyramid Equivalents Database (MPED).251 
Additional groups were added for cruciferous vegetables, coffee and tea because of their 
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suggested influence on estrogen metabolism or breast cancer. A number of other groups 
were omitted to reduce the redundancy of some commonly eaten foods. Namely, the 
“total” groups for each section was excluded. For example, the “total fruits” group was 
removed because of the foods that would be contained in the “total fruits” group are 
accounted for in the “citrus fruits, melons, and berries” or the “other fruits” groups. In 
total, 32 food groups were used. The food groups, presented in Table 3.1, were used as 
the predictor variables in the RRR analysis, which is explained in greater detail in section 
3.6.1.  
  
3.4 Estrogen metabolite measurement 
 Serum samples collected at baseline and stored at −80°C from women in the 
PLCO nested study were thawed at 4°C. The previously described LC/MS-MS assay was 
used to concurrently quantify levels of 15 EMs. The parent estrogens were measured 
along with their metabolites in the 2-, 4-, and 6-hydroxylation pathways make up the 15 
EM (estrone, estradiol, 2OHE-1, 2-methoxyestrone, 2-hydroxyestradiol, 2-
methoxyestradiol, 2-hydroxyestrone-3-methyl ether, 4OE-1, 4-methoxyestrone, 4-
methoxyestradiol, 16OHE-1, estriol, 17-epiestriol, 16-ketoestradiol, and 16-epiestriol). 
Quantification of the individual metabolic pathways allows for ratios of those pathways 
to be used, which is potentially influential in the development of postmenopausal breast 
cancer.11 The specifics of sample preparation and LC/MS-MS methods have been 
described in greater detail elsewhere.41 An enzyme hydrolytic step is used to elucidate the 
unconjugated and conjugated forms of parent estrogens. Quality control was assessed 
using four samples which were inserted into each batch by blinded laboratory staff. The 
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CV for all EMs was <5%, with even lower CV evident for the parent estrogens (<3%) 
and unconjugated estradiol (<2%).35 Levels of EMs between 1–2 pmol/L were able to be 
quantified in this population of postmenopausal women, with no EMs in the study at 
undetectable readings.35 
 
3.5 Breast cancer ascertainment 
 Incident breast cancer cases among postmenopausal women in PLCO were 
identified primarily through self-report via annually mailed follow-up questionnaires, or 
through the National Death Index, physician reports, state cancer registries, and next of 
kin reports. Over 96% of the cases were confirmed through hospital records.252 Using 
most recent follow-up data from PLCO, a total of 1,652 cases of breast cancer have been 
ascertained over an average follow-up of about 11.5 years, with 1,316 of the cases 
diagnosed as invasive (before analytic exclusions). Prior to 2007, breast cancer cases in 
PLCO were confirmed from medical records with only information on diagnosis date and 
codes from the second edition of the International Classification of Diseases for 
Oncology. After 2007, a Breast Cancer Supplemental form was used to capture more 
information, include ER status of the tumor. There was limited data on ER status of in 
situ cases before the implementation of the supplemental form, as ER status was not 
routinely assessed among in situ cases in the past. The supplemental form was available 
for 98% of the cases. ER status was available for 70% of total cases (75% of invasive and 
35% of in situ cases). 
 In the SS, incident breast cancer cases were ascertained via completion of annual 
health updates, biennial surveys, and the National Death Index. Response rates for the 
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surveys were over 94%.253 Medical record abstraction was used to confirm over 80% of 
cases and to identify information on treatment and diagnosis, such as ER subtype.254  
Agreement between self-reports and medical records were over 99% for total breast 
cancer, invasive breast cancer and ER-positive breast cancer. Thus, self-reported 
information is used when medical records were not obtained.  Currently, 2,081 incident 
postmenopausal cases (n=1,589 invasive) have been reported among SS participants 
(before analytic exclusions). 
 
3.6 Statistical approaches 
 The first step in the dissertation work was to develop the ERDP using data from 
the nested PLCO study (Aim #1). After the ERDP was derived, it was applied in a 
prospective investigation with postmenopausal breast cancer risk among women 
randomized to the intervention arm of PLCO (Aim #1) and women enrolled in SS (Aim 
#2). The final application of the ERDP in the dissertation work was incorporating it into 
the ERLS (Aim #3). In a similar fashion to the ERDP, the ERLS was used in a 
prospective investigation of an association with postmenopausal breast cancer risk among 
women randomized to the intervention arm of PLCO (Aim #3). Development of the 
ERDP and ERLS, along with a description of how they were used in prospective analyses 
are described in the following sections. All statistical tests and models were performed in 
SAS 9.4 (SAS Inc., Cary, NC) using two-sided tests with α=0.05. 
3.6.1 Derivation of estrogen-related dietary pattern 
 Unconjugated estradiol and the 2/16 ratio were identified a priori for inclusion 
because of the cumulative evidence, particularly from recent studies using the advanced 
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LC/MS-MS, which has supported their role in the development of postmenopausal breast 
cancer.11,35,84,255 Furthermore, these two EMs were associated with postmenopausal breast 
cancer risk in the nested PLCO study used to derive the ERDP.35 It is hypothesized that 
unconjugated estradiol the 2/16 ratio are representative of total exposure from circulating 
estrogens as well as the competing metabolic pathways which are suspected to have 
opposing influences with regards to breast cancer risk, respectively.11 The bulk of this 
evidence, as well as biologic plausibility of the hypothesized relationships, have been 
presented in section 2.1.  
To identify foods that are correlated with unconjugated E2 and the 2/16 ratio, 
RRR modeling was applied to the subsample of 653 participants with EM data. An 
approach using RRR determines linear functions of predictors, which in the present case 
are food groups, by maximizing the explained variation in multiple disease-specific 
response variables, comprised of E2 and the 2/16 ratio.256 The primary benefit of using 
RRR in nutritional epidemiology is it combines data-driven and hypothesis-driven 
approaches into one.31 The hypothesis-driven aspect comes from the response variables 
that are predefined by the investigators to be important mediators in disease risk. The 
data-driven aspect comes from identification of predictor variables, or food groups, 
which explain the greatest variation in EMs specific to our study population. Previous 
comparisons of RRR with other data-driven methods, such as principal component 
analysis, have shown stronger association with RRR in predicting cardiometabolic 
diseases.31,257 A limitation of RRR is its dependence on selecting response variables that 
are strongly associated with disease risk. If the response variables do not mediate disease 
risk, it is unlikely an association between dietary factors and the disease endpoint will be 
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identified. However, we believed there is clear and sufficient evidence of a strong 
association between estrogen metabolism and breast cancer risk, as outlined in section 
2.1. 
 In order to ensure RRR factors are based on how much variation in the outcome 
they explain, all intakes are centered and scaled so that their mean ± standard deviation 
(SD) is equal to 0 ± 1. Only the first factor was retained for development of the ERDP 
because it represented a dietary pattern that explains the largest variation in the EM. 
Initially, all 32 food groups were entered into the model at once. Those with a variable 
importance in projection statistic (VIP) greater than 0.8 were retained and re-entered into 
the RRR model, as they represented the food groups which are the strongest contributors 
to RRR factors scores.258 RRR factors scores can only be calculated in participants with 
EM data, therefore, to apply the ERDP to the full analytic populations in PLCO and SS, 
we calculated the ERDP score so that it is perfectly correlated with the RRR factor scores 
among the subsample. To do so, food group intakes were centered and scaled, then 
multiplied by the corresponding model weight for each of the retained food groups, 
which was then summed to calculate the total ERDP score. This same calculation method 
was applied to score the ERDP for the full analytic cohorts in PLCO and SS. Scores with 
higher ERDP values theoretically represent diets with the largest collective potential to 
affect unconjugated E2 and the 2/16 ratio. 
3.6.2 Estrogen-related lifestyle score  
 After the ERDP was derived and evaluated on its own, it was incorporated into 
the ERLS. The other lifestyle components with sufficient evidence of an effect on 
estrogen metabolism that completed the score were alcohol consumption, obesity status, 
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and PA.12 The parameters used as criteria for scoring all of the components, with the 
exception of the ERDP, were similar to those outlined in the WCRF/AICR Second Expert 
Report, and the USDA’s 2015 DGA.13,25 Scoring criteria for the ERDP component was 
based on the median score for the PLCO population. Women with a score greater than or 
equal to the median received a 0, as those diets were hypothesized to be positively 
associated with estrogen metabolism and subsequent breast cancer risk. Women with an 
ERDP score below the median received a 1. Due to the strength of evidence for 
associations between alcohol intake and obesity status with breast cancer risk, and robust 
evidence of an estrogenic effect, they were given a stronger weight in the scoring of the 
ERLS by assigning women to one of three levels instead of only two levels.13 For alcohol 
intake, women who abstained from drinking (0 drink/week) were scored a 2; women who 
consumed >0 to 7 drinks/week were scored a 1; and those who consumed >7 drinks/week 
were scored a 0. Women were scored a 2 if they were normal weight (BMI <25.0 kg/m2), 
a 1 if overweight (BMI 25.0-29.9 kg/m2), and 0 if obese (BMI ≥30.0 kg/m2). For PA, 
women who reported >2 hours/week of vigorous PA were considered active and scored a 
1, and those who reported ≤2 hours/week were scored a 0. The score for each of the four 
different ERLS components was summed. Women with the minimum score of 0 were 
hypothesized to have the largest risk profile, and those with a maximum of 6 were 
hypothesized to have the lowest collective risk profile from estrogen-related lifestyle 
factors. A summary of the ERLS scoring is portrayed in Table 3.2. 
3.6.3 Prospective investigations 
 The methods used in the prospective application of the ERDP in both study 
populations and of the ERLS in PLCO were principally the same. The primary exposure 
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in Aims #1 and #2 was the ERDP, and the ERLS in Aim #3. The primary outcome for all 
prospective investigations was postmenopausal breast cancer followed by investigations 
of ER subtypes of postmenopausal breast cancer. Using descriptive statistics, study 
participants for the full intervention arm of PLCO and SS were characterized in terms of 
potential confounders and effect modifiers within strata of ERDP score quartiles in Aims 
#1 and #2. In Aim #3, women from the intervention arm of PLCO were characterized by 
categories of ERLS score (0-2; 3; 4; 5-6). Statistical comparisons of ERDP quartiles and 
ERLS categories were performed using t-tests and chi-square tests for continuous and 
categorical variables, respectively.   
3.6.3a The ERDP 
 In time-to-event analyses, the association between breast cancer and ERDP scores 
were determined in Aims #1 and #2. The lowest ERDP quartile served as the referent, 
representing diets least associated with estrogen. Cox proportional hazards models were 
used to analyze the relationship between ERDP scores and incident breast cancer events, 
with person-time contributed as time scale variable. A test for the proportional hazards 
assumption was performed by inclusion of an interaction term between exposure with 
follow-up time, log of follow-up time, and was evaluated using Martingale-based 
residuals. Estimates of associations were presented as HRs with 95% CIs. An initial 
model was performed with adjustment for age and a second model adjusted for age and 
total caloric intake. The third model included multivariable adjustment. Potential 
confounders were selected based on a directed acyclic graph (DAG) for the hypothesized 
relationship between the ERDP and postmenopausal breast cancer (Figures 3.2 & 3.3) as 
well as evidence from the previous literature and model selection procedures. According 
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to the DAG, age, education, PA, and BMI in young adulthood represent the minimally 
sufficient set of confounders to include. Demographic factors of age, education, 
race/ethnicity and study center were included in the multivariable-adjusted models, along 
with total caloric intake for their putative roles as confounders for breast cancer. The 
remaining covariates included in multivariable-adjusted models were chosen using 
stepwise model selection for each of the aims with entry/exit criteria of p=0.2 to improve 
model efficiency and reduce the potential for over adjustment. Potential confounders for 
the stepwise model selection included: baseline BMI, BMI in young adulthood, HRT, OC 
use, family history of breast cancer, smoking status, bilateral oophorectomy, prior 
hysterectomy, parity, age at first birth, age at menarche, and age at menopause. 
Categorization of each of the potential confounders are described in more detail in the 
chapters corresponding to each aim (4, 5, & 6). Each of the previously described three 
models were performed within strata of ER subtype. A competing risk model was 
performed to assess a differential association for the ERDP on ER+ and ER- subtypes 
using a Wald test for heterogeneity in the stratified Lunn-McNeil approach.259 A 
sensitivity analysis was performed to evaluate BMI as a potential mediator in the 
association between the ERDP and breast cancer. BMI was omitted from the full Cox 
proportional hazards model in order to assess the potential for mediator bias. It is possible 
BMI lies on the causal pathway between ERDP and breast cancer, as seen in Figure 3.2, 
therefore adjusting for it would be inappropriate and introduce bias into the association. 
Other sensitivity analyses related to the respective study populations were also conducted 
and are described further in the chapters corresponding to each analytic aim.  
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 Lastly, the role of potential effect modifiers was assessed in the final Cox 
proportional hazards models. It is hypothesized that other estrogen-related risk factors 
may modify the association between the ERDP and breast cancer as a result of their 
relative estrogenic effects. To assess effect modification, an interaction term was 
included in the model between the ERDP and the following risk factors: BMI, HRT, 
alcohol consumption, parity, and PA. 
 Unmeasured confounding may introduce bias into epidemiologic investigations. 
While the PLCO and SS collected data on all known risk factors for breast cancer, it is 
possible that early life nutritional factors may confound the relationship between the 
ERDP and breast cancer. The SS has information on early life diet, but PLCO does not. 
Therefore, we planned to use effect estimates between early life diet in SS to estimate the 
potential for unmeasured confounding in PLCO using the methods proposed by 
VanderWeele et al.260 However, intake of meat, plant, and fish servings at age 10 were 
not associated with postmenopausal breast cancer in SS, nor was a vegetarian diet before 
the age of 21 associated (data not shown), therefore these methods were not applied. It is 
possible that the recall of intake at these younger ages was afflicted by measurement 
error, which may partially explain the null associations and would argue for pursuing 
unmeasured confounding analyses. However, this type of analyses requires the estimation 
of effect for the unmeasured confounders which is difficult to assess from the available 
literature. Furthermore, both study populations contained data on BMI as a young adult, 
which has been shown to have an inverse association with breast cancer.24 Therefore, we 
were able to account for one early life nutritional factor with a known influence on breast 
cancer risk. 
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3.6.3b The ERLS  
 Many of the same techniques used to investigate the ERDP in Aims #1 and #2 
were used to investigate the ERLS in Aim #3, with slight differences with respect to 
confounders and effect modifiers. Again, a time-to-event analysis was performed with 
person-time contributed as time scale variable and the lowest ERLS scores of 0-2 as the 
referent. According to the DAG, age, BMI at young adulthood, education, and 
race/ethnicity are the minimally sufficient set needed for adjustment. Three different Cox 
proportional hazards models were performed: an initial model with adjustment for age, a 
second model with adjustment for age and total caloric intake, and a final model with 
multivariable adjustment for potential confounders. The same approach to confounders 
outlined above in the ERDP studies was used, with the exception of those included in the 
development of the ERLS (alcohol, BMI, and PA). As with the ERDP, the previously 
described three models were performed within strata of ER subtype in order to assess a 
differential effect using a competing risk model, and effect modification by other 
potential estrogen-related risk factors was evaluated using a stratified approach.  
3.6.3c Power Calculations 
 Estimates for statistical power over a range of effect sizes and baseline 
probabilities of disease are displayed in Table 3.3. The NCI’s Power software was 
utilized in all calculations, with α=0.05.261 The analytic study population, described in 
section 4.3.1 includes 27,488 participants. The analytic population in SS, as described in 
section 5.3.1, includes 37,752. As shown in the table, we had sufficient power to detect 
moderately small effect sizes (≥1.2) across a range of baseline disease probabilities. The 
baseline probability of breast cancer in both populations is around 6%. 
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3.7 Limitations and strengths 
The present work was susceptible to minor, yet reconcilable limitations. As with 
most prospective nutritional epidemiologic studies, there was the potential for bias due to 
the selection of subjects, loss to follow-up, and dietary measurement error. Although 
FFQs may not generate accurate estimates for absolute intakes of nutrients, they have 
been shown to be effective in ranking individuals, as was the purpose in this study.173 As 
previously mentioned, the two different FFQs used in the PLCO and SS may introduce 
some bias as a result of slight differences in the measurement of certain foods. There is 
always potential for unmeasured confounding, but the use of studies designed to 
investigate relationships with cancer helped to provide complete information on any 
known confounders.   
 It was possible the food pattern derived from a subsample of PLCO participants 
would not result in an association with breast cancer risk in the full PLCO screening arm. 
However, we planned to test the association in the SS to see if a lack of an association 
held true for another group of women. If no association was identified in both the PLCO 
and SS, it was possible the ERDP may still contribute to risk as a part of a lifestyle score, 
which was evaluated in Aim #3. It also is possible that the ERDP does not explain 
enough variation in EMs to influence breast cancer risk on its own, therefore we 
incorporated it into a lifestyle score to assess its influence with other estrogen-related risk 
factors. A minor limitation in regards to study populations was the lack of heterogeneity 
of race and ethnicities. However, our populations are predominately non-Hispanic White 
women, who experience the highest incidence of breast cancer so our results have public 
health significance. 
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There are many strengths in the approach and design to offset some of the 
limitations in the proposed research. The use of large, prospective cancer cohorts allowed 
for the associations of interest to be investigated with complete information on known 
confounders and enough power to detect moderately small effects. The application of 
RRR to derive the ERDP has shown larger associations than other data-driven methods in 
nutritional epidemiology while also incorporating hypothesized pathogenic 
pathways.31,257 A major improvement upon the previous estrogen-correlated dietary 
pattern was in our assessment of EMs. EMs were measured using a more sensitive assay, 
and EMs which have been shown to be most strongly related to breast cancer risk were 
used in the RRR. 
The resulting information from the proposed dissertation work will help to 
address a critical gap in translational breast cancer research. The burden of breast cancer 
is far-reaching, as it remains the most frequently diagnosed cancer and one of the most 
fatal cancers among women.2 There is still a major need to identify primary prevention 
methods for breast cancer, and investigations into diet to date have been inconclusive.43 
Derivation of a dietary pattern evaluating the influence of diet as a whole based on a 
plausible mechanistic pathway may help to resolve the inconsistencies in previous 
studies. Overall, the present dissertation research contributes much-needed information 
about risk factors for a relatively common cancer among women, and potentially 
identifies novel intervention targets for primary prevention
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3.8 Tables and figures  
Table 3.1 Food groups used in the development of the estrogen related dietary pattern 
(ERDP) 
 
Food Group Units/day 
Whole grain ounces 
Non-whole/refined grain ounces 
Dark-green vegetables cups 
Cruciferous vegetables cups 
Orange vegetables cups 
White potatoes cups 
Other starchy vegetables cups 
Tomatoes cups 
Other vegetables cups 
Citrus fruits, melons, and berries cups 
Other fruits cups 
Milk cups 
Yogurt cups 
Cheese cups 
Meat (beef, pork, veal, lamb, game) ounces 
Organ meats (meat, poultry) ounces 
Frankfurters and luncheon meats ounces 
Poultry ounces 
Fish and shellfish high in ω-3 fatty acids ounces 
Fish and shellfish low in ω-3 fatty acids ounces 
Eggs ounces 
Cooked dry beans and peas cups 
Soybean products ounces 
Nuts and seeds ounces 
Discretionary oil grams 
Discretionary solid fat grams 
Added sugars teaspoons 
Beer drinks 
Liquor drinks 
Wine drinks 
Tea cups 
Coffee cups 
ERDP: estrogen-related dietary pattern; MPED: My Pyramid 
Equivalents Database. 
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Table 3.2 Scoring parameters for estrogen-related lifestyle score (ERLS) 
 
ERLS factor Score Description 
ERDP 0 ≥ median ERDP score 
  1 < median ERDP score  
     
Alcohol use 0 Heavy: >7 drinks/week 
  1 Moderate: >0 to 7 drinks/week 
  2 Abstainer: 0 drinks/week 
     
Weight Status 0 Obese: BMI ≥30 kg/m2 
  1 Overweight: BMI 25.0-29.9 kg/m2 
  2 Normal weight: BMI <25 kg/m2 
     
Physical Activity (PA) 0 Inactive: ≤2 hours/week of vigorous PA 
  1 Active: >2 hours/week of vigorous PA 
BMI: body mass index; ERDP: estrogen related dietary pattern; ERLS: estrogen related lifestyle score; 
PA: physical activity  
 72 
Table 3.3 Power calculationsa 
 
    Baseline Probability of Breast Cancer 
Study Effect size 0.04 0.05 0.06 0.07 
PLCO 
1.1 0.25 0.30 0.35 0.39 
1.2 0.72 0.80 0.86 0.91 
1.3 0.99 0.99 >0.99 >0.99 
SSS 
1.1 0.33 0.39 0.45 0.41 
1.2 0.84 0.91 0.95 0.97 
1.3 0.98 >0.99 >0.99 >0.99 
ERDP: estrogen-related dietary pattern; ERLS: estrogen-related lifestyle 
score; PLCO: Prostate, Lung, Colorectal and Ovarian Cancer Screening 
Trial; SS: The Sister Study. 
aα=0.05; PLCO n=27,488; SS=37,752; 
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Figure 3.1 Estrogen synthesis and metabolisma  
 
aAdapted from Furhman et al.35 
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Figure 3.2 Directed acyclic graph for the association between ERDP and postmenopausal 
breast cancera 
 
BMI: body mass index; ERDP: estrogen-related dietary pattern; HRT: hormone 
replacement therapy; OC: oral contraceptive; PA: Physical activity. 
aParity, age at menarche, age at menopause, age at first birth, and 
oophorectomy/hysterectomy are included in reproductive factors.  
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Figure 3.3 Directed acyclic graph for the association between ERLS and postmenopausal 
breast cancera  
 
BMI: body mass index; ERDP: estrogen-related dietary pattern; ERLS: estrogen-related 
lifestyle score; HRT: hormone replacement therapy; OC: oral contraceptive; PA: Physical 
activity. 
aParity, age at menarche, age at menopause, age at first birth, and 
oophorectomy/hysterectomy are included in reproductive factors.
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4.1 Abstract 
Increased exposure to estrogen is an established risk factor for postmenopausal breast 
cancer, and dietary factors have been shown to influence estrogen metabolism. However, 
investigations of diet and breast cancer have been inconclusive. We developed a dietary 
pattern associated with levels of unconjugated estradiol and the ratio of 2- and 16-
hydroxylated estrogen metabolites in a subsample of Prostate, Lung, Colorectal and 
Ovarian Screening Trial (PLCO) participants (n=653) using reduced rank regression, and 
examined its association with postmenopausal breast cancer prospectively in the larger 
PLCO cohort (n=27,488). The newly developed estrogen-related dietary pattern (ERDP) 
was comprised of foods with positively weighted intakes (non-whole/refined grains, 
tomatoes, cruciferous vegetables, cheese, fish/shellfish high in ω-3 fatty acids, 
franks/luncheon meats) and foods with negatively weighted intakes (nuts and seeds, other 
vegetables, fish/shellfish low in ω-3 fatty acids, yogurt, coffee). A 1-unit increase in the 
ERDP score was associated with a 9%, 13%, and 13% increase in total breast cancer risk 
(HR: 1.09, 95%CI: 1.01-1.18), invasive (HR: 1.13; 95%CI: 1.04=1.04-1.24) and estrogen 
receptor (ER)-positive (HR: 1.13, 95%CI: 1.02- 1.24) breast cancer, respectively, after 
adjustment for confounders. Associations were seen for the fourth quartile of ERDP for 
overall breast cancer (HR: 1.14; 95% CI: 0.98, 1.32), invasive cases (HR: 1.20, 95%CI: 
1.02, 1.42) and ER -positive cases (HR: 1.19; 95%CI: 0.99-1.41) compared to the first. 
The increased risk associated with increasing ERDP score was more apparent in strata of 
some effect modifiers (non-hormone replacement therapy users and non-obese 
participants) where the relative estrogen exposure due to that factor was lowest. Our 
results suggest a dietary pattern based on EM is positively associated with 
postmenopausal breast cancer risk, possibly through an estrogenic influence. 
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4.2 Introduction 
Breast cancer, the most commonly diagnosed cancer among women worldwide, is 
a disease of strong hormonal influence.1 Serum and urinary levels of estrogen metabolites 
(EMs) have consistently been associated with postmenopausal breast cancer risk in 
prospective studies.11 Therefore, modifiable lifestyle risk factors for postmenopausal 
breast cancer that are associated with estrogen metabolism may present opportunities for 
primary prevention.  
Diet is commonly studied as a point of intervention for reducing cancer risk, 
however there have been conflicting results in dietary investigations into breast cancer 
risk, with the exception of alcohol which is considered an established risk factor.17–19,24 It 
is likely that the practice of studying dietary components in isolation may contribute to 
the inconclusive findings for associations with breast cancer, as it does not take into 
account the interactions between nutrients and phytochemicals.25 Therefore, it is 
beneficial to study diet in its entirety using dietary pattern analyses when investigating a 
potential association with breast cancer.26 Emerging evidence has supported an 
association between some dietary patterns and incident breast cancer risk.17,18,27 Many of 
the diets that have indicated an inverse relationship with breast cancer are characterized 
by high intakes of fruits and vegetables, and diets with increased risk typically have 
higher intakes of fat and animal products.17,21,28  
 In order to address some of the inconclusive findings in the literature on diet and 
breast cancer, it may be advantageous to consider the mechanistic pathway by which a 
potential association may occur. Nutritional factors can influence many hormonal 
processes in women, such as the development of breasts, and the onset of both menarche 
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and menopause.29,30 Therefore, diet may have a role in altering estrogen metabolism and 
subsequently breast cancer risk, although data on the relationship between diet and 
estrogen metabolism is scarce.13 A relatively new approach to dietary pattern analyses, 
reduced rank regression (RRR), allows for the use of biomarkers, such as EMs, in 
developing a dietary pattern that can then be investigated in association with disease 
endpoints.31 Previously, Fung et al. developed a dietary pattern correlated with serum 
levels of estradiol and estrone sulfate using RRR, but the pattern subsequently was not 
associated with breast cancer among postmenopausal women in the Nurses’ Health Study 
(NHS).32 However, application of the same estrogen-correlated dietary pattern in a 
Swedish cohort identified a positive association with incident breast cancer.27  
 In the present analysis, we used RRR to develop a dietary pattern that is 
associated with EMs that are hypothesized to be associated with breast cancer risk. Using 
a liquid chromatography-tandem mass spectrometry assay (LC/MS-MS), 15 EMs can be 
measured in an accurate and reproducible method with enough sensitivity to detect the 
low levels present in postmenopausal women.262 Measurement of the parent estrogens’ 
downstream EMs allows for ratios of competing metabolic pathways to be quantified. 
There is evidence that 2-hydroxylation of the parent estrogens is inversely associated, and 
16-hydroxylation is positively associated with postmenopausal breast cancer.11 Therefore, 
increases in the ratio of 2- to 16-hydroxylated EMs (2/16) is hypothesized to indicate a 
beneficial shift in estrogen metabolism with respect to breast cancer risk.11 Based on this 
evidence, and established evidence linking unconjugated estradiol (E2) to 
postmenopausal breast cancer risk,11,57 we used RRR to develop a dietary pattern 
associated with 2/16 and E2. This newly developed estrogen related dietary pattern 
 80 
(ERDP) was applied in a prospective cohort of women to examine an association with 
total postmenopausal breast cancer and by estrogen-receptor (ER) subtype. The potential 
for effect modification by other estrogen-related risk factors was examined. 
 
4.3  Methods 
4.3.1 Study Population 
The Prostate, Lung, Colorectal & Ovarian Cancer Screening Trial (PLCO) is a 
large population-based trial designed to determine the effects of screening on cancer 
prognosis and mortality. Design and implementation has been described in detail 
elsewhere.33 Briefly, 76,685 men and 78,216 women aged 55 to 74 were recruited at 10 
different screening centers across the United States between 1993 and 2001. Eligible 
participants underwent a physical examination and filled out a questionnaire with 
information on demographics, medical history, family history, lifestyle factors, and recent 
history of participation in screening examinations at baseline. Follow-up continued for 13 
years or until December 31, 2009. For the current study, the analysis was restricted to 
screening arm participants (n=39,104) as this group provided blood samples used for 
assessing estrogen metabolites and were asked to complete the dietary instrument (DQX). 
Over 82% of participants in the screening arm completed the DQX. The population was 
further limited to women who completed the baseline questionnaire, a valid DQX (caloric 
intake between 1st and 99th percentiles, <8 missing line items), and without a personal 
history of cancer (n=28,438). Participants were further excluded if they had an extreme 
body mass index (BMI) (<15 or >55 kg/m2; n=74), if they did not contribute any  
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person-time (n=58) or were missing covariate data (n=818), bringing the final analytic 
sample to 27,488. 
 
4.3.2 Subsample and EM Assay 
 A subset of postmenopausal women randomized to the screening arm of PLCO 
for whom information on serum EMs was available was utilized to derive the ERDP. 
Complete information on the nested study has been published elsewhere.35 Briefly, the 
nested study population was drawn from all 1,141 incident breast cancer cases diagnosed 
from the start of recruitment in 1993 through June 30, 2005, and a random sample of 
1,141 control subjects. After excluding women who were not postmenopausal, were 
using hormone replacement therapy (HRT) at baseline, or had prior diagnoses of cancer, 
the sample was reduced to 390 cases and 453 controls. For the purposes of the present 
analysis, cases who were diagnosed <2 years after serum sample donation (n=98) were 
excluded to avoid the possibility of disease processes affecting estrogen levels. Women 
without a valid DQX (n=77) or with implausible EM levels (i.e., if they were outside of 
25th and 75th percentile, plus/minus three times interquartile range; n=15) were further 
excluded. The final analytic sample for the RRR procedure included 393 controls and 260 
subsequent cases, with a mean of 5.25 years from sample donation to breast cancer 
diagnosis. 
 Serum samples from women in the subsample were collected at baseline, stored at 
−80°C and were thawed at 4°C. The LC/MS-MS assay was used to measure the parent 
estrogens along with their metabolites in the 2-, 4-, and 16-hydroxylation pathways, for a 
total of15 EMs. The specifics of sample preparation and LC/MS-MS methods have been 
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described elsewhere.41 The coefficient of variation for all EMs was <5%, with even lower 
coefficients evident for the parent estrogens (<3%) and E2 (<2%).35 
 
4.3.2 Dietary Measurement 
 The DQX, a 137-item food frequency questionnaire, was designed specifically for 
PLCO and asked about typical frequency of intake over the past year. Typical portion 
size was assessed for 77 of the items. Nutrient and food intake amounts were calculated 
using US dietary data and the pyramid food group servings database from the US 
Department of Agriculture (USDA).263 Food and nutrient values were used to create food 
groups based on the USDA’s My Pyramid Equivalents Database (MPED), with 
additional groups created for cruciferous vegetables, tea, and coffee.251 The 32 groups 
used in the present analysis are shown in Table 3.1. 
 
4.3.4 Breast Cancer Ascertainment 
Incident breast cancer cases were identified primarily through self-report via 
annually mailed follow-up questionnaires. Other sources of ascertainment included the 
National Death Index, physician reports, state cancer registries, and next of kin reports. 
Over 96% of the cases were confirmed through hospital records.252 In the analytic cohort, 
a total of 1,569 incident breast cancer cases occurred. A supplemental form was 
implemented in 2007 to capture more detailed information about the diagnosis, available 
for 98% of cases.  
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4.3.5 Development of the ERDP 
 To identify foods that are correlated with unconjugated E2 and the 2/16 ratio, 
RRR modeling was applied to the subsample of 653 participants with EM data. An 
approach using RRR determines linear functions of predictors, which in the present case 
are food groups, by maximizing the explained variation in multiple disease-specific 
response variables, comprised of E2 and the 2/16 ratio.256 In order to ensure RRR factors 
are based on how much variation in the outcome they explain, all intakes were centered 
and scaled so that their mean ± standard deviation (SD) is equal to 0 ± 1. Only the first 
factor was retained for development of the ERDP because it represented a dietary pattern 
that explained the largest variation in the EM. Initially, all 32 food groups were entered 
into the model at once. Those with a variable importance in projection statistic (VIP) 
greater than 0.8 were retained and re-entered into the RRR model, as they represent the 
food groups which are the strongest contributors to RRR factors scores.258 The model 
weights were extracted from the final RRR model from PROC PLS and SAS version 9.4 
(SAS Inc., Cary, NC).  To calculate the ERDP score in the full analytic PLCO cohort 
food group intakes were centered and scaled, then multiplied by their corresponding 
model weights (Table 4.1) for each of the retained food groups. The total ERDP score 
was calculated by summing over the weighted intakes. This same calculation method was 
applied to score the ERDP for the full analytic cohort.  
 
4.3.6 Statistical Analysis 
Baseline comparisons of participant characteristics by ERDP quartiles were 
performed using t-tests and chi-square tests for continuous and categorical variables, 
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respectively. Cox proportional hazards models were applied to prospectively analyze the 
relationship between ERDP scores and incident breast cancer events, with person-time 
contributed as a time scale variable. ERDP scores were categorized into quartiles, with 
the first quartile set as the referent. The first quartile hypothetically represents diets with 
an estrogen profile associated with the lowest breast cancer risk (low levels of 
unconjugated E2 and high 2/16 ratio). The hazard ratio and 95%CI also were calculated 
for the continuous ERDP score variable, and the p-value reported as a test for trend. 
Covariates for multivariable adjusted models were chosen using stepwise model selection 
with entry/exit criteria of p=0.2. We adjusted for age (years), HRT use (current; former; 
never), body mass index (BMI) (kg/m2), alcohol consumption (abstainer; 1-7;  >7 
drinks/week), family history of breast cancer (yes; no), education (less than high school; 
high school and some college; college degree; graduate degree), bilateral oophorectomy 
(yes; no), parity (6 categories), age at menopause (5 categories), hours of vigorous 
physical activity per week (6 categories), and total energy intake (kcal/day). Age at first 
birth, age at menarche, oral contraceptive use, race/ethnicity, smoking status, and prior 
hysterectomy were also considered as potential confounders but were not included after 
performing the stepwise model selection. The potential for effect modification by BMI 
(18.5-29.9 kg/m2; ≥30 kg/m2), baseline HRT use (yes; no), alcohol consumption (<1 
drink/week; ≥1/week), parity (nulliparous; parous), and vigorous physical activity per 
week (<2 hours; ≥2 hours) was assessed using a multiplicative interaction term in the 
model. All models were performed with overall breast cancer and by ER subtype. A 
competing risk model was used to assess a differential association for the ERDP on ER+ 
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and ER- subtypes using a Wald test for heterogeneity in the stratified Lunn-McNeil 
approach.259 
 
4.4 Results 
 Unconjugated E2 and the 2/16 ratio were moderately and inversely correlated (r= 
-0.51; p<0.0001) in the subsample of 653 women. After applying the VIP criteria, 11 
food groups with a VIP >0.8 were retained and re-entered into the RRR procedure. The 
final list of food groups included in the ERDP is shown in Table 4.1. Overall, 4.9% of 
the variation in the EMs was explained by the ERDP. Intakes of non-whole/refined 
grains, tomatoes, cruciferous vegetables, cheese, fish/shellfish high in ω-3 fatty acids, and 
franks/luncheon meats were added; and intakes of nuts and seeds, other vegetables, 
fish/shellfish low in ω-3 fatty acids, yogurt, and coffee were subtracted to calculate the 
ERDP score. The “other vegetables” group includes vegetables except for tomatoes, 
potatoes and orange, dark leafy, cruciferous, and starchy vegetables. For example, this 
group includes cucumber, onion, green pepper, beet, celery, and lettuce. The resulting 
ERDP scores were weakly but significantly correlated with unconjugated E2 (r=0.27; 
p<0.0001) and the 2/16 ratio (r=-0.16; p<0.0001) (Table 4.2). When considering the 
intakes of ERDP food groups, the strongest correlates with unconjugated E2 were non-
whole/refined grains (r=.10; p=0.01), cheese (r=0.16; p<0.0001), yogurt (r=-0.10; 
p=0.01), and franks/luncheon meats (r=0.11; p=0.001). Only intakes for non-
whole/refined grains (r=-0.09; p=0.02) and cheese (r=-0.08; p=0.05) were significantly 
correlated with the 2/16 ratio. Increasing ERDP scores are positively correlated with 
unconjugated E2 and negatively correlated with the 2/16 ratio.  
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 Table 4.1 compares the mean intakes of included food groups across extreme 
quartiles of unconjugated E2 and the 2/16 ratio. On average, participants in the highest 
quartile of unconjugated E2 consumed higher amounts of non-whole/refined grains (4.45 
vs. 3.90; p=0.01), cheese (0.43 vs. 0.29; p<0.01), and franks/luncheon meats (0.34 vs. 
0.21; p=0.01) compared to participants in the first quartile. Mean consumption of coffee 
(2.30 vs. 3.09; p=0.04) and yogurt (0.08 vs 0.12; p=0.03) were significantly lower among 
participants in the highest quartile of unconjugated E2 compared to the first. There were 
no significant differences in mean intakes when comparing extreme quartiles of the 2/16 
ratio. 
 There were 1,592 confirmed incident cases of breast cancer (n=1,248 invasive) 
over an average follow-up of 10.9 years. Among the cases, 1,097 were ER+ and 189 were 
ER-. The mean ± SD ERDP score was -0.006± 0.646 with a range of -4.515 to 6.578. 
Women who were diagnosed with breast cancer during follow-up had significantly higher 
mean ERDP scores at baseline compared to women who were not diagnosed during 
follow-up (0.037 vs. -0.009, respectively; p=0.006). Baseline characteristics for the full 
analytic cohort, stratified by ERDP quartiles, are shown in Table 4.3. There was a 
stepwise increase in the number of total cases from the first to fourth quartiles although 
the differences across quartiles was not significant (p=0.12). Women in the fourth 
quartile of the ERDP were younger, had a higher mean BMI, higher daily caloric intake, 
were more likely to have had a bilateral oophorectomy, and were more likely to be non-
Hispanic White compared to women in the first quartile. There was no clear trend for 
alcohol, with a higher proportion of both abstainers and heavier drinkers in the highest 
quartile of ERDP. A similar pattern was seen for physical activity. There were no 
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differences in HRT use, parity, family history of breast cancer, or age at menopause 
across ERDP quartiles. Participants in the highest quartile of ERDP score consumed the 
most non-whole/refined grains, tomatoes, cheese, and franks/luncheon meats. On the 
contrary, participants in the lowest quartile consumed the most coffee, nuts and seeds, 
fish/shellfish low in ω-3 fatty acids, yogurt, and other vegetables. 
 Results from the time-to-event analyses are shown in Table 4.4. In models using 
ERDP quartiles, participants in the fourth quartile were at increased risk of 
postmenopausal total breast cancer (HR: 1.14; 95% CI: 0.98, 1.32) and invasive breast 
cancer (HR: 1.20; 95%CI: 1.02, 1.42) after multivariable adjustment. All quartiles were 
positively associated with risk, with increasing magnitude of effect estimates with 
increasing quartiles, compared to the first for total (p-trend=0.04) and invasive breast 
cancer (p-trend=0.005). The continuous ERDP variable was positively associated with 
total and invasive breast cancer risk. A 1-unit increase in ERDP was associated with a 9% 
increase in risk (HR: 1.09; 95% CI: 1.01, 1.18) for total and 13% increase in risk for 
invasive (HR: 1.13; 95%CI: 1.04, 1.24) after multivariable adjustment.  
The ERDP was associated with ER+ but not ER- breast cancer (Table 4.4).  The 
multivariable effect estimates for continuous ERDP were 1.13 (95%CI: 1.02-1.24; p-
trend=0.02) and 1.07 (95%CI: 0.85-1.35; p-trend=0.54), respectively. The competing risk 
model did not indicate evidence of a differential effect of the ERDP by ER subtypes 
(p=0.87; data not shown).  
 There was no evidence for effect modification by alcohol consumption and PA. 
However, there was some indication that HRT, BMI, and parity may modify the effect of 
the ERDP (Table 4.5). In stratified results, estimates of association were higher in strata 
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of some effect modifiers where estrogen exposure is thought to be lowest (e.g., among 
HRT non-users, and participants with lower BMI). In the case of parity, estimates were 
higher in nulliparous women. 
 
4.5 Discussion 
We developed a dietary pattern that was significantly associated with serum levels 
of unconjugated E2 and the 2/16 ratio in postmenopausal women. Intakes of non-
whole/refined grains, cheese, franks/luncheon meats, and yogurt were most strongly 
correlated with the derived pattern. When applied in a prospective cohort of women, the 
ERDP was positively associated with total and invasive postmenopausal breast cancer 
risk, and the association was present in ER+ but not ER- breast cancer. The risk 
associated with high ERDP scores was higher within strata of some effect modifiers 
hypothesized to have lower exposure to estrogen. These results suggest that women who 
consume a diet that adheres to higher ERDP scores may be at moderately increased risk 
of developing postmenopausal breast cancer, possibly through an influence on estrogen 
metabolism. 
This is the first study to develop a dietary pattern based on estrogen metabolism 
that is specific to breast cancer risk, due to inclusion of the 2/16 ratio. Quantification of 
estrogen’s downstream metabolic pathways that may be indicative of breast cancer risk 
was possible through use of a highly sensitive LC/MS-MS assay. Previously, Fung et al. 
used RRR to derive a dietary pattern correlated to estradiol and estrone sulfate. High 
scores for the pattern were characterized by high intakes of red meat, legumes, and pizza; 
and low intakes of whole grains and coffee. In the MPED food groups used in the ERDP, 
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food items that make up mixed dishes are decomposed into their individual food groups, 
(for example, pizza is decomposed into cheese, tomatoes, and refined grains). We 
observed moderate similarities between the ERDP and Fung et al.’s estrogen pattern with 
regard to cheese and tomatoes (in the form of pizza in Fung et al.’s pattern), coffee, and 
their respective directions of association with the derived patterns. Fung et al. observed 
an inverse association between whole grains and estrogen, and although whole grains 
were not a significant contributor to the ERDP, non-whole/refined grains had a 
significant positive association, suggesting the importance of choosing whole grains and 
limiting processed grains. 
Other literature on dietary patterns and estrogen metabolism is scarce. However, 
the Alternate Healthy Eating Index and the Western pattern, comprised of processed 
foods and animal products, have been inversely and positively associated with estradiol, 
respectively.144 An intervention study using the Mediterranean Diet, usually high in fruits 
and vegetables, legumes, oils, and other foods that result in a higher proportion of 
unsaturated fats compared to saturated fats, reported a roughly 40% decrease in total 
urinary estrogen levels (p<0.02) in postmenopausal women, showing some anti-
estrogenic properties.147 Although there is evidence linking alcohol52 and soy products130 
with estrogen metabolism, they were not included in the ERDP because they failed to 
meet the inclusion criteria of a VIP >0.8 in the first RRR model. This indicated these 
groups did not explain a large enough variation in the EMs, possibly due to a small range 
of intakes for these groups in our subsample of women.  
Evidence of a moderate but significant association between the ERDP and 
postmenopausal breast cancer was observed in our study population. A significant 
 90 
association was limited to ER+ subtypes, possibly due to an influence on estrogen 
metabolism. Fung et al.’s estrogen diet pattern was not associated with total 
postmenopausal breast or ER subtype-specific cancer risk in NHS,32 which the authors 
concluded was a result of the low correlation between their pattern and the estrogens 
(r=0.22 and r=0.24 for estradiol and estrone sulfate, respectively), which may be 
insufficient to affect breast cancer risk. However, when the same pattern was applied in 
the Swedish Mammography Cohort (SMC) a 29% increase in risk of developing breast 
cancer (HR: 1.29; 95% CI: 1.08, 1.55) was observed when comparing women in the 
highest quartile with the lowest, and no heterogeneity was observed between the ER 
subtypes.27 The authors cited a wider range of intakes, higher consumption of coffee, and 
lower levels of other breast cancer risk factors in SMC as reasons for results that differed 
from the NHS. Our results are consistent with those of the SMC. Explanations for 
different results between the previous studies and ours are difficult to discern because of 
our use of different EMs which resulted in a different dietary pattern. The use of LC/MS-
MS to accurately quantify the EMs, and inclusion of the 2/16 ratio that has more 
consistently been associated with breast cancer risk than other EMs is a strength of our 
investigation.  
Qualitative evidence of effect modification by HRT, BMI, and parity in the 
association between the ERDP and postmenopausal breast cancer risk was observed. 
Based on prior evidence, we expect women who are not using HRT or who are not obese 
to have lower lifetime exposure to estrogen.67 In these women, a dietary influence, 
through estrogen or other pathway may be easier to detect than in women with higher 
lifetime estrogen exposure. In the NHS, no effect modification by BMI was observed 
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using their estrogen correlated dietary pattern, though other effect modifiers were not 
examined.32 It is possible a woman’s nulliparity is a result of low fertility due to low 
hormone levels.264 However, nulliparous women typically experience more menstrual 
cycles, resulting in greater lifetime exposure to estrogen and higher breast cancer risk,219 
therefore these results need to be explored further. 
There are multiple possible mechanisms by which the ERDP effects estrogen 
metabolism and breast cancer risk, such as through influences on microbiome 
diversity.265 The intestinal microbiome is strongly influenced by dietary behaviors, and 
the composition of the microbiome can have implications on many important 
physiological processes.266 The fate of conjugated, or inactive, estrogens is dependent on 
the state of the intestinal microbiome, which influences whether or not the conjugated 
estrogens are excreted through feces or transformed to their unconjugated forms and 
subsequently reabsorbed.267 If reabsorbed, there is a greater estrogenic exposure 
throughout the body. Therefore, diet may influence development of a microbiome that is 
favorable to excretion of estrogens, lowering breast cancer risk, or one that is conducive 
to reabsorption of the estrogens which increases risk. In addition to absolute exposure to 
estrogen, the composition of EMs is also influenced by the micriobiome.268 More 
specifically, there is evidence of microbial effects on interconversions of the parent 
estrogens and hydroxylation down the 16-pathway from in vitro and human studies.269,270 
The intestinal microbiome is strongly influenced by fiber intake, or lack thereof, through 
consumption of grains and vegetables, both of which are included in the ERDP.266 The 
ERDP also is comprised of animal products, such as meats, cheese, and yogurt, which 
can impact microbiome diversity.271–273 Considering the presence of a microbial influence 
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on estrogen metabolism and its established relationship with diet, modification of the 
intestinal microbiome is a plausible mechanism by which the ERDP influences estrogen 
metabolism and breast cancer risk.  
Considering other mechanisms, it is possible the ERDP was associated with breast 
cancer through effects on inflammation. Coffee, as well as processed meats, dairy, and 
refined grains which are common in the Western diet, have all exhibited associations with 
inflammation,274,275 and inflammation may play a role in mammary tumor 
development.276 The Mediterranean Diet, characterized by foods with anti-inflammatory 
properties has been inversely associated with breast cancer,48 and a dietary pattern based 
on inflammatory potential has shown evidence of an association with breast cancer50 and 
breast cancer mortality.51  
There are some limitations in our study that need to be considered when 
interpreting the results. As with most prospective nutritional investigations, there is the 
potential for bias due to the selection of subjects, loss to follow-up, and dietary 
measurement error. Although food frequency questionnaires may not generate accurate 
estimates for absolute intakes of nutrients, they have been shown to be effective in 
ranking individuals, as is the purpose in this study.173 Unexpected results from fish with 
low and high ω-3 fatty acids could have been due to preparation methods that were not 
ascertained. Low numbers of ER- cases may have limited our ability to detect an 
association in this subtype and a heterogeneity in effect by ER subtype, however, there 
were ample ER+ cases for analyses. A limitation of the PLCO study population is the 
lack of racial/ethnic diversity. However, non-Hispanic White women experience the 
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highest incidence of breast cancer compared to other races/ethnicities in the US, so 
results are generalizable to this group at the highest risk.  
There are strengths in the approach and design to note, as well. The use of a large, 
prospective cancer cohort allowed the associations of interest to be investigated with 
enough power to detect moderately small effects and with information on multiple known 
risk factors with which to adjust for potential confounding. The application of RRR to 
derive the ERDP provides the ability to incorporate a hypothesized pathogenic pathway 
in dietary pattern development.31,257 As noted, the EMs included in the RRR models have 
been shown to be strongly related to breast cancer risk and were measured using a more 
sensitive assay method, thus improving upon the previous RRR-derived estrogen dietary 
pattern.32 
In conclusion, we identified a dietary pattern to be associated with an estrogen 
profile (high E2 and low 2/16 ratio) hypothesized to increase breast cancer risk. Women 
who had high ERDP scores tended to consume higher amounts of non-whole/refined 
grains, tomatoes, cheese, franks/luncheon meats; and lower amounts of nuts and seeds, 
cruciferous vegetables, other vegetables, fish/shellfish, yogurt, and coffee. A subsequent 
prospective investigation indicated that this estrogenic diet was associated with an 
increased risk of postmenopausal breast cancer risk, possibly through an influence on 
estrogen metabolism. Future studies should be conducted in populations from other 
regions with larger variation in intakes in food groups, or in study populations using 
open-ended dietary assessment tools to capture all foods or food groups that potentially 
influence estrogen metabolism 
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4.6 Tables 
 
Table 4.1 Comparison of mean (±standard deviation) food or beverage intake across extreme quartiles of estrogen metabolites for the 
eleven foods and beverages included in the estrogen-related dietary pattern (ERDP) 
 
    Unconjugated E2 2/16 Ratio 
  Model Weight
a Q1 (n=164) Q4 (n=163) p-valueb Q1 (n=163) Q4 (n=163) p-valueb 
Non-whole/refined grains (oz/day) 0.12 3.90 ± 1.81 4.45 ± 2.00 0.01 4.39 ± 2.06 4.10 ± 1.91 0.18 
Tomatoes (cups/day) 0.09 0.40 ± 0.22 0.45 ± 0.27 0.06 0.43 ± 0.30 0.43 ± 0.24 0.79 
Other vegetables (cups/day) -0.13 0.96 ± 0.52 0.95 ± 0.45 0.89 1.02 ± 0.58 1.07 ± 0.60 0.42 
Cruciferous vegetables (cups/day) 0.08 0.28 ± 0.21 0.26 ± 0.20 0.6 0.30 ± 0.26 0.32 ± 0.23 0.46 
Cheese (cups/day) 0.16 0.29 ± 0.23 0.43 ± 0.38 <0.01 0.38 ± 0.37 0.33 ± 0.26 0.2 
Yogurt (cups/day) -0.12 0.12 ± 0.19 0.08 ± 0.15 0.03 0.09 ± 0.17 0.12 ± 0.21 0.15 
Fish/shellfish high in ω-3 fatty  
acids (oz/day) 
0.2 0.16 ± 0.17 0.15 ± 0.15 0.55 0.15 ± 0.17 0.16 ± 0.19 0.53 
Fish/shellfish low in ω-3 fatty  
acids (oz/day) 
-0.27 0.53 ± 0.47 0.49 ± 0.38 0.46 0.46 ± 0.36 0.52 ± 0.49 0.21 
Franks and luncheon meats (oz/day) 0.08 0.21 ± 0.23 0.34 ± 0.56 0.01 0.28 ± 0.31 0.22 ± 0.28 0.07 
Nuts and seeds (oz/day) -0.11 0.45 ± 0.70 0.38 ± 0.42 0.32 0.44 ± 0.79 0.44 ± 0.64 0.99 
Coffee (cups/day) -0.1 3.09 ± 3.59 2.30 ± 3.27 0.04 2.64 ± 3.34 3.18 ± 3.73 0.17 
ERDP: estrogen related dietary pattern; EM: estrogen metabolite 
aModel weight from final RRR model that is used for ERDP scoring. 
bt-test for the comparison of means in the first and fourth quartiles. 
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Table 4.2 Correlations for the estrogen-related dietary pattern (ERDP) and food group intakes with factor score and estrogen 
metabolite response variables among subset of women with estrogen metabolite values (n=653)a 
 
  
RRR Factor Score 
Unconjugated 
Estradiol 
2/16 Pathway 
Ratio 
Total ERDP score 1.00 (<0.01) 0.27 (<0.01) -0.16 (<0.01) 
Non-whole/refined grains (oz/day) 0.41 (<0.01) 0.10 (0.01) -0.09 (0.02) 
Tomatoes (cups/day) 0.28 (<0.01) 0.08 (0.03) -0.03 (0.48) 
Other vegetables (cups/day) -0.07 (0.07) -0.03 (0.46) 0.00 (0.90) 
Cruciferous vegetables (cups/day) -0.02 (0.61) -0.03 (0.47) -0.04 (0.34) 
Cheese (cups/day) 0.55 (<0.01) 0.16 (<0.01) -0.08 (0.05) 
Yogurt (cups/day) -0.34 (<0.01) -0.10 (0.01) 0.05 (0.25) 
Fish/shellfish high in ω-3 fatty acids 
(oz/day) 
-0.06 (0.10) -0.02 (0.56) 0.00 (0.98) 
Fish/shellfish low in ω-3 fatty acids (oz/day) -0.18 (<0.01) -0.04 (0.27) 0.04 (0.32) 
Franks and luncheon meats (oz/day) 0.39 (<0.01) 0.11 (<0.01) 0.00 (0.92) 
Nuts and seeds (oz/day) -0.14 (<0.01) -0.05 (0.17) -0.05 (0.24) 
Coffee (cups/day) -0.22 (<0.01) -0.06 (0.10) 0.03 (0.51) 
ERDP: estrogen related dietary pattern; EM: estrogen metabolite; RRR: reduced rank regression 
aPearson's correlation coefficient (p-value). 
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Table 4.3 PLCO population characteristics across the estrogen-related dietary pattern (ERDP) quartiles 
 
    
ERDP Quartile 
(score range) 
   
1st 2nd 3rd 4th 
(-4.515,  
-0.350) 
(-0.351,  
-0.021) 
(-0.022, 0.328) (0.329, 6.578) 
n  6,872 6,872 6,872 6,872 
Breast cancer cases Total 366 392 403 431 
  Invasive 280 309 331 348 
  ER+  246 275 274 302 
  ER-  45 41 55 48 
ERDP score (mean ± SD) -0.77 ± 0.43 -0.18 ± 0.09 0.14 ± 0.10 0.77 ± 0.48 
Age (mean ± SD) 62.6 ± 5.3 62.8 ± 5.4 62.5 ±5.3 61.8 ± 5.2 
BMI (kg/m2; mean ± SD) 26.6 ± 5.1 26.6 ± 5.1 27.1 ± 5.3 28.1 ± 5.9 
BMI at age 20 (kg/m2; mean ± SD) 21.4 ± 2.9 21.1 ± 2.7 21.2 ± 2.7 21.4 ± 3.0 
Total energy intake (kcal/day; mean ± SD) 1,691 ± 578 1,542 ± 528 1,659 ± 535 2,078 ± 621 
HRT use (%)      
  Current 51.7 51.9 51.6 51.6 
  Former 15.8 16.4 16 15.8 
  Never 32 31.3 32 32.1 
Race (%)       
  White, Non-Hispanic 88.4 90.6 91.9 93.1 
  Black, Non-Hispanic 4.8 4.5 4.1 3.9 
  Hispanic 1.1 1.2 1.4 1.4 
  Asian 5.1 3.1 2.1 1.1 
Alcohol (%)      
  Abstainer 24.4 25.7 28.7 29.9 
  0-7 drinks/week 62.4 60.8 58.4 55.5 
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  >7 drinks/week 13.2 13.5 12.9 14.6 
Smoking (%)      
  Current 9.6 8.8 7.8 9.3 
  Former 38.7 33.7 31.8 32.4 
  Never 51.7 57.5 60.4 58.3 
Education (%)      
  < High school 5.4 5.8 5.9 5.6 
  High school grad and some college 62.2 65.2 65.2 64 
  College grad 15.9 15.3 15.6 16.1 
  Postgraduate 16.6 13.8 13.4 14.3 
Live births (%)      
  None 9.9 8.8 8.5 8.6 
  1 7.4 6.6 7 7.2 
  2 24.6 23.8 23.1 22.7 
  3 25.2 25.4 25.3 25.5 
  ≥ 4 32.9 35.4 36.1 36 
Age at menopause (%)      
  < 40 14.4 14 13.3 13.3 
  40-44 14.3 13.6 14.5 13.4 
  45-59 23.9 23.9 23.2 23.2 
  50-54 36.2 37.3 37.9 38.2 
  ≥55 11.2 11.3 11.2 12 
Family history of breast cancer (%)      
  No 85 85.7 84.6 84.3 
  Yes, immediate female  13.9 13.4 14.1 14.5 
  Male only 0.2 0.1 0.2 0.1 
Bilateral oophorectomy (%)      
  No 90.3 88.9 88.5 88.3 
  Yes 9.8 11.1 11.5 11.7 
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Hours of vigorous PA per week (%)      
  None 12.2 14.5 15.6 19.4 
  < 1  16.3 18.9 19.4 19.7 
  1 11.3 12.4 11.7 12.3 
  2 17.7 16.5 17 16.1 
  3 17.8 16.7 17 14.9 
  ≥4 24.9 21 19.3 17.6 
Non-whole/refined grains (oz/day; mean ± SD) 3.51 ± 1.58 3.50 ± 1.52 4.10 ± 1.60 5.66 ± 2.19 
Tomatoes (cups/day; mean ± SD) 0.38 ± 0.23 0.36 ± 0.22 0.41 ± 0.24 0.56 ± 0.42 
Other vegetables (cups/day; mean ± SD) 1.14 ± 0.64 0.93 ± 0.51 0.90 ± 0.48 0.98 ± 0.52 
Cruciferous vegetables (cups/day; mean ± SD) 0.30 ± 0.28 0.27 ± 0.24 0.27 ± 0.24 0.30 ± 0.28 
Cheese (cups/day; mean ± SD) 0.23 ± 0.18 0.24 ± 0.18 0.32 ± 0.21 0.60 ± 0.40 
Yogurt (cups/day; mean ± SD) 0.25 ± 0.30 0.10 ± 0.15 0.07 ± 0.12 0.06 ± 0.12 
Fish/shellfish high in ω-3 fatty acids (oz/day; mean ± SD) 0.19 ± 0.21 0.14 ± 0.15 0.13 ± 0.15 0.17 ± 0.22 
Fish/shellfish low in ω-3 fatty acids (oz/day; mean ± SD) 0.65 ± 0.63 0.45 ± 0.37 0.43 ± 0.35 0.49 ± 0.42 
Franks and luncheon meats (oz/day; mean ± SD) 0.14 ± 0.17 0.16 ± 0.17 0.22 ± 0.22 0.42 ± 0.45 
Nuts and seeds (oz/day; mean ± SD) 0.63 ± 0.97 0.35 ± 0.48 0.33 ± 0.42 0.38 ± 0.45 
Coffee (cups/day; mean ± SD) 3.83 ± 4.22 2.37 ± 2.50 1.86 ± 2.18 1.86 ± 2.29 
ERDP: estrogen related dietary pattern; ER: estrogen receptor; BMI: body mass index; HRT: hormone replacement therapy; PA: physical activity; PLCO: 
Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; SD: standard deviation 
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Table 4.4 Hazard ratios (95% CI) for the relationship between the estrogen-related dietary pattern (ERDP) score and postmenopausal 
breast cancer in PLCO 
 
    ERDP quartiles 
Estimate for continuous 
ERDP scorea, p-trend 
    1st 2nd 3rd 4th  
Total breast cancer           
  No. of cases 366 392 403 431   
  Age-adjusted 1.00 (ref) 1.07 (0.93, 1.24) 1.10 (0.95, 1.26) 1.18 (1.03, 1.36) 
1.12 (1.03, 1.20) 
p=0.005 
  Age- and-TEI adjusted 1.00 (ref) 1.09 (0.94, 1.25) 1.10 (0.95, 1.27) 1.15 (1.00, 1.33) 
1.10 (1.01, 1.18)  
p=0.02 
  Multivariable-adjustedb 1.00 (ref) 1.08 (0.94, 1.25) 1.10 (0.95, 1.27) 1.14 (0.98, 1.32) 
1.09 (1.01, 1.18) 
p=0.04 
Invasive        
  No. of cases 280 309 331 348   
  Age-adjusted 1.00 (ref) 1.11 (0.94, 1.30) 1.18 (1.00, 1.38) 1.25 (1.07, 1.47) 
1.16 (1.07, 1.26) 
p=0.0006 
  Age- and-TEI adjusted 1.00 (ref) 1.12 (0.95, 1.32) 1.18 (1.01, 1.38) 1.21 (1.03, 1.43) 
1.14 (1.04, 1.24) 
p=0.003 
  Multivariable-adjustedb 1.00 (ref) 1.12 (0.95, 1.31) 1.18 (1.01, 1.39) 1.20 (1.02, 1.42) 
1.13 (1.04, 1.24) 
p=0.005 
ER+         
  No. of cases 246 275 274 302   
  Age-adjusted 1.00 (ref) 1.12 (0.94, 1.33) 1.11 (0.93, 1.32) 1.23 (1.04, 1.46) 
  
1
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1.15 (1.05, 1.26) 
p=0.003 
  Age- and-TEI adjusted 1.00 (ref) 1.13 (0.95, 1.35) 1.11 (0.94, 1.32) 1.20 (1.01, 1.42) 
1.13 (1.03, 1.24) 
p=0.01 
  Multivariable-adjustedb 1.00 (ref) 1.13 (0.95, 1.34) 1.11 (0.94, 1.32) 1.19 (0.99, 1.41) 
1.13 (1.02, 1.24) 
p=0.02 
ER-        
  No. of cases 45 41 55 48   
  Age-adjusted 1.00 (ref) 0.92 (0.60, 1.40) 1.21 (0.82, 1.80) 1.06 (0.71, 1.59) 
1.09 (0.87, 1.35) 
p=0.46 
  Age- and-TEI adjusted 1.00 (ref) 0.93 (0.61, 1.43) 1.22 (0.82, 1.81) 1.01 (0.66, 1.53) 
1.06 (0.85, 1.32) 
p=0.63 
  Multivariable-adjustedb 1.00 (ref) 0.94 (0.61, 1.44) 1.24 (0.83, 1.84) 1.04 (0.68, 1.59) 
1.07 (0.85, 1.35) 
p=0.54 
Person-years accumulated 74,615 74,375 74,932 74,468   
ERDP: estrogen related dietary pattern; TEI: total energy intake; ER: estrogen receptor; BMI: body mass index; HRT: hormone replacement therapy; PA: 
physical activity; PLCO: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial 
aHR corresponds to 1-unit increase in ERDP score. 
bIncludes adjustment for age, TEI, BMI, BMI at age 20, HRT, alcohol use, education, bilateral oophorectomy, parity, age at menopause, PA, race/ethnicity, 
recruitment center, and family history of breast cancer. 
  
1
0
1
 
Table 4.5 Hazard ratios (95% CI) for the relationship between the estrogen-related dietary pattern (ERDP) score and postmenopausal 
breast cancer within strata of estrogen-related risk factors in PLCOa 
 
    
ERDP quartiles 
p interactionb 
    1st 2nd 3rd 4th 
HRT use at baseline     0.64 
  No 1.00 (ref) 1.20 (0.96, 1.50) 1.27 (1.02, 1.59) 1.24 (0.99, 1.56)   
  Yes 1.00 (ref) 1.02 (0.85, 1.23) 1.01 (0.84, 1.21) 1.07 (0.88, 1.29)   
BMI (kg/m2)      0.59 
  18.5-29.9 1.00 (ref) 1.09 (0.92, 1.28) 1.14 (0.97, 1.34) 1.20 (1.02, 1.43)   
  ≥30 1.00 (ref) 1.12 (0.83, 1.51) 1.01 (0.75, 1.35) 0.99 (0.75, 1.32)   
Alcohol consumption     0.90 
  <1 drink/week 1.00 (ref) 1.11 (0.92, 1.34) 1.15 (0.96, 1.38) 1.15 (0.95, 1.39)   
  ≥1 drinks/week 1.00 (ref) 1.05 (0.84, 1.32) 1.03 (0.82, 1.30) 1.14 (0.90, 1.44)   
Parity      0.58 
  Nulliparous 1.00 (ref) 1.24 (0.77, 2.00) 1.44 (0.90, 2.28) 1.45 (0.91, 2.32)   
  Parous 1.00 (ref) 1.06 (0.91, 1.24) 1.07 (0.92, 1.24) 1.10 (0.95, 1.28)   
Vigorous PA     0.61 
  <2 hours/week 1.00 (ref) 1.18 (0.95, 1.47) 1.11 (0.89, 1.38) 1.12 (0.90, 1.40)   
  ≥2 hours/week 1.00 (ref) 1.01 (0.83, 1.22) 1.10 (0.91, 1.33) 1.17 (0.96, 1.42)   
ERDP: estrogen related dietary pattern; TEI: total energy intake; ER: estrogen receptor; BMI: body mass index; HRT: hormone replacement therapy; PA: 
physical activity; PLCO: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial 
aIncludes adjustment for age, TEI, BMI, BMI at age 20, HRT, alcohol use, education, bilateral oophorectomy, parity, age at menopause, PA, race/ethnicity, 
recruitment center, and family history of breast cancer. 
bP-value for the product term of ERDP quartiles with the potential effect modifier. 
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5.1 Abstract 
 Introduction: The results of previous studies on diet and postmenopausal breast 
cancer risk have been inconclusive. There is some evidence that dietary patterns 
developed to correlate with estrogen have positive associations with breast cancer, 
however, results are mixed. We applied an estrogen-related dietary pattern (ERDP) that 
was developed in a subsample of the Prostate, Lung, Colorectal, and Ovarian Cancer 
Screening Trial (PLCO) to the Sister Study and examine associations with 
postmenopausal breast cancer. Methods: Participants from the Sister Study without a 
personal history of cancer and who contributed postmenopausal person-time at risk were 
included in the present analysis. Intakes of non-whole/refined grains, tomatoes, 
cruciferous vegetables, other vegetables, cheese, yogurt, fish/shellfish, franks/luncheon 
meats, nuts and seeds, and coffee were measured via food frequency questionnaires and 
used to calculate the ERDP. Cox proportional hazards models were used to estimate 
hazard ratios (HR) and 95% confidence intervals (CI) for the association between the 
ERDP and postmenopausal breast cancer. Results: Over 274,308 person-years of follow-
up 1,951 incident cases occurred. ERDP was not associated with total, invasive, ER+, or 
ER- subtypes of breast cancer either as a continuous or categorical variable. The 
association did not differ across strata of other estrogen-related risk factors. Results were 
robust to various sensitivity analyses. Conclusion: Our investigation did not support 
previous studies observing an association between an estrogen-derived dietary pattern 
and postmenopausal breast cancer risk. Null results may be partially explained by higher 
levels of other breast cancer risk factors, such as a family history of breast cancer within 
the study population. 
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5.2 Introduction 
Breast cancer accounts for nearly one-third of incident cancer cases among U.S. 
women and imposes a significant disease burden.277 Primary prevention may help ease 
this burden, yet the identification of modifiable lifestyle factors for prevention remains a 
large gap in translational breast cancer research.43 Diet represents a commonly studied 
lifestyle behavior in cancer prevention, however, results from studies of individual 
dietary components has yielded inconsistent results.17–19,24 Among dietary factors, only 
alcohol is recognized by the World Cancer Research Fund and American Institute for 
Cancer Research to have a probable influence on postmenopausal breast cancer risk, as 
determined by the observational evidence and biologic plausibility from experimental 
studies.24 
  It is possible that focusing on a known biologic mechanism while considering the 
totality of diet and not only individual foods or nutrients may result in the identification 
of stronger dietary associations with breast cancer. In postmenopausal breast cancer, 
circulating or urinary estrogen metabolites have been associated with disease risk.11 
Postmenopausal women have low endogenous levels of estrogen, therefore relatively 
small changes in estrogen resulting from dietary exposures may play a role in breast 
cancer risk.   
 Accordingly, we and others have developed dietary patterns based on associations 
between specific food groups and measured levels of estrogens or estrogen 
metabolites.27,32   Results of studies linking these dietary patterns to postmenopausal 
breast cancer risk have been mixed.  In the Nurses’ Health Study (NHS), a dietary pattern 
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based on estradiol (E2) and estrone sulfate was not associated with postmenopausal 
breast cancer risk.32 However, the same pattern was applied in a group of Swedish 
women and a positive association with breast cancer was observed.27 A second estrogen-
related dietary pattern (ERDP) was developed using data from a nested study of 
participants from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial 
(PLCO).35,278 The ERDP was developed using unconjugated E2 and the ratio of 2- to 16-
hydroxylated (2/16 ratio) estrogen metabolites (EM). Fifteen downstream metabolites, 
including the 2- and 16-pathways, could be quantified using a liquid chromatography-
tandem mass spectrometry assay (LC/MS-MS) which has enough sensitivity to detect the 
low levels present in postmenopausal women.262 The ERDP was positively associated 
with postmenopausal breast cancer risk in a time-to-event analysis in the PLCO cohort.278 
 We applied the ERDP in a study population different from the one in which it was 
developed and examined its association with postmenopausal breast cancer risk. 
Outcomes included total and invasive breast cancer, as well as estrogen receptor (ER) 
subtypes of breast cancer. The potential for a differential effect in strata of other 
estrogen-related risk factors was assessed. We hypothesized the ERDP to be positively 
associated with breast cancer. We expected to see the strongest associations in ER+ 
subtypes and among strata of other risk factors where the relative estrogen exposure was 
lowest.  
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5.3 Methods 
5.3.1 Study Population  
The Sister Study, an initiative of the National Institute of Environmental Health 
Sciences, is a large prospective cohort study to investigate environmental and genetic 
determinants of breast cancer.34 A total of 50,884 women aged 35 to 74 who had a sister 
who was diagnosed with breast cancer were recruited between 2003 and 2009 from all 50 
U.S. states and Puerto Rico. Women completed self-administered questionnaires and a 
computer-assisted telephone interview to ascertain information on demographics and 
potential risk factors. Breast cancer incidence was assessed annually via a brief study 
update and a comprehensive follow-up questionnaire was administered every two to three 
years. The Institutional Review Board of the National Institute of Environmental Health 
Sciences and the Copernicus Group Institutional Review Board approved the study. In 
the present analysis, participants were excluded if they had a personal history of cancer 
(n=2,757), or if they did not contribute any person-time at risk for postmenopausal breast 
cancer (n=8,004). Participants were further excluded if they reported an extreme caloric 
intake (<500 or >5,000 kcal/day; n=1,163), had an extreme body mass index (BMI; <15 
or >50 kg/m2; n=68), or if they had missing covariate data (n=1,140); bringing the total 
analytic sample to 37,752.  
 
5.3.2 Dietary Assessment  
Intakes over the prior 12 months, as measured by the 110-item 1998 Block food 
frequency questionnaire (FFQ) at baseline, were used to calculate the ERDP. Briefly, the 
ERDP was previously developed using reduced rank regression modeling to identify food 
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groups that were associated with serum levels of unconjugated E2 and the 2/16 ratio in a 
nested case-control study of 653 postmenopausal women from PLCO. The resulting 
ERDP was comprised of non-whole/refined grains, tomatoes, cruciferous vegetables, 
cheese, fish/shellfish high in ω-3 fatty acids, franks/luncheon meats, nuts and seeds, other 
vegetables, fish/shellfish low in ω-3 fatty acids, yogurt, and coffee. Intakes of the food 
groups were centered and scaled, then multiplied by their corresponding model weights 
which were derived using the PLCO data (Table 4.1). The total ERDP score was 
calculated by summing over the weighted intakes. In the present study, intakes from the 
FFQ were categorized into food groups using the U.S. Department of Agriculture’s Food 
Patterns Equivalents Database.279 Additional food groups were created for cruciferous 
vegetables and coffee. Higher ERDP scores are hypothesized to be positively associated 
with unconjugated E2 and inversely associated with the 2/16 ratio. 
 
5.3.3  Breast Cancer Ascertainment 
 Participants were followed until breast cancer diagnosis, death, or end of follow-
up. Incident breast cancer cases were ascertained via completion of annual health updates 
and biennial surveys. Response rates for the surveys were over 94%.253 Access to medical 
records was requested after a breast cancer diagnosis was self-reported. Medical record 
abstraction was used to confirm over 80% of cases and to identify information on 
treatment and diagnosis, such as ER subtype.200 The positive predictive value of self-
reported breast cancer, invasive cancer, and ER breast cancer was over 90% and therefore 
self-reported information is used when medical records could not be obtained.254 
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5.3.4  Statistical Approach 
Baseline comparisons of participant characteristics by ERDP quartiles were 
performed using t-tests and chi-square tests for continuous and categorical variables, 
respectively. Cox proportional hazards models were applied to analyze the relationship 
between ERDP scores and incident breast cancer events, using age as the time scale 
variable. The proportional hazards assumption was evaluated using Martingale-based 
residuals and was not violated by exposure variables or covariates. ERDP scores were 
categorized into quartiles, with the first quartile set as the referent. The first quartile 
hypothetically represents diets with an estrogen profile associated with the lowest breast 
cancer risk (low levels of unconjugated E2 and high 2/16 ratio). The hazard ratios and 
95%CIs also were calculated for the continuous ERDP score variable, and the p-value 
reported as a test for trend. Demographic factors of age (years), education (less than high 
school; high school and some college; college degree; graduate degree), race/ethnicity 
(non-Hispanic White, non-Hispanic Black, Hispanic, Asian, other), and total caloric 
intake (kcal/day) were included in the multivariable-adjusted models for their putative 
roles as confounders, as identified by a DAG.  The remaining covariates included in 
multivariable-adjusted models were chosen using stepwise model selection with 
entry/exit criteria of p=0.2, and include hormone replacement therapy (HRT) use (never, 
former – estrogen + progesterone, former – estrogen only, current – estrogen + 
progesterone, current – estrogen only, ever – unknown type), baseline body mass index 
(BMI; kg/m2), BMI at age 30 kg/m2),  physical activity (metabolic equivalent of task 
(MET)-hours/week), alcohol consumption (abstainer, ≤1 drink/day, >1 drink/day), 
number of first degree relatives with history of breast cancer, age at menarche, age at 
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menopause, parity, and prior hysterectomy (yes, no). Oral contraceptive (OC) use, age at 
first birth, bilateral oophorectomy, and smoking status were considered but were not 
retained after stepwise selection in order to improve model efficiency and reduce the 
potential for over adjustment. Models were used with total breast cancer, invasive only, 
and ER subtypes among invasive cases as outcomes. A competing risk model assessed a 
differential association for the ERDP on ER+ and ER- subtypes using a Wald test for 
heterogeneity in the stratified Lunn-McNeil approach.259 Effect modification by baseline 
HRT use (yes, no), BMI (18.5-29.9 kg/m2, ≥30 kg/m2), alcohol consumption (abstainer, 
≤1 drink/day, >1 drink/day), parity (nulliparous, parous), and whether or not participants 
met the Physical Activity Guidelines for Americans (PAG; <500 MET-min/week, ≥500 
MET-min/week).280 Soy products are not a component of the ERDP. However, soy foods 
(e.g., tofu, tempeh, soy milk, and other soy substitutes) may modify dietary influences on 
breast cancer due to their high phytoestrogen content.167 Additional questions on soy food 
intake were added to the Sister Study FFQ. Therefore, the association between the ERDP 
and breast cancer was assessed in strata of soy food consumption (non-consumer, >0 to 
4.9 g/day, ≥5 g/day). 
Multiple sensitivity analyses were conducted. The first set of sensitivity analyses 
assessed changing parameters in the model. If BMI lies on the causal pathway between 
the ERDP and postmenopausal breast cancer, there is the potential for mediator bias. 
Therefore, a sensitivity analysis was conducted by removing BMI as a covariate. Because 
hormone receptor status was not routinely obtained for in situ cases during the study 
period, ER receptor subtype analyses were limited to invasive cases.  However, a 
sensitivity analysis was carried out including in situ cases.  A second set of sensitivity 
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analyses examined the relationship between the ERDP and breast cancer in population 
subgroups. Minority population recruitment was prioritized at later stages in the 
recruitment process and therefore minority women have slightly shorter average follow-
up time. Thus, the relationship was investigated when restricting to non-Hispanic Whites. 
In another subgroup analysis, participants who contributed ≤12 months of follow-up were 
excluded to minimize the possibility of reverse causality. The final subgroup analysis was 
restricted to women with no more than one full sister having a history of breast cancer, as 
effects of lifestyle factors such as diet may be harder to detect in women with a strong 
inherited risk. All statistical tests were two-sided at α=0.05, with the exception of 
interaction p-values which were considered statistically significant at p<0.10. All 
analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC). 
 
5.4 Results 
 There were 1,951 incident cases of postmenopausal breast cancer over 274,308 
person-years of follow-up. Among the 1,484 invasive cases, 1,098 and 199 were ER+ and 
ER-, respectively. The mean ± standard deviation (SD) ERDP score was -0.05 ± 0.71 
with a range of  -8.32 to 4.67. Average ERDP scores among women who were diagnosed 
with incident breast cancer during follow-up were not significantly different than women 
who were not diagnosed (-0.06 vs 0.04, respectively; p=0.28). Baseline characteristics 
across strata of ERDP quartiles are shown in Table 5.1. Women in the fourth ERDP 
quartile were typically younger, had a higher BMI at baseline and at age 30, consumed 
more calories but less alcohol, and were more likely to have never used HRT or be 
former users of an estrogen + progesterone formula of HRT. These women also were 
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more likely to be non-Hispanic White or Hispanic. Intakes of non-whole/refined grains, 
tomatoes, cheese, franks and luncheon meats were highest among participants in the 
fourth ERDP quartile. Conversely, participants in the first ERDP quartile consumed 
higher amounts of other vegetables, yogurt, fish/shellfish, nuts and seeds, and coffee.  
 In multivariable models comparing the highest ERDP quartile with the first 
(Table 5.2), or diets with the most estrogenic potential compared to the least potential, no 
association was observed for total (HR: 0.98; 95%CI: 0.86, 1.11; ptrend=0.70), invasive 
(HR: 0.96; 95%CI: 0.83, 1.11; ptrend=0.41),  invasive ER+ (HR: 0.91; 95%CI: 0.77, 1.07; 
ptrend=0.12), or invasive ER- (HR: 1.23; 95%CI: 0.82, 1.84; ptrend=0.17) breast cancer. 
Results from a competing risk model indicated there was no differential effect of the 
ERDP on ER+ and ER- subtypes (p=0.18; data not shown). Table 5.3 shows evidence for 
potential effect modification between the ERDP and total breast cancer by alcohol 
consumption (p=0.03), parity (p=0.03), and whether or not participants met the criteria of 
500 MET-min/week from the PAG (p=0.07). In the fourth ERDP quartile estimates of 
association were highest among participants who consumed ≥1 alcohol drink per day 
(HR: 1.18; 95%CI: 0.83, 1.69), were nulliparous (HR: 1.34; 95%CI: 1.00, 1.80), or who 
exercised for 500 MET-min/week (HR: 1.13; 95%CI: 0.95, 1.34), although CIs included 
the null value. There was no evidence of effect modification by HRT use at baseline 
(p=0.34) or BMI status at baseline (p=0.44).  
No association for the relationship between the ERDP and postmenopausal breast 
cancer was observed in sensitivity models with different model parameters (Table 5.4) or 
within different population subgroups (Table 5.5). Similarly, there was no association 
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between the ERDP and total breast cancer within strata of soy food consumption levels 
(Table 5.6).  
 
5.5 Discussion 
 A dietary pattern derived in PLCO to correlate with a high-risk estrogen profile 
(high unconjugated E2, low 2/16 ratio) was applied in the Sister Study, prospective 
cohort of women with a family history of breast cancer. Results from the time-to-event 
analysis showed no association for the ERDP with total, invasive, or ER subtypes of 
postmenopausal breast cancer. Participants in the fourth ERDP quartile, who were 
suspected to have the most estrogenic potential from their diets, did not experience 
greater risk of postmenopausal breast cancer compared to individuals in the first quartile.  
 Prior application of the ERDP in PLCO participants yielded a 9% increase in risk 
of total postmenopausal breast cancer for a 1-unit increase in ERDP score (Table 4.4). 
Furthermore, a 20% and 19% increase in risk was observed for invasive (HR: 1.20; 
95%CI: 1.01, 1.42) and ER+ cases (HR: 1.19; 95%CI: 0.99, 1.41) when comparing 
participants in the fourth quartile of ERDP scores to the first. In addition to the potential 
for a true null association, differences in results from the PLCO and present analyses may 
be due to differences in the FFQs used to measure dietary intakes as well as due to 
characteristics of the populations with respect to other breast cancer risk factors. As the 
FFQs used in the present analysis and the PLCO cohort are close-ended, the intakes of 
the food groups used in the ERDP are dependent upon quantity and description of the line 
items containing those foods. It is likely that these differences resulted in different 
distributions of the scores between the two populations, as evident by the range of -8.23 
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to 4.67 in the Sister Study compared to a range of -4.52 to 6.58 in PLCO participants. 
Furthermore, there was a stepwise decrease in person-time contributed across the ERDP 
quartiles. Participants in the fourth quartile, which was hypothesized to be most strongly 
associated with breast cancer, were younger and contributed the least amount of person-
time (Table 5.2). It is possible that some of these participants with the most estrogenic 
diets did not contribute enough postmenopausal time at risk in order for a dietary 
influence on estrogen to take effect and result in incident breast cancer, although the 
relative difference time contributed per person was minimal. 
It is also possible that the relative prevalence of other breast cancer risk factors 
between the two populations contributed to different results. A prominent difference 
between the two study populations is the presence of a family history of breast cancer for 
all Sister Study participants compared to a much lower proportion in PLCO (discussed 
further in section 7.1). Women with at least one first-degree relative have roughly two 
times the risk of developing postmenopausal breast cancer.281 Therefore, it is plausible 
that the increase in risk associated with a family history of breast cancer may render a 
dietary association more difficult to detect, although evidence for a modifying effect by 
family history in dietary studies is limited.227 In addition to inherited risk, Sister Study 
participants had higher levels of other risk factors compared to PLCO. For example, 
participants in the present analysis were less educated, more likely to drink alcohol, had 
higher prevalence of past hysterectomy, and were more likely to experience the onset of 
menopause after the age of 55. Harris et al. also cited lower prevalence of other risk 
factors in the Swedish women as a potential explanation as to why they observed an 
association with the estrogen correlated dietary pattern which was not seen in the NHS.27 
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 Although significant p-values were observed for modifying effects of alcohol, 
parity, and PA on the ERDP’s association with breast cancer, all of the estimates of 
association were null and there were no clear trends in the quartiles. There was a 
suggestion of higher risk for the ERDP among nulliparous women (HRQ4vsQ1: 1.34; 
95%CI: 1.00, 1.80). It is possible that some women did not have children as a result of 
low or imbalanced hormones affecting their fertility,264 which would potentially explain 
why a hormone-related dietary influence was detected and the association observed in the 
fourth ERDP quartile for nulliparous women.  
 An important take away from these results, along with those from Harris et al., are 
the implications of adapting dietary patterns, particularly a posteriori patterns, across 
study populations with different dietary assessment tools. Intakes of commonly 
consumed foods in one population may be measured differently or be completely absent 
in another population, thereby having an influence on the scoring of the dietary pattern. 
For example, in the NHS estrogen correlated dietary pattern, pizza was a contributing 
food group. However, pizza is not commonly consumed in Sweden, so Harris et al. 
dichotomized pizza consumption into consumers versus not, rather than use the 
servings/day intake as in the NHS. It is likely that an estrogen-related dietary pattern 
derived from RRR in a population with different diets, such as in Asia, could result in a 
different pattern of food groups with little to no overlap. An open-ended dietary 
questionnaire would allow for full ascertainment of foods that may influence estrogen 
metabolism, which was not applicable in the present population or the one in which the 
ERDP was derived. 
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 There are some other minor limitations in addition to the challenges associated 
with applying dietary patterns across different study populations. As with all self-reported 
data, there is the potential for inaccurate reporting, which could result in misclassification 
of dietary intakes or other risk factors. There also is the potential for selection bias due to 
loss to follow up, although response rates in this highly motivated cohort were high 
(>90%). Our study was primarily comprised of non-Hispanic White women, therefore 
generalizability may be limited, although breast cancer incidence is highest in this 
population.277 Low numbers of ER- cases may have made it difficult to detect a potential 
association and assess a differential effect of the ERDP on ER subtypes. Strengths in the 
present analysis include a prospective study population with complete information on 
known confounders for the relationship between diet and breast cancer. The large sample 
size allowed for relatively small effects to be detected, therefore it is unlikely that a lack 
of power contributed to the null results.  
In conclusion, the ERDP, which was based on an estrogen profile hypothesized to 
increase breast cancer risk, was not associated with risk of postmenopausal breast cancer. 
All participants in the present study population had a family history of breast cancer, 
therefore the inherited risk and high prevalence of other breast cancer risk factors may 
have contributed to the lack of an association. Our analysis highlights the difficulties in 
comparing a posteriori dietary patterns across populations, and suggests the importance 
of considering dietary measurement tools when interpreting results from dietary 
investigations.
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5.6 Tables 
 
Table 5.1 Sister Study population characteristics across quartiles of the estrogen-related dietary pattern (ERDP) score 
 
    
ERDP Quartile 
(score range) 
    
1st 
(-8.230 -0.444) 
2nd 
(-0.445, -0.058) 
3rd 
(-0.059, 0.347) 
4th 
(0.348, 4.670) 
n 9,438 9,438 9,438 9,438 
Breast cancer cases Total 515 472 481 483 
  Invasive 393 372 349 370 
  Invasive ER+ 308 272 247 271 
  Invasive ER- 46 45 53 55 
ERDP score (mean ± SD) -0.90 ± 0.48 -0.24 ± 0.11 0.13 ± 0.12 0.82 ± 0.47 
Age (mean ± SD) 58.3 ± 7.3 58.0 ± 7.5 57.1 ± 7.8 56.0 ± 7.6 
BMI (kg/m2; mean ± SD) 27.0 ± 5.5 27.3 ± 5.6 28.0 ± 6.1 28.7 ± 6.6 
BMI at age 30 (kg/m2; mean ± SD) 22.7 ± 3.3 22.7 ± 3.3 23.0 ± 3.5 23.4 ± 4.0 
Total caloric intake (kcal/day) 1,600 ± 590 1,440 ± 533 1,527 ± 535 1,910 ± 650 
MET-hours/week (mean ± SD) 53.3 ± 31.9 51.1 ± 31.0 49.6 ± 30.9 49.7 ± 31.0 
Age at menarche (mean ± SD) 12.6 ± 1.5 12.6 ± 1.5 12.6 ± 1.5 12.7 ± 1.6 
Age at menopause (mean ± SD) 50.3 ± 5.8 50.1 ± 5.9 49.9 ± 6.1 49.8 ± 5.9 
Number of relatives with family history (mean ± SD) 1.27 ± 0.59 1.28 ± 0.59 1.27 ± 0.58 1.26 ± 0.56 
Parity (mean ± SD) 1.95 ± 1.35 2.01 ± 1.36 2.01 ± 1.37 1.96 ± 1.36 
Nulliparous (%) 18.2 16.6 17.2 18.5 
HRT status (%)      
  Never 44.5 45.7 47.9 51.8 
  Former - Estrogen+Progesterone 24.2 22.7 21.7 19.3 
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  Former - Estrogen only 16.8 17.0 15.5 14.6 
  Former - unknown what type 2.6 2.6 2.8 2.9 
  Current - Estrogen+Progesterone 5.2 4.9 5.1 4.6 
  Current - Estrogen only 6.7 7.1 7.0 6.8 
Race/ethnicity (%)      
  White, Non-Hispanic 85.7 84.8 85.1 86.5 
  Black, Non-Hispanic 8.2 8.0 7.9 5.5 
  Hispanic 2.8 4.3 4.5 5.1 
  Asian 0.9 0.7 0.4 0.3 
  Other 2.4 2.2 2.1 2.6 
Alcohol (%)      
  Abstainer  17.7 18.5 19.8 21.1 
  ≤1 drink/day 70.9 70.0 69.7 67.1 
  >1 drink/day 11.4 11.5 10.5 11.8 
Smoking (%)      
  Current 7.9 7.8 7.6 8.0 
  Former 41.7 38.5 34.9 35.1 
  Never 50.4 53.7 57.6 56.9 
Education (%)      
  < HS 0.9 1.1 1.2 1.2 
  HS grad and some college 32.4 35.0 36.2 34.8 
  College grad 39.5 39.1 39.6 41.3 
  Postgraduate 27.2 24.8 23.0 22.7 
Hysterectomy      
  No 65.6 65.6 65.1 66.9 
  Yes 34.4 34.4 34.9 33.1 
Non-whole/refined grains (oz/day; mean ± SD) 2.32 ± 1.26 2.39 ± 1.24 2.82 ± 1.34 3.94 ± 1.98 
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Tomatoes (cups/day; mean ± SD) 0.24 ± 0.17 0.23 ± 0.17 0.25 ± 0.19 0.35 ± 0.27 
Other vegetables (cups/day; mean ± SD) 0.63 ± 0.51 0.44 ± 0.33 0.40 ± 0.29 0.45 ± 0.31 
Cruciferous vegetables (cups/day; mean ± SD) 0.23 ± 0.27 0.20 ± 0.25 0.22 ± 0.25 0.29 ± 0.40 
Cheese (cups/day; mean ± SD) 0.26 ± 0.21 0.28 ± 0.21 0.36 ± 0.24 0.66 ± 0.41 
Yogurt (cups/day; mean ± SD) 0.23 ± 0.28 0.10 ± 0.14 0.08 ± 0.12 0.06 ± 0.11 
Fish/shellfish high in ω-3 fatty acids (oz/day; mean ± SD) 0.18 ± 0.23 0.14 ± 0.17 0.13 ± 0.17 0.15 ± 0.22 
Fish/shellfish low in ω-3 fatty acids (oz/day; mean ± SD) 0.58 ± 0.63 0.40 ± 0.37 0.38 ± 0.34 0.42 ± 0.41 
Franks and luncheon meats (oz/day; mean ± SD) 0.38 ± 0.32 0.41 ± 0.33 0.51 ± 0.37 0.78 ± 0.59 
Nuts and seeds (oz/day; mean ± SD) 2.11 ± 2.26 1.31 ± 1.32 1.14 ± 1.17 1.20 ± 1.20 
Coffee (cups/day; mean ± SD) 2.19 ± 1.71 1.58 ± 1.43 1.19 ± 1.28 1.02 ± 1.25 
BMI: body mass index; ER: estrogen receptor; ERDP: estrogen related dietary pattern; HRT: hormone replacement therapy; HS: high school; MET: metabolic 
equivalent of task. 
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Table 5.2 Hazard ratios (95% CI) for the relationship between the estrogen related dietary pattern (ERDP) score and postmenopausal 
breast cancer in the Sister Study 
 
    ERDP quartiles 
 
    1st 2nd 3rd 4th 
Estimate for 
continuous ERDP 
scorea 
Total breast cancer           
  No. of cases 515 472 481 483   
  Age-adjusted 1.00 (ref) 0.93 (0.82, 1.05) 0.98 (0.87, 1.11) 1.03 (0.91, 1.17) 
1.02 (0.95, 1.08) 
p=0.60 
  Age- and TEI-adjusted 1.00 (ref) 0.94 (0.83, 1.06) 0.99 (0.87, 1.12) 1.00 (0.88, 1.14) 
1.00 (0.94, 1.07) 
p=0.93 
  Multivariable-adjustedb 1.00 (ref) 0.93 (0.82, 1.05) 0.97 (0.85, 1.10) 0.98 (0.86, 1.11) 
0.99 (0.93, 1.06) 
p=0.70 
Invasive        
  No. of cases 393 372 349 370   
  Age-adjusted 1.00 (ref) 0.96 (0.83, 1.10) 0.94 (0.81, 1.09) 1.04 (0.90, 1.20) 
1.02 (0.95, 1.09) 
p=0.65 
  Age- and TEI-adjusted 1.00 (ref) 0.98 (0.85, 1.13) 0.95 (0.82, 1.10) 1.00 (0.87, 1.16) 
1.00 (0.93, 1.07) 
p=0.92 
  Multivariable-adjustedb 1.00 (ref) 0.96 (0.83, 1.10) 0.92 (0.79, 1.06) 0.96 (0.83, 1.11) 
0.97 (0.90, 1.04) 
p=0.41 
Invasive ER+       
  No. of cases 308 272 247 271   
  Age-adjusted 1.00 (ref) 0.89 (0.76, 1.05) 0.85 (0.72, 1.01) 0.99 (0.84, 1.16) 
0.98 (0.90, 1.07) 
p=0.71 
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  Age- and TEI-adjusted 1.00 (ref) 0.91 (0.78, 1.08) 0.86 (0.73, 1.02) 0.95 (0.80, 1.12) 
0.96 (0.89, 1.05) 
p=0.37 
  Multivariable-adjustedb 1.00 (ref) 0.90 (0.76, 1.06) 0.84 (0.71, 0.99) 0.91 (0.77, 1.07) 
0.94 (0.86, 1.02) 
p=0.12 
Invasive ER-       
  No. of cases 46 45 53 55   
  Age-adjusted 1.00 (ref) 0.99 (0.66, 1.49) 1.19 (0.80, 1.77) 1.26 (0.85, 1.87) 
1.17 (0.96, 1.43) 
p=0.11 
  Age- and TEI-adjusted 1.00 (ref) 1.00 (0.66, 1.51) 1.20 (0.81, 1.78) 1.24 (0.83, 1.85) 
1.16 (0.95, 1.42) 
p=0.15 
  Multivariable-adjustedb 1.00 (ref) 0.99 (0.66, 1.50) 1.19 (0.80, 1.76) 1.23 (0.82, 1.84) 
1.16 (0.94, 1.42) 
p=0.17 
Person-years accumulated 69,826 69,274 68,102 67,106   
ER: estrogen receptor; ERDP: estrogen related dietary pattern; TEI: total energy intake. 
aHR corresponds to 1-unit increase in ERDP score. 
bIncludes adjustment for age, TEI, BMI, BMI at age 30, HRT, race/ethnicity, alcohol use, number of family members with a history of breast cancer, age at 
menarche, age at menopause, parity, and hysterectomy. 
 
 
  
1
2
1
 
Table 5.3 Hazard ratios (95% CI) for the relationship between the estrogen related dietary pattern (ERDP) score and postmenopausal 
breast cancer within strata of estrogen-related risk factors in the Sister Studya 
 
    ERDP quartiles 
p interactionb     1st 2nd 3rd 4th 
HRT use at baseline         0.34 
  No 1.00 (ref) 0.89 (0.77, 1.02) 0.96 (0.84, 1.10) 0.94 (0.81, 1.08)   
  Yes 1.00 (ref) 1.14 (0.84, 1.55) 1.03 (0.75, 1.41) 1.28 (0.94, 1.74)   
BMI (kg/m2)     0.44 
  <30 1.00 (ref) 0.92 (0.79, 1.07) 1.02 (0.88, 1.18) 0.96 (0.82, 1.12)   
  ≥30 1.00 (ref) 0.92 (0.73, 1.16) 0.85 (0.68, 1.07) 1.00 (0.80, 1.25)   
Alcohol consumption     0.03 
  Abstainer 1.00 (ref) 1.14 (0.85, 1.54) 1.07 (0.80, 1.45) 0.90 (0.66, 1.22)   
  <1 drink/week 1.00 (ref) 0.81 (0.70, 0.95) 0.88 (0.76, 1.02) 0.98 (0.84, 1.14)   
  ≥1 drinks/week 1.00 (ref) 1.29 (0.93, 1.80) 1.37 (0.98, 1.92) 1.18 (0.83, 1.69)   
Parity      0.03 
  Nulliparous 1.00 (ref) 1.03 (0.76, 1.41) 0.93 (0.68, 1.28) 1.34 (1.00, 1.80)   
  Parous 1.00 (ref) 0.90 (0.79, 1.03) 0.97 (0.84, 1.11) 0.91 (0.79, 1.04)   
Meets Physical Activity Guidelines     0.07 
  
<500 MET-
min/week 
1.00 (ref) 0.94 (0.78, 1.13) 0.91 (0.76, 1.10) 0.84 (0.70, 1.02)   
  
≥500 MET-
min/week 
1.00 (ref) 0.90 (0.76, 1.07) 1.01 (0.85, 1.20) 1.13 (0.95, 1.34)   
BMI: body mass index; ERDP: estrogen related dietary pattern; HRT: hormone replacement therapy.  
aIncludes adjustment for age, TEI, BMI, BMI at age 30, HRT, race/ethnicity, alcohol use, number of family members with a history of 
breast cancer, age at menarche, age at menopause, parity, and hysterectomy. 
bP-value for the product term of ERDP quartiles with the potential effect modifier. 
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Table 5.4 Sensitivity analyses with different model parameters 
 
    ERDP quartiles Estimate for continuous 
ERDP scorea     1st 2nd 3rd 4th 
ER+ including non-invasive cases      
 No. of cases 383 340 335 337  
  1.00 (ref) 0.90 (0.78, 1.04) 0.91 (0.79, 1.06) 0.92 (0.79, 1.07) 
0.95 (0.88, 1.03) 
p=0.19 
ER+ including non-invasive cases      
 No. of cases 63 59 71 71  
  1.00 (ref) 0.95 (0.67, 1.36) 1.18 (0.84, 1.67) 1.21 (0.86, 1.72) 
1.11 (0.93, 1.33) 
p=0.25 
Assess BMI mediator biasc      
 No. of cases 515 472 481 483  
    1.00 (ref) 0.94 (0.83, 1.06) 0.99 (0.88, 1.12) 1.02 (0.89, 1.15) 
1.01 (0.95, 1.08) 
p=0.81 
BMI: body mass index; ER: estrogen receptor; ERDP: estrogen related dietary pattern.  
aHR corresponds to 1-unit increase in ERDP score. 
bIncludes adjustment for age, TEI, BMI, BMI at age 30, HRT, race/ethnicity, alcohol use, number of family members with a history of breast cancer, age at 
menarche, age at menopause, parity, and hysterectomy. 
cIncludes adjustment for all variables in "b" except for BMI. 
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Table 5.5 Sensitivity analyses among different analytic population subgroupsa 
 
      ERDP quartiles Estimate for 
continuous ERDP 
scoreb     n 
1st 2nd 3rd 4th 
Restricting to non-Hispanic 
Whites 32,282 
          
  No. of cases  453 416 429 416   
   
 
1.00 (ref) 0.92 (0.81, 1.06) 0.97 (0.85, 1.11) 0.96 (0.84, 1.10) 
0.99 (0.93, 1.05) 
p=0.70 
Excluding participants with 
≤12 months follow-up 
37,369       
  No. of cases  489 439 455 452   
   
 
1.00 (ref) 0.91 (0.80, 1.03) 0.97 (0.85, 1.10) 0.97 (0.85, 1.11) 
0.98 (0.91, 1.04) 
p=0.48 
Excluding participants with 
>1 full family member with 
breast cancer 
27,828       
  No. of cases  337 300 308 318   
      1.00 (ref) 0.90 (0.77, 1.06) 0.95 (0.81, 1.11) 1.00 (0.85, 1.17) 
0.99 (0.92, 1.08) 
p=0.89 
ERDP: estrogen related dietary pattern.  
aIncludes adjustment for age, TEI, BMI, BMI at age 30, HRT, race/ethnicity, alcohol use, number of family members with a history of breast cancer, 
age at menarche, age at menopause, parity, and hysterectomy. 
bHR corresponds to 1-unit increase in ERDP score. 
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Table 5.6 Relationship between the estrogen related dietary pattern (ERDP) and postmenopausal breast cancer across strata of soy 
food consumptiona 
 
    Consumption of soy foods 
  ERDP Quartile 
Non-consumers  
(0 g/day) 
Low consumers  
(>0 to 4.9 g/day) 
High consumers  
(≥5 g/day) 
Total (no. of cases)   351 992 608 
  1st 1.00 (ref) 1.00 (ref) 1.00 (ref) 
  2nd 1.02 (0.76, 1.38) 0.95 (0.79, 1.13) 0.84 (0.67, 1.05) 
  3rd 0.81 (0.60, 1.11) 0.98 (0.82, 1.17) 1.06 (0.85, 1.32) 
  4th 0.92 (0.67, 1.25) 1.00 (0.83, 1.20) 1.01 (0.80, 1.26) 
Invasive (no. of cases)  266 753 465 
  1st 1.00 (ref) 1.00 (ref) 1.00 (ref) 
  2nd 0.97 (0.69, 1.37) 0.99 (0.81, 1.21) 0.90 (0.70, 1.15) 
  3rd 0.83 (0.59, 1.19) 0.93 (0.76, 1.14) 0.97 (0.76, 1.25) 
  4th 0.88 (0.61, 1.25) 0.99 (0.80, 1.22) 0.99 (0.76, 1.28) 
Invasive ER+ (no. of cases)  185 572 341 
  1st 1.00 (ref) 1.00 (ref) 1.00 (ref) 
  2nd 0.88 (0.60, 1.35) 0.96 (0.76, 1.22) 0.81 (0.61, 1.08) 
  3rd 0.78 (0.51, 1.19) 0.92 (0.72, 1.16) 0.77 (0.57, 1.04) 
  4th 0.77 (0.50, 1.17) 0.98 (0.77, 1.25) 0.90 (0.67, 1.21) 
Invasive ER- (no. of cases)  35 98 66 
  1st 1.00 (ref) 1.00 (ref) 1.00 (ref) 
  2nd 0.91 (0.35, 2.38) 0.98 (0.54, 1.78) 1.08 (0.53, 2.21) 
  3rd 0.77 (0.29, 2.09) 1.16 (0.65, 2.05) 1.55 (0.79, 3.03) 
  4th 1.21 (0.46, 3.19) 1.18 (0.66, 2.12) 1.36 (0.68, 2.72) 
ER: estrogen receptor; ERDP: estrogen related dietary pattern. 
aIncludes adjustment for age, TEI, BMI, BMI at age 30, HRT, race/ethnicity, alcohol use, number of family members with a history of breast cancer, age at 
menarche, age at menopause, parity, and hysterectomy. 
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6.1 Abstract 
Lifestyle factors have been associated with estrogen metabolism, which has a strong 
mechanistic role in the development of postmenopausal breast cancer. We aimed to 
investigate the combined effect of estrogen-related lifestyle factors on postmenopausal 
breast cancer risk using data from 27,153 women enrolled in the Prostate, Lung, 
Colorectal and Ovarian Cancer Screening Trial. We created an estrogen-related lifestyle 
score (ERLS) by incorporating a previously developed measure of estrogenic diet, 
alcohol intake, body mass index (BMI), and physical activity. The scores ranged from 0-6 
with alcohol and BMI accounting for higher weights than the other factors. To evaluate 
the preventive possibilities of a low estrogen-related lifestyle, and to keep the direction of 
the score consistent with other published lifestyle scores, higher scores were set to 
correspond with potentially lower estrogenic lifestyle. The association between the ERLS 
and incident breast cancer was examined using Cox proportional hazards models. 
Participants with an ERLS of 4 or ≥5 had a 23% (HR: 0.77; 95%CI: 0.67-0.89) and 34% 
(HR: 0.66; 95%CI: 0.56-0.78) lower risk of breast cancer, respectively, compared to 
those with an ERLS ≤2 after multivariable adjustment. Estimates were similar when 
restricting to invasive cases or estrogen receptor positive subtypes. No single lifestyle 
component appeared to drive the association.  Our findings suggest that the combined 
effect of a lifestyle characterized by a low estrogenic diet, low alcohol consumption, low 
body weight, and high levels of physical activity are associated with a reduction in 
postmenopausal breast cancer risk, possibly through an influence on estrogen 
metabolism. 
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6.2 Introduction 
Breast cancer is the second most diagnosed cancer worldwide.282 In the US, an 
estimated 250,000 new cases of breast cancer will be diagnosed in 2017, accounting for 
approximately 30% of all cancer diagnoses in women.277 Over two-thirds of breast 
cancers occur in post-menopausal women over the age of 55.2 Although many well-
established risk factors for postmenopausal breast cancer have been identified, not all 
represent opportunities for primary prevention to help lessen this burden.  
There is sufficient evidence to link several lifestyle factors to the development of 
postmenopausal breast cancer.2,13 Both sides of the energy balance equation -  excess 
intake in the form of adiposity and greater energy expenditure in the form of physical 
activity (PA) - show evidence of a positive and negative association with breast cancer, 
respectively.2,24 Consumption of alcohol increases breast cancer risk.2,24 Although 
evidence of a dietary association with breast cancer is less robust, it is still suggestive.18,44 
Lifestyle factors often cluster together in individuals who adopt healthy or unhealthy 
lifestyles, so it can be advantageous to study lifestyle factors using a combined lifestyle 
score.245 A handful of studies have used indices to assess modifiable lifestyle factors as 
one aggregate score and have reported consistent, yet moderate, inverse associations 
between a healthy lifestyle and breast cancer.14–16,246–250 Previous lifestyle indices were 
based on adherence to cancer prevention guidelines,14,250 included behaviors specific to a 
study population,15 or were simply based on what is thought to constitute healthy 
behaviors.16,246  
Consideration of a disease mechanism in the development of a lifestyle score may 
help to identify stronger associations than previous studies. In the case of postmenopausal 
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breast cancer, the prominent influence of estrogen exposure on mammary carcinogenesis 
is well-documented.4 Regarding modifiable lifestyle behaviors, increased adiposity and 
consumption of alcohol are positively associated with estrogen,140 whereas PA is 
inversely associated with estrogen;212 all of which are associated with breast cancer risk.2 
There is recent evidence of dietary patterns developed to correlate with estrogen levels 
that were subsequently associated with postmenopausal breast cancer risk in some 
studies,27,278 but not all.32,283 One of those patterns, the estrogen-related dietary pattern 
(ERDP) developed by our group, was based on an estrogen profile that is specific to 
breast cancer risk: high unconjugated estradiol (E2) and a low ratio of 2- to 16-
hydroxylated metabolites (2/16).  
In the present analysis, we aimed to assess the relationship between a lifestyle 
score based on estrogen-related lifestyle factors and postmenopausal breast cancer risk. 
We created the estrogen-related lifestyle score (ERLS) using the ERDP, alcohol 
consumption, body mass index (BMI), and PA as scoring components, and examined 
associations with overall postmenopausal breast cancer and by estrogen receptor (ER) 
subtype, with consideration of potential effect modifiers. We hypothesized that higher 
ERLS scores, representative of a lower combined estrogenic effect of lifestyle factors, 
would be inversely associated with postmenopausal breast cancer, and that more 
substantial associations would be present for ER+ cases, and among strata of effect 
modifiers associated with lower estrogen exposure. 
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6.3 Methods 
6.3.1 Study Population 
The Prostate, Lung, Colorectal & Ovarian Cancer Screening Trial (PLCO) is an 
initiative of the National Cancer Institute to examine the effects of screening on cancer 
prognosis and mortality. Design and implementation have been described in detail 
elsewhere.33 Briefly, recruitment of 76,685 men and 78,216 women aged 55 to 74 took 
place at 10 different screening centers across the United States between 1993 and 2001. 
Women in the screening arm participated in chest x-ray, flexible sigmoidoscopy, a digital 
rectal examination, a CA-125 blood test and transvaginal ultrasound. The current 
analyses used only data from women randomized to the intervention arm of the study 
(n=39,104) who completed a dietary questionnaire (DQX) at baseline, because 
participants in the control arm completed a different dietary questionnaire three years 
post-baseline. The study population was limited to women who completed the baseline 
questionnaire, had a valid DQX (between 1st and 99th percentiles of caloric intake, <8 
missing line items), and without a personal history of cancer (except for non-melanoma 
skin cancer) at baseline, bringing the sample to 28,438. Participants were further 
excluded if they had an extreme (<15 or >55 kg/m2; n=74) or missing (n=179) BMI, did 
not have data on PA (n=112), or if they did not contribute any person-time (n=58). After 
excluding participants with missing covariate data (n=862) the final analytic sample 
comprised 27,153 participants. A subsample of women had estrogen metabolite (EM) 
data, measured by liquid chromatography-tandem mass spectrometry assay of serum 
samples collected at baseline. This subsample, used in the development of the ERDP,278 
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came from a nested case-control study35 and is comprised of 386 controls and 250 
confirmed breast cancer cases who were diagnosed >2 years after blood sample donation.  
 
6.3.2 Data Collection  
 Eligible participants filled out a questionnaire with information on demographics, 
medical history, family history, lifestyle factors, and recent history of participation in 
screening examinations at baseline. Participants self-reported their height and weight, 
which was used to calculate BMI. Dietary data were collected via the DQX, a 137-item 
food frequency questionnaire designed specifically for PLCO to assess typical frequency 
of intake over the past year. Nutrient and food intake amounts were calculated using US 
dietary data and the pyramid food group servings database from the US Department of 
Agriculture (USDA).263 Separate line items were included for beer, liquor, and wine; 
which were used to calculate alcohol drinks per day. The DQX also contained a question 
on the number of hours per week spent performing vigorous PA, with the response 
categories of: <1, 1, 2, 3, and ≥4.  
 
6.3.3 Calculating of ERLS Scoring 
The dietary component of the ERLS was characterized using previously described 
ERDP scores (ref to submitted paper). Briefly, reduced rank regression modeling was 
performed to identify a dietary pattern that was associated with serum levels of 
unconjugated E2 and the 2/16 ratio in a nested case-control of 653 postmenopausal 
women. The newly developed ERDP is comprised of non-whole/refined grains, tomatoes, 
cruciferous vegetables, cheese, fish/shellfish high in ω-3 fatty acids, franks/luncheon 
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meats, nuts and seeds, other vegetables, fish/shellfish low in ω-3 fatty acids, yogurt, and 
coffee. Intakes of these food groups were centered and scaled, then multiplied by their 
corresponding model weights. The total ERDP score was calculated by summing over the 
weighted intakes. Higher ERDP scores are positively associated with unconjugated E2 
and inversely associated with the 2/16 ratio. The dietary component of the ERLS score 
was based on the median ERDP score (-0.0206419) for the analytic PLCO population. 
Women with a score greater than or equal to the median received a 0, as those diets are 
hypothesized to be positively associated with estrogen metabolism and subsequent breast 
cancer risk. Women with an ERDP score below the median received a 1. 
Scoring parameters for the remaining ERLS components are similar to those 
outlined in the WCRF/AICR Second Expert Report, and the USDA’s 2015 Dietary 
Guidelines for Americans.13,25 Due to the strength of evidence for associations between 
alcohol intake and obesity status with breast cancer risk, and evidence of an estrogenic 
effect, these variables were given a stronger weight in the scoring of the ERLS,13 by 
using a three-level variable rather than two-level variable in the scoring. For alcohol 
intake, women who abstained from drinking (0 drink/week) were scored a 2; women who 
consumed >0 to 7 drinks/week were scored a 1; and those who consumed >7 drinks/week 
were scored a 0. Women were scored a 2 if they were normal weight (BMI <25.0 kg/m2), 
a 1 if overweight (BMI 25.0-29.9 kg/m2), and 0 if obese (BMI ≥30.0 kg/m2). For PA, 
women who reported >2 hours/week of vigorous PA were considered active and scored a 
1, and those who reported ≤2 hours/week were scored a 0. The score for each of the four 
different ERLS components was summed. Women with the minimum score of 0 were 
hypothesized to have the largest risk profile, and those with a maximum of 6 were 
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hypothesized to have the lowest combined risk profile from estrogen-related lifestyle 
factors. A summary of the ERLS scoring is portrayed in Table 3.3. 
 
6.3.4 Breast Cancer Ascertainment 
Incident breast cancer cases were identified primarily through self-report via 
annually mailed follow-up questionnaires. Follow-up was from start of enrollment in 
1993 through December 31, 2009. Other sources of ascertainment included the National 
Death Index, physician reports, state cancer registries, and next of kin reports. Over 96% 
of the cases were confirmed through hospital records.252 In the analytic cohort, a total of 
1,568 incident breast cancer cases occurred. A supplemental form was implemented in 
2007 to capture more detailed information about the diagnosis, including estrogen 
receptor status. Data on ER status was available for 70% of cases. 
 
6.3.5 Statistical Approach 
Baseline comparisons of participant characteristics by categories of the ERLS 
were performed using t-tests and chi-square tests for continuous and categorical 
variables, respectively. Pearson correlation coefficients were used to quantify the strength 
of the relationship between the ERLS and EMs in the subsample of women with data on 
EMs. Cox proportional hazards models were applied to analyze the relationship between 
the ERLS and incident breast cancer events, with person-time calculated from date of 
completed DQX to end of follow-up or event.284 The proportional hazards assumption 
was evaluated using Martingale-based residuals and was not violated by exposure 
variables or covariates.285 The ERLS was grouped as follows: ≤2 (referent group), 3, 4, or 
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≥5. The three lowest scores (0, 1, and 2) and the two highest scores (5 and 6) were 
combined into single categories due to low numbers of cases. The first category 
hypothetically represents lifestyles with a higher exposure to estrogen. The hazard ratio 
(HR) and 95% confidence intervals (CI) also were calculated for the continuous ERLS 
score variable, and the p-value reported as a test for trend. Demographic factors of age 
(years), race/ethnicity (non-Hispanic White, non-Hispanic Black, Hispanic, Asian, other) 
and study center (10 categories) were included in the multivariable-adjusted models, 
along with total caloric intake (kcal/day) for their putative roles as confounders for breast 
cancer. The remaining covariates included in multivariable-adjusted models were chosen 
using stepwise model selection with entry/exit criteria of p=0.2. Further adjustment for 
hormone replacement therapy (HRT) use (current; former; never; unknown), family 
history of breast cancer (yes; no; unknown), education (less than high school; high school 
and some college; college degree; graduate degree), BMI at age 20 (kg/m2), bilateral 
oophorectomy (yes; no), parity (6 categories), and age at menopause (5 categories) was 
included in the multivariable models. Age at first birth, age at menarche, oral 
contraceptive use, smoking status, and prior hysterectomy also were considered as 
potential confounders but were not included after performing the stepwise model 
selection. Effect modification by baseline HRT use (yes; no) and parity (nulliparous; 
parous) was examined in stratified results, and by including an interaction term in the 
model. All models were performed with overall breast cancer and within strata of ER 
subtype. A competing risk model was performed to assess a differential association for 
the ERLS on ER+ and ER- subtypes using a Wald test for heterogeneity in the stratified 
Lunn-McNeil approach.259 In secondary analyses, we evaluated associations between 
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individual components of the ERLS and postmenopausal breast cancer with additional 
adjustment for each of the ERLS components that were not the main independent 
variable of interest. Additionally, to evaluate whether the observed association between 
the ERLS and postmenopausal breast cancer was primarily influenced by a single ERLS 
component, we removed the components one at a time from the total ERLS score to see if 
the estimate of association with breast cancer changed significantly. All statistical tests 
were two-sided at α=0.05 and all analyses were conducted using SAS 9.4 (SAS Institute, 
Cary, NC). 
 
6.4 Results 
 Over an average follow-up of 10.9 years, 1,576 incident cases of breast cancer 
were reported, with 1,261 of those cases being invasive. Among cases where ER status 
was ascertained, 1,089 were ER+ and 187 were ER-. In our subsample of participants 
with EM data that was used to derive the ERDP, the ERLS was moderately correlated 
with unconjugated E2 (r=-0.33; p<0.01) and the 2/16 ratio (r=0.20; p<0.01). The 
distribution of characteristics across ERLS categories for the full analytic cohort are 
shown in Table 6.1. Participants in the highest ERLS category had the lowest occurrence 
of total and ER+ breast cancer. In addition, they had the lowest total caloric intake, 
lowest proportion of non-Hispanic Whites but highest proportion of Asians, were more 
educated, and had the highest proportions of HRT users and never smokers at baseline.  
 In Cox models with varying levels of adjustment, participants in the highest 
ERLS category, representing lifestyles hypothesized to have the least estrogenic 
potential, experienced the lowest risk of postmenopausal breast cancer compared to the 
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lowest ERLS category (Table 6.2). In the multivariable-adjusted model, participants with 
an ERLS of 4 or ≥5 (lower estrogen) had a 23% (HR: 0.77; 95%CI: 0.67-0.89) and 34% 
(HR: 0.66; 95%CI: 0.56-0.78) reduction in risk of breast cancer, respectively, compared 
to those with an ERLS ≤2 (higher estrogen) (p-trend<0.0001). A 1-unit increase in ERLS 
was associated with a 11% lower risk (HR: 0.89; 95%CI: 0.85-0.92) after adjustment. 
Estimates were similar for invasive cases only. When restricting to ER+ subtype, the 
magnitude of the inverse associations strengthened slightly for those with an ERLS of 4 
(HR: 0.73, 95%: 0.62-0.87) and ERLS ≥5 (HR: 0.63; 95%CI: 0.51-0.77). No significant 
effect estimates were observed for ER- subtypes, but the HR for ERLS ≥5 was reduced 
and results from the competing risk model indicated there was no differential association 
for the different ER subtypes (p=0.62). There was no evidence of effect modification by 
baseline HRT use (pinteraction=0.54) or parity (pinteraction=0.75) (Table 6.3).  
 Table 6.4 shows results from investigations of individual ERLS scoring 
components. In all models, the category that was associated with a score of 0, 
representative of higher estrogen exposure, was the referent. A modest reduction in risk 
was observed in participants with score of 1 for the ERDP (HR: 0.92; 95%CI: 0.83-1.02). 
Significant reductions in risk were seen among individuals with an alcohol score of 2  
(HR: 0.79; 95%CI: 0.66-0.95), or 1 (HR: 0.83; 95%CI: 0.72-0.95); individuals with a 
BMI score of 2 (HR:0.72; 95%CI: 0.62-0.83), or 1 (HR: 0.88; 95%CI: 0.76-1.00); and for 
those with a score of 1 for PA (HR: 0.92; 95%CI: 0.83-1.02). The estimates of 
association for the ERLS remained relatively unchanged after removing individual 
components, one at a time (Table 6.5). 
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6.5 Discussion 
In this large prospective cohort study of postmenopausal women, our findings 
suggest that the combined effect of modifiable lifestyle factors, namely diet, alcohol 
intake, BMI, and PA, is associated with risk of postmenopausal breast cancer. 
Specifically, women who were consuming a diet with less estrogenic potential, less 
alcohol, had a lower BMI, and were engaging in more physical activity were at reduced 
risk for breast cancer compared to women with less healthy lifestyles. A 1-unit increase 
in the ERLS score towards the direction of a lifestyle that was hypothesized to have 
lower estrogen exposure was associated with a 11% reduction in risk. The ERLS was 
moderately correlated with two EMs thought to be important indicators of breast cancer 
risk in a subsample of women. However, the association between ERLS and breast 
cancer did not differ by ER subtypes. The association was not modified by HRT use or 
parity.  
Considering the prominence of an estrogenic influence on the development of 
breast cancer, the ERLS was developed to characterize the combined effect of estrogen-
related lifestyle factors. Other lifestyle components, such as smoking or breastfeeding, 
were omitted from the ERLS as evidence of an estrogenic disease mechanism is not 
substantial.67 All individual components of the ERLS exhibited inverse associations with 
postmenopausal breast cancer in multivariable-adjusted models, but none of the estimates 
of association were larger than their combined effect in the ERLS. According to the 
World Cancer Research Fund (WCRF) and American Institute for Cancer Research’s 
(AICR) 2017 Continuous Update Project (CUP),24 there is strong evince of increasing 
risk of postmenopausal breast cancer with body fatness (represented by BMI in the 
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ERLS) and alcohol.  The CUP also has designated PA to have strong evidence of an 
influence on breast cancer risk, therefore we anticipated seeing an association.24 
Furthermore, in a prior PLCO investigation, a 1-unit increase in ERDP scores was 
associated with a significant 9% increase in risk of developing postmenopausal breast 
cancer.278 The association between ERLS and postmenopausal breast cancer remained 
significant, with relatively no attenuation in effect estimates, even after individual ERLS 
components were removed from the total score. These results suggest there was no single 
component of the ERLS that drove the observed significant association in models with 
total ERLS.  
To the best of our knowledge, this was the first application of a lifestyle score 
with a focus on estrogen metabolism as the primary mechanistic pathway. Prior research 
on lifestyle scores and breast cancer in prospective studies have yielded similar results. 
An a priori healthy lifestyle index score (HLIS) based on diet, tobacco use, alcohol, PA, 
and BMI reported 21% lower risk of breast cancer (HR: 0.79, 95% CI: 0.73-0.85) among 
the most healthy group in the European Prospective Investigation into Cancer and 
Nutrition (EPIC) cohort.246 When the HLIS was applied in the same cohort, but with a 
slight dietary modification to include fish, folate, glycemic index, and other breast cancer 
risk-specific dietary components, the estimate of the inverse association was slightly 
stronger (HR: 0.74; 95% CI: 0.66–0.83).16 The association was strongest for ER-
/progesterone receptor (PR)- breast cancer (HR: 0.60; 95% CI: 0.40-0.90), but also 
significant for ER+/PR+ (HR: 0.81; 95% CI: 0.67-0.98), suggesting disease pathways that 
did not influence estrogen may have played a role.16 Also using data from EPIC, a 
lifestyle score was developed to evaluate adherence to the WCRF/AICR 
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recommendations on body fatness, PA, energy dense foods and drinks, plant foods, 
animal foods, alcohol use, and breastfeeding in women. Compared to the lowest scores, 
all categories showed a significant inverse association with breast cancer, with the 
strongest association in those with greatest adherence to the prevention guidelines (HR: 
0.84; 95% CI: 0.78-0.90).14 Adherence to WCRF/AICR recommendations has exhibited 
positive associations with breast cancer risk in other populations, as well, 247–249 including 
the Iowa Women’s Health Study where association did not differ in the presence of non-
modifiable risk factors for breast cancer.249  
Evidence from case-control studies have shown similar, yet stronger associations. 
In a case-control study of Mexican women, those in the highest quintile of a healthy 
index comprised of diet, PA, alcohol consumption, and tobacco smoking had 80% less 
odds of developing postmenopausal breast cancer compared to the lowest quintile (odds 
ratio (OR): 0.20; 95% CI: 0.11-0.37).15 Increasing scores associated with a lifestyle score 
focused on limiting red meat, cream, and cheese; consuming more white meat, fish, fruit 
and vegetables; lower alcohol consumption; not smoking; higher PA; lower BMI; and 
longer cumulative duration of breastfeeding was associated with a reduction in risk 
among indigenous New Zealanders (OR: 0.47; 95% CI: 0.23-0.94), but not among non-
indigenous participants (OR: 0.86; 95% CI: 0.67-1.11), when comparing the highest to 
lowest quartiles.250 
There is evidence that high levels of circulating unconjugated E2 and a low 2/16 
ratio may be representative of an estrogen profile that increases the risk of 
postmenopausal breast cancer.11 In our subsample of women with EM data, the ERLS 
was inversely and positively correlated with unconjugated E2 and the 2/16 ratio, 
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respectively. Additionally, each component of the ERLS has been associated with 
estrogen metabolism.140,212,278 Therefore, it is plausible that the combined effect of these 
lifestyle behaviors on postmenopausal breast cancer risk works through an influence on 
estrogen metabolism. Dietary behaviors are known to influence the intestinal 
microbiota,266 which can subsequently influence excretion or reabsorption of active 
estrogens.267 Alcohol consumption may increase aromatase activity, promoting the 
conversion of testosterone into estrogen.286 Adipose tissue is the largest source of 
endogenous estrogen in postmenopausal women,2 and there is strong evidence for a 
positive linear association between adipose tissue and estrogen levels in postmenopausal 
women.207 The inverse association between PA and estrogen may be a result of reducing 
adipose-derived estrogen, or possibly through increased levels of SHBG, limiting the 
amount of available estrogen in active tissues.24,62 
Some limitations should be considered. Similar to most prospective 
investigations, there is the potential for bias due to the selection of subjects, loss to 
follow-up, and measurement error. Although food frequency questionnaires may not 
generate accurate estimates for absolute intakes of nutrients, they are useful for ranking 
individuals, and only food or food groups (not nutrients) intakes were utilized in this 
study.173 The use of BMI is an imperfect proxy for adiposity, and BMI values were 
derived from self-reported height and weight. However a validation study in a similar 
U.S. population showed strong correlation between self-reported and measured weight.287 
Our ability to detect an association for ER- cases was limited due to low numbers, 
however, this was not an issue for ER+ cases. A limitation for the PLCO study 
population is the lack of racial/ethnic diversity. However, non-Hispanic White women 
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experience the highest incidence of breast cancer in the US, so results are generalizable to 
this high-risk group.  
There are many strengths to our analysis, as well. The use of a large, prospective 
cancer cohort provided adequate power to detect small associations with complete 
information on known risk factors to appropriately adjust for confounders. The inclusion 
of the ERDP and pre-identification of a plausible mechanistic pathway aided in making a 
meaningful interpretation of our results. This was a novel approach to developing a 
lifestyle score that is disease- and mechanism-specific. 
In conclusion, our findings suggest that modifiable lifestyle behaviors have a 
combined effect on postmenopausal breast cancer risk, possibly through an alteration of 
estrogen metabolism. A lifestyle that is characterized by consumption of a diet with low 
estrogenic potential, low alcohol consumption, a low BMI, and high levels of PA may 
help to lower the risk of developing breast cancer in postmenopausal women. A 
collective change in lifestyle is likely more influential than focusing on specific 
behaviors. 
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6.6 Tables 
 
Table 6.1 Population characteristics across estrogen related lifestyle score (ERLS) categories 
 
    ERLS 
    ≤2 3 4 ≥5 
n   7,469 7,565 7,345 4,774 
Breast cancer cases      
  Total 459 491 400 226 
  Invasive 368 401 308 184 
  ER+  321 342 272 154 
  ER- 56 56 48 27 
ERDP score (mean ± SD) 0.31 ± 0.63 0.05 ± 0.62 -0.14 ± 0.58 -0.39 ± 54 
  (ERLS: 0) ≥ median, % 78.6 56.8 38.6 12.0 
  (ERLS: 1) < median, % 21.4 43.2 61.4 88.0 
Alcohol (drinks/week, mean ± SD) 4.1 ± 8.1 3.4 ± 7.1 2.3 ± 5.1 0.8 ± 1.5 
  (ERLS: 0) >7, % 22.2 17.2 9.5 0.0 
  (ERLS: 1) >0-7, % 69.4 65.6 69.1 53.1 
  (ERLS: 2) 0, % 8.4 17.2 21.4 46.9 
BMI (kg/m2, mean ± SD) 31.9 ± 5.5 27.3 ± 4.7 24.6 ± 3.3 23.0 ± 2.3 
  (ERLS: 0) ≥30, % 64.3 20.5 3.6 0.0 
  (ERLS: 1) 25.0-29.9, % 31.5 50.9 37.6 11.6 
  (ERLS: 2) <25, % 4.2 28.6 58.8 88.4 
Hours of vigorous PA per week (%)      
  (ERLS: 0) ≤2 81.1 51.4 28.6 8.8 
  (ERLS: 1) >2 18.9 48.6 71.4 91.2 
Age (mean ± SD) 61.9 ± 5.2 62.4 ± 5.3 62.7 ± 5.4 63.0 ± 5.5 
Total caloric intake (kcal/day, mean± SD) 1,894 ± 639 1,763 ± 598 1,677 ± 572 1,577 ± 529 
BMI at age 20 (kg/m2, mean ± SD) 22.3 ± 3.3 21.3 ± 2.8 20.7 ± 2.4 20.4 ± 2.1 
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HRT status (%)      
  Current 45.4 51.7 54.3 57.2 
  Former 17.8 15.9 15.4 14.8 
  Never 36.2 32.1 29.8 27.7 
  Unknown 0.6 0.3 0.5 0.3 
Race (%)       
  White, Non-Hispanic 92.3 91.8 91.4 89.3 
  Black, Non-Hispanic 5.2 4.7 3.3 2.4 
  Hispanic 1.2 1.2 1.2 1.1 
  Asian 0.6 1.8 3.5 6.8 
  Other 0.7 0.5 0.6 0.4 
Smoking (%)      
  Current 9.5 9.8 8.2 6.7 
  Former 37.7 34.5 33.3 28.3 
  Never 52.8 55.7 58.5 65.0 
Education (%)      
  < HS 6.7 6.1 4.7 4.6 
  HS grad and some college 68.2 64.0 62.3 61.7 
  College grad 13.5 15.8 17.4 16.6 
  Postgraduate 11.6 14.1 15.6 17.1 
Live births (%)      
  None 6.6 7.6 7.6 7.8 
  1 6.9 7.3 7.1 7.3 
  2 21.7 23.3 25.5 26.3 
  3 25.7 25.3 26.1 26.2 
  ≥ 4 39.1 36.5 33.7 32.4 
Age at menopause (%)      
  < 40 15.3 13.5 12.6 12.9 
  40-44 14.1 14.0 13.4 14.3 
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  45-59 22.7 23.1 23.4 25.3 
  50-54 36.4 37.8 38.9 36.8 
  ≥55 11.5 11.6 11.7 10.7 
Bilateral oophorectomy (%)      
  No 88.0 88.9 89.7 89.2 
  Yes 12.0 11.1 10.3 10.8 
Family history of breast cancer (%)      
  No 84.3 84.7 85.4 85.2 
  Yes 14.5 14.4 13.7 14.0 
  Unknown 1.2 1.0 0.9 0.9 
BMI: body mass index; ER: estrogen receptor; ERDP: estrogen related dietary pattern; ERLS: estrogen related lifestyle score; HRT: hormone replacement 
therapy; HS: high school; PA: physical activity; SD: standard deviation 
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Table 6.2 Hazard ratios (95% CI) for the relationship between estrogen related lifestyle score (ERLS) and postmenopausal breast 
cancer 
 
    ERLS Estimate for continuous 
ERLS,a p-trend     ≤2 3 4 ≥5 
Total breast cancer  
     
  No. of cases  459 491 400 226   
  Age-adjusted 1.00 (ref) 1.05 (0.92, 1.19) 0.87 (0.76, 0.99) 0.75 (0.64, 0.88) 
0.92 (0.89, 0.96) 
p<0.0001 
  Age- and HRT-adjusted  1.00 (ref) 1.02 (0.90, 1.16) 0.84 (0.73, 0.96) 0.72 (0.61, 0.84) 
0.91 (0.88, 0.95) 
p<0.0001 
  Multivariable-adjustedb 1.00 (ref) 0.97 (0.85, 1.11) 0.77 (0.67, 0.89) 0.66 (0.56, 0.78) 
0.89 (0.85, 0.92) 
p<0.0001 
Invasive        
  No. of cases  368 401 308 184   
  Age-adjusted 1.00 (ref) 1.07 (0.92, 1.23) 0.83 (0.72, 0.97) 0.76 (0.64, 0.91) 
0.92 (0.88, 0.96) 
p=0.0003 
  Age- and HRT-adjusted  1.00 (ref) 1.05 (0.91, 1.21) 0.81 (0.69, 0.94) 0.73 (0.61, 0.88) 
0.91 (0.87, 0.95) 
p<0.0001 
  Multivariable-adjustedb 1.00 (ref) 0.99 (0.86, 1.15) 0.74 (0.63, 0.87) 0.67 (0.56, 0.82) 
0.89 (0.85, 0.93) 
p<0.0001 
ER+         
  No. of cases 321 342 272 154   
  Age-adjusted 1.00 (ref) 1.04 (0.89, 1.21) 0.84 (0.71, 0.98) 0.73 (0.60, 0.88) 
0.91 (0.87, 0.96) 
p=0.0001 
  Age- and HRT-adjusted  1.00 (ref) 1.01 (0.87, 1.18) 0.81 (0.69, 0.95) 0.70 (0.57, 0.84) 
0.90 (0.86, 0.94) 
p<0.0001 
  Multivariable-adjustedb 1.00 (ref) 0.96 (0.82, 1.12) 0.73 (0.62, 0.87) 0.63 (0.51, 0.77) 
0.87 (0.83, 0.92) 
p<0.0001 
ER-        
  No. of cases 56 56 48 27   
  Age-adjusted 1.00 (ref) 1.04 (0.72, 1.52) 0.91 (0.61, 1.34) 0.79 (0.50, 1.26) 
0.95 (0.84, 1.06) 
p=0.34 
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  Age- and TEI-adjusted 1.00 (ref) 1.04 (0.71, 1.51) 0.90 (0.61, 1.34) 0.78 (0.49, 1.25) 
0.94 (0.84, 1.06) 
p=0.32 
  Multivariable-adjustedb 1.00 (ref) 1.04 (0.71, 1.53) 0.92 (0.61, 1.38) 0.84 (0.52, 1.37) 
0.96 (0.85, 1.09) 
p=0.52 
CI: confidence interval; ER: estrogen receptor; ERLS: estrogen related lifestyle score; HRT: hormone replacement therapy; TEI: total energy intake 
aHR corresponds to 1-unit increase in ERLS score. 
bIncludes adjustment for age, TEI, HRT, education, BMI at age 20, bilateral oophorectomy, parity, age at menopause, family history of breast cancer, 
race/ethnicity, and study center. 
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Table 6.3 Hazard ratios (95% CI) for the relationship between the estrogen related lifestyle score (ERLS) and postmenopausal breast 
cancer within strata of estrogen-related risk factorsa 
 
    ERLS 
p interactionb     ≤2 3 4 ≥5 
HRT use at baseline         0.54 
  No 1.00 (ref) 0.97 (0.80, 1.17) 0.71 (0.57, 0.88) 0.67 (0.51, 0.87)   
  Yes 1.00 (ref) 0.97 (0.82, 1.16) 0.82 (0.68, 0.98) 0.66 (0.53, 0.82)   
Parity      0.75 
  Nulliparous 1.00 (ref) 0.82 (0.52, 1.29) 0.67 (0.41, 1.08) 0.49 (0.27, 0.90)   
  Parous 1.00 (ref) 0.99 (0.86, 1.14) 0.78 (0.67, 0.90) 0.67 (0.56, 0.80)   
CI: confidence interval; ERLS: estrogen related lifestyle score; HRT: hormone replacement therapy; TEI: total energy intake  
aIncludes adjustment for age, TEI, HRT, education, BMI at age 20, bilateral oophorectomy, parity, age at menopause, family history of breast cancer, 
race/ethnicity, and study center. 
bP-value for the product term of ERDP quartiles with the potential effect modifier. 
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Table 6.4 Hazard ratios (95% CI) for the relationship between the individual estrogen related lifestyle score (ERLS) components and 
postmenopausal breast cancer 
 
    No. of cases Age-adjusted 
Age- and HRT-
adjusted Multivariable-adjusteda 
ERDP score         
  ≥ median  827 1.00 (ref) 1.00 (ref) 1.00 (ref) 
  < median 749 0.91 (0.82, 1.00) 0.90 (0.82, 1.00) 0.92 (0.83, 1.02) 
Alcohol (drinks/week)      
  >7  264 1.00 (ref) 1.00 (ref) 1.00 (ref) 
  >0 to 7  1,025 0.79 (0.69, 0.91) 0.80 (0.70, 0.92) 0.83 (0.72, 0.95) 
  0 287 0.71 (0.60, 0.84) 0.71 (0.60, 0.84) 0.79 (0.66, 0.95) 
BMI (kg/m2)      
  ≥30 388 1.00 (ref) 1.00 (ref) 1.00 (ref) 
  25.0 to 29.9 578 1.00 (0.88, 1.13) 0.97 (0.85, 1.10) 0.88 (0.76, 1.00) 
  25 610 0.90 (0.80, 1.03) 0.86 (0.76, 0.98) 0.72 (0.62, 0.83) 
Hours of vigorous PA per week      
  ≤2 733 1.00 (ref) 1.00 (ref) 1.00 (ref) 
  >2 843 0.95 (0.86, 1.05) 0.93 (0.84, 1.03) 0.92 (0.83, 1.02) 
BMI: body mass index; CI: confidence interval; ERDP: estrogen related dietary pattern; ERLS: estrogen related lifestyle score; HRT: hormone replacement 
therapy; PA: physical activity; TEI: total energy intake 
aIncludes adjustment for each other ERLS component that is not the main predictor, age, TEI, HRT, education, BMI at age 20, bilateral oophorectomy, parity, 
age at menopause, family history of breast cancer, race/ethnicity, and study center. 
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Table 6.5 Hazard ratios (95% CI) for the relationship between estrogen related lifestyle 
score (ERLS) and postmenopausal breast cancer removing individual ERLS components 
from the total scorea 
 
Component removed from total ERLS: 
Estimate for continuous 
ERLS,b p-trend 
ERDP 
0.88 (0.83, 0.92) 
p<0.0001 
Alcohol 
0.89 (0.85, 0.93) 
p<0.0001 
BMI 
0.90 (0.85, 0.95) 
p=0.0003 
PA 
0.87 (0.83, 0.92) 
p<0.0001 
aIncludes additional adjustment for age, TEI, HRT, education, BMI at age 
20, bilateral oophorectomy, parity, age at menopause, family history of 
breast cancer, race/ethnicity, and study center. 
bHR corresponds to 1-unit increase in ERLS score. 
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CHAPTER 7 
DIET, LIFESTYLE, AND ESTROGEN METABOLISM IN RELATION 
TO POSTMENOPAUSAL BREAST CANCER: A SYNTHESIS OF 
DISSERTATION FINDINGS
7.1 Summary of findings 
 We characterized women’s diets based on associations with an estrogen profile 
that is hypothesized to be associated with increased postmenopausal breast cancer risk; 
high unconjugated E2 and a low 2/16 ratio. Starting with 32 food and beverage groups, 
we identified 11 key contributors to the variation in the EMs of interest. Intakes of non-
whole/refined grains, tomatoes, cruciferous vegetables, cheese, fish/shellfish high in ω-3 
fatty acids, franks/luncheon meats were positively weighted for ERDP scoring; whereas 
intakes for nuts and seeds, other vegetables, fish/shellfish low in ω-3 fatty acids, yogurt, 
coffee were negatively weighted. Next, the ERDP was scored in two prospective cohorts 
of postmenopausal women and examined for an association with breast cancer risk. In the 
PLCO, the cohort from which the ERDP was developed, a positive association between 
the ERDP and postmenopausal breast cancer risk was observed, in that the highest 
quartile of the ERDP was associated with a 20% increased risk of invasive breast cancer 
compared to the lowest quartile. However, the ERDP was not associated with 
postmenopausal breast cancer risk among women in the SS.  
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Possible reasons for the different findings between the two study populations 
could be because all SS participants had a family history of breast cancer which reflected 
shared genetic and early life environment, differences in dietary measurements and 
subsequent ERDP scoring distributions between the studies, or due to a chance finding in 
the PLCO when in truth there is no association. To examine the potential role of inherited 
risk affecting the observed associations in the PLCO, we conducted further analyses 
stratified by family history of breast cancer. As shown in Table 7.1, no association was 
observed when restricting to PLCO participants with a family history of breast cancer, as 
is characteristic of the full SS cohort, thus supporting the idea that high inherited risk 
from shared genetic profiles and early life environments may be masking an association 
with diet in the SS. Table 7.2 shows how intakes of some food groups differ significantly 
between the two populations, likely due to differences in the descriptions and number of 
line items containing foods within those groups in the different FFQs. These differences 
in intake measurement translated to different distributions of ERDP scores across the two 
populations. Scores in PLCO were slightly skewed right, whereas scores in SS were 
slightly skewed left. Considering the more negative distribution in SS, it is possible that 
participants in SS did not consume enough pro-estrogenic foods to observe an 
association. Lastly, participants in SS had an average shorter duration of follow-up. 
Therefore, if their dietary estrogenic potential measured at baseline requires a longer time 
period to influence breast cancer risk, we may have only been able to evaluate the 
association effectively in PLCO. This would not be relevant if their diet at baseline is 
similar to their diet in previous years, but literature on the stability of dietary patterns in 
adulthood is varied, so it is difficult to defend that assumption.288–291 
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Lastly, the ERDP was incorporated into an estrogen-related lifestyle score 
(ERLS) with other estrogen-related lifestyle factors. The ERLS was comprised of the 
ERDP, alcohol consumption, BMI, and PA; with increasing scores hypothesized to have 
a combined anti-estrogenic potential. An inverse association between the ERLS and 
postmenopausal breast cancer risk was observed in PLCO, with women conforming to 
more of the healthy lifestyle factors having a 34% reduced risk of breast cancer compared 
to fewer healthy lifestyle factors, supporting the hypothesis that modifiable lifestyle 
factors related to lower estrogenic potential are associated with reduced risk of breast 
cancer. 
 
7.2 Biological mechanisms 
The ERDP was hypothesized to be related to postmenopausal breast cancer risk 
through a biologic mechanism related to estrogen metabolism. One possible way by 
which ERDP food groups may affect estrogen metabolism is through an influence on 
microbiome diversity.265 Diversity of the intestinal microbiome, which is strongly 
influenced by dietary behaviors, can impact many important physiological processes, 
such as whether or not estrogens are excreted through feces or transformed to their 
unconjugated forms and subsequently reabsorbed.267 If reabsorbed, there is a greater 
estrogenic exposure throughout the body. Similarly, there is evidence of microbial effects 
on interconversions of the parent estrogens and hydroxylation down the 16-pathway from 
in vitro and human studies, suggesting the microbiome may also influence estrogen 
metabolism.269,270 The intestinal microbiome is strongly influenced by fiber intake, or 
lack thereof, through consumption of grains and vegetables, both of which are included in 
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the ERDP.266 The ERDP also is comprised of animal products, such as meats, cheese, and 
yogurt, which can impact microbiome diversity.271–273 Therefore, diet may influence 
breast cancer risk through an influences on a woman’s estrogen profile, mediated by 
microbial effects. Many of the foods in the ERDP are also characteristic of a Western 
dietary pattern , which has been associated with systemic inflammation.275 Conversely, 
coffee, also a part of the ERDP, has exhibited anti-inflammatory effects.274 Inflammation 
may play a role in mammary tumor development, therefore it may also play a role in a 
potential association between the ERDP and breast cancer.276  
In addition to the aforementioned mechanistic pathways for the relationship 
between the ERDP and postmenopausal breast cancer, it is possible other components of 
the ERLS also work through estrogen metabolism. Alcohol consumption may increase 
aromatase activity, promoting the conversion of testosterone into estrogen.286 Adipose 
tissue is the largest source of endogenous estrogen in postmenopausal women,2 and there 
is strong evidence for a positive linear association between adipose tissue and estrogen 
levels in postmenopausal women.207 The inverse association between PA and estrogen 
may be a result of reducing adipose-derived estrogen, or possibly through increased 
levels of SHBG, limiting the amount of available estrogen in active tissues.24,62 Similarly 
to the ERDP, other components of the ERLS may work through inflammatory 
mechanisms, as well, with alcohol, adipose tissue, and physical activity all exhibiting 
associations with inflammatory markers.292  
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7.3 Implications for public health 
The results of the present dissertation help to address a critical gap in translational 
breast cancer research. The burden of breast cancer is extensive, as it accounts for nearly 
a third of all cancers diagnosed among women.2 Costs of treatment are extensive, as is 
the potential for secondary health effects among the large numbers of breast cancer 
survivors. To help ease this burden, primary prevention methods utilizing modifiable 
lifestyle factors are needed.43 Diet is a commonly investigated lifestyle factor, though 
previous studies have largely yielded inconsistent results in relation to breast cancer. By 
focusing on the whole diet and a biologic mechanism specific to breast cancer, this 
dissertation adds to the literature on whether disease-specific dietary recommendations 
are warranted. Our findings suggest that a diet associated with estrogen metabolism may 
influence breast cancer risk, although the dietary pattern established in one study was not 
associated with breast cancer in a different study population. Thus, further research 
capturing the “optimal” diet for estrogen metabolism across multiple populations is 
warranted. Furthermore, we have shown that the combined effect of adopting lifestyle 
factors associated with lower estrogen exposure may be efficacious to reduce the risk of 
postmenopausal breast cancer. 
Overall, our results suggest that a diet low in non-whole/refined grains, tomatoes, 
cheese, franks/luncheon meats; while high in nuts and seeds, cruciferous vegetables, 
other vegetables, fish/shellfish, yogurt, and coffee may protect against breast cancer 
through an influence on estrogen metabolism. More research is needed to determine the 
effects of an estrogen-related diet in other populations, including those with a strong 
inherited risk or different dietary habits. In addition to diet, a lifestyle that is 
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characteristic of a healthy body weight, low consumption of alcohol, and increased PA 
may help to prevent postmenopausal breast cancer incidence.  
 
7.4 Strengths and limitations 
Some limitations must be considered when interpreting results from the present 
dissertation. There was the potential for bias due to the selection of subjects, such as in 
SS participants where some women with a particularly strong inherited risk may have 
taken necessary lifestyle changes to reduce their risk. However, all women in the cohort 
are aware of their family history of breast cancer therefore we do not expect a differential 
effect based on inherited risk. Loss to follow-up represents the potential for selection 
bias, however response rates in SS have been >90% for all survey periods. In PLCO, over 
75% of participants were followed for at least 10 years and 95% of participants were 
followed for at least 4 years, suggesting a low number of early drop outs. FFQs are prone 
to measurement error, and specifically have been shown to poorly estimate current total 
energy intake in relation to a recovery biomarker (doubly labeled water).293,294 We used 
only food or food-group data from the FFQs, rather than macronutrient or micronutrient 
data, thus, eliminating one source of error that results from converting food intake to 
nutrient intake using food composition databases. Any dietary measurement error would 
likely have been non-differential with respect to breast cancer outcome, thus biasing 
effect estimates toward the null. Use of multiple FFQs to assess diet in adulthood would 
have reduced intra-individual variation and better captured the estrogenic potential of 
diet, however evidence of changes in adulthood diet is limited288–291 and FFQs are 
designed to assess usual diet. Because FFQs contain a predetermined list of foods and 
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beverages, the use of FFQs to develop the ERDP limited our ability to identify all foods 
that were associated with EM in the RRR modeling, as compared with an open-ended 
dietary assessment method such as 24 hour recalls or food records. While the PLCO and 
SS populations were similar with regard to SES and race/ethnicity distributions, 
differences in FFQs across the two study populations may have limited the comparability 
of our findings from Aim #1 and #2. Differences in the descriptions and numbers of line 
items for certain food groups may have affected our observed associations through an 
impact on the distribution of ERDP scores. A minor limitation in regards to study 
populations was the lack of heterogeneity of race and ethnicities. However, our 
populations are predominately non-Hispanic White women who experience the highest 
incidence of breast cancer, so the results have major public health relevance. While we 
adjusted for important potential confounders, residual or unmeasured confounding cannot 
be ruled out. A low percentage of variation in EMs was explained by the ERDP, therefore 
it is difficult to assess the role of estrogen metabolism in explaining the association with 
breast cancer. However, the percentage of EM variation explained in the ERDP was 
similar and slightly larger than other RRR analyses using intermediate biomarkers.32,295  
There are major strengths in the approach and design to offset some of the 
limitations. Analyses were conducted with information on known confounders and with 
enough power to detect moderately small effects through the use of large, prospective 
cancer cohorts. Follow up was substantial enough for an adequate number of events to 
accrue, although shorter duration in SS compared to PLCO may have contributed to the 
difference in results across the two study populations. Equally small proportions (~5%) 
of cases and controls were excluded because of missing exposure or covariate data for 
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both populations, therefore we do not expect missing data to have influenced the 
differential results.  
Using RRR to create the ERDP based on EM biomarkers allowed for 
consideration of an a priori mechanistic hypothesis to facilitate interpretation of results. 
The EMs used to develop the ERDP were measured using a sensitive assay and have 
been shown to be strongly related to breast cancer risk in the PLCO population.35 Finally, 
the use of prospective cohort studies where diet was assessed prior to disease diagnosis 
minimizes the potential for recall bias which can afflict case-control studies. 
 
7.5 Suggestions for future work 
 Most large prospective cohort studies in the US and worldwide have used FFQs to 
assess usual diet. FFQs are generally less expensive and more feasible in large 
population-based studies than other dietary assessment methods, such as 24 hour recalls 
or foods records. However, the previously mentioned limitations resulting from using an 
FFQ to derive the dietary pattern may be improved upon through use of an open-ended 
dietary assessment tool, such as a 24-hour recall of food record. In doing so, all foods 
consumed that may influence estrogen metabolism in a given population can be 
measured. Similarly, the development of an estrogenic dietary pattern should be 
conducted in multiple populations with different dietary habits in order to examine how 
the contributing foods vary, or if associations with breast cancer vary depending on the 
diets of each population. Another suggestion for improvement in future studies is to 
measure EMs at multiple times to reduce intra-individual variability in the intermediate 
outcome used to develop the ERDP. To confirm a mechanistic pathway that works 
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through estrogen metabolism, construct validation needs to be performed, such as by 
evaluating the relationship between our diet score and serum EM in another study 
population. Studies with serum EMs measured at an intermediate time point between 
dietary exposure and breast cancer outcomes would help to clarify the potential role of 
estrogen metabolism. Alternatively, clinical trials could be effective in determining 
differences in EM levels across experimental groups of high and low adherers to the 
ERDP. 
 
7.6 Concluding remarks 
In conclusion, we developed a dietary pattern associated with a high-risk estrogen 
profile (high E2 and low 2/16 ratio) that is hypothesized to increase breast cancer risk. 
Women who had high ERDP scores tended to consume higher amounts of non-
whole/refined grains, tomatoes, cheese, franks/luncheon meats; and lower amounts of 
nuts and seeds, cruciferous vegetables, other vegetables, fish/shellfish, yogurt, and coffee. 
A subsequent prospective investigation indicated that this estrogenic diet was associated 
with an increased risk of postmenopausal breast cancer risk in the study cohort in which 
it was developed, PLCO. However, application of the dietary pattern in a second 
population with a high inherited risk, SS, resulted in no association with breast cancer. 
Taking the results from Aims #1 and #2 together, we emphasize the importance of 
considering dietary assessment tools when comparing interpretations from a posteriori 
patterns across populations, as well as the need for studies of lifestyle factors across strata 
of participants with or without a family history of breast cancer. 
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When the dietary pattern was incorporated into a lifestyle score with alcohol 
intake, BMI, and PA, a combined effect on postmenopausal breast cancer risk was 
observed in the PLCO. A lifestyle that is characterized by consumption of a diet with low 
estrogenic potential, low alcohol consumption, normal-weight BMI, and high levels of 
PA may help to lower the risk of developing breast cancer in postmenopausal women. A 
collective change in lifestyle is likely more influential than focusing on specific 
behaviors. 
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7.8 Tables 
Table 7.1 Hazard ratios (95% CI) for the relationship between the estrogen related dietary pattern (ERDP) score and postmenopausal 
breast cancer in PLCO participants stratified by family history of breast cancera 
 
  ERDP quartiles Estimate for continuous 
ERDP scoreb   1st 2nd 3rd 4th 
Without family history of breast cancer     
Total breast cancer cases 297 328 331 356  
 1.00 (ref) 1.11 (0.95, 1.30) 1.11 (0.95, 1.30) 1.17 (0.99, 1.37) 
1.11 (1.02, 1.21) 
p=0.02 
Invasive cases 229 261 270 290  
 
1.00 (ref) 1.15 (0.96, 1.37) 1.18 (0.99, 1.41) 1.23 (1.03, 1.48) 
1.17 (1.06, 1.29) 
p=0.002 
      
With family history of breast cancer     
Total breast cancer cases 69 64 72 75  
 1.00 (ref) 1.00 (0.71, 1.42) 1.05 (0.75, 1.47) 1.03 (0.73, 1.45) 
1.01 (0.83, 1.22) 
p=0.94 
Invasive cases 51 48 61 58  
  
1.00 (ref) 0.99 (0.67, 1.48) 1.19 (0.82, 1.73) 1.10 (0.74, 1.63) 
1.01 (0.81, 1.26) 
p=0.93 
ERDP: estrogen-related dietary pattern 
aIncludes adjustment for age, TEI, BMI, BMI at age 20, HRT, alcohol use, education, bilateral oophorectomy, parity, age at menopause, PA, race/ethnicity, 
and recruitment center. 
bHR corresponds to 1-unit increase in ERDP score. 
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Table 7.2 Comparison of food group intakes in PLCO and the Sister Study 
 
  PLCO   Sister Study 
  Mean SD Min Max   Mean SD Min Max 
Total ERDP Score -0.01 0.65 -4.51 6.58   -0.05 0.71 -8.23 4.67 
Non-whole/refined grains (oz/day) 4.19 1.95 0.3 16.3   2.87 1.62 0.0 18.7 
Tomatoes (cups/day) 0.43 0.30 0.0 8.5   0.27 0.21 0.0 3.1 
Other vegetables (cups/day) 0.99 0.55 0.0 6.2   0.48 0.38 0.0 5.4 
Cruciferous vegetables (cups/day) 0.28 0.26 0.0 3.9   0.23 0.30 0.0 4.7 
Cheese (cups/day) 0.35 0.30 0.0 4.3   0.39 0.32 0.0 2.6 
Yogurt (cups/day) 0.12 0.20 0.0 2.2   0.12 0.19 0.0 1.8 
Fish/shellfish high in ω-3 fatty acids (oz/day) 0.16 0.19 0.0 2.9   0.15 0.20 0.0 3.8 
Fish/shellfish low in ω-3 fatty acids (oz/day) 0.50 0.47 0.0 10.3   0.45 0.46 0.0 8.9 
Franks and luncheon meats (oz/day) 0.23 0.30 0.0 6.4   0.52 0.45 0.0 5.8 
Nuts and seeds (oz/day) 0.42 0.63 0.0 9.9   1.44 1.60 0.0 23.2 
Coffee (cups/day) 2.48 3.03 0.0 17.4   1.50 1.48 0.0 9.0 
PLCO: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; SD: standard deviation 
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